1
Filed pursuant to Rule 424(b)(3)
Registration No. 333-72663
14,035,452 SHARES
LIFEPOINT, INC.
COMMON STOCK
LifePoint, Inc. ("we" or the "Company") is in the late stages of developing its
first product, a device using a person's saliva to test on-site, without having
to take a sample to a laboratory, for the presence in his or her body of (1)
drugs of abuse, such as cocaine, heroin and marijuana, and (2) alcohol. We do
not expect to begin marketing this product before the third quarter of 2000.
The Company is not offering for sale any securities pursuant to this
prospectus. Instead, most of the stockholders of the Company in the list
beginning on page 52 of this prospectus will be selling an aggregate of
12,000,000 shares of our Common Stock when and if they convert their outstanding
shares of our Series A 10% Cumulative Convertible Preferred Stock, of which an
aggregate of 845,500 shares have already been issued upon conversion. Such
stockholders also may sell up to 500,000 additional shares of our Common Stock
which is our current estimate as to the shares which may be issued to them as
dividends during the next three years, of which an aggregate of 1,306 shares
have already been issued as dividends. In addition, the remaining selling
stockholders named in that list will be selling an aggregate of 1,535,452 shares
of our Common Stock when and if they exercise their Common Stock purchase
warrants previously received from us.
The selling stockholders will be selling, from time to time, pursuant to
this prospectus, their shares at the prices quoted for the Common Stock in the
over-the-counter market. Our Common Stock is currently reported on the NASD's
OTC Bulletin Board under the symbol: LFPT. On March 23, 1999, the high bid and
low asked prices as so reported were $2.60 and $2.375, respectively, per share.
The selling stockholders may also attempt to sell their shares in isolated
transactions, at negotiated prices, with institutional or other investors. There
will be no underwriter's discounts or commissions except for the charges if a
selling stockholder sells through a broker-dealer. All net proceeds from a sale
will go to the selling stockholder and none to the Company.
-------------------------
THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD PURCHASE SHARES ONLY
IF YOU CAN AFFORD A COMPLETE LOSS. SEE "RISK FACTORS" BEGINNING ON PAGE 5.
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.
This Prospectus is dated April 5, 1999
2
TABLE OF CONTENTS
PAGE
----
Summary............................. 3
Risk Factors........................ 5
Use of Proceeds..................... 11
Business............................ 11
Market for the Common Stock and
Related Stockholder Matters....... 27
Management.......................... 30
Security Ownership of Certain
Beneficial Owners and
Management........................ 37
Description of Securities........... 40
Plan of Distribution................ 47
The Selling Stockholders............ 52
Legal Matters....................... 63
Experts............................. 63
Commission Position on
Indemnification................... 63
Selected Financial Data............. 64
Management's Discussion and Analysis
of Financial Condition and Results
of Operations..................... 66
Index to Financial Statements....... F-1
Audited Financial Statements........ F-2
Unaudited Financial Statements...... F-19
2
3
SUMMARY
Because this is a summary, it does not contain all of the information that may
be important to you as a prospective purchaser of shares of our Common Stock
from a Selling Stockholder. You should read the entire prospectus carefully,
including the risk factors and the financial statements, before you decide to
purchase a share of our Common Stock.
KEY QUESTIONS AND ANSWERS.
1. WHO ARE WE?
LifePoint, Inc. is a Delaware corporation, with its sole office at 10400
Trademark Street, Rancho Cucamonga, California 91730. The Company's telephone
number is (909) 466-8047. You should make inquiries relating to this prospectus
to Linda H. Masterson, our President and Chief Executive Officer, by writing her
at the Company's address or by calling her at extension 223.
2. WHAT BUSINESS ARE WE IN?
We are in the late stages of developing our first product, using technology
licensed to us from the United States Navy and our own patented technology. Our
device will use a person's saliva to test on-site, without having to take the
sample to a laboratory, the presence in a person's body of (1) drugs of abuse,
such as cocaine, heroin and marijuana, and (2) alcohol.
3. WHAT IS OUR RECORD OF REVENUES AND EARNINGS?
Because we have not offered for sale any product or services, we have had no
revenues. Through December 31, 1998, we incurred losses of $13,786,545. Because
we do not expect to begin marketing our first product described above before the
third quarter of 2000 at the earliest, our operational losses will continue
through that date, if not longer.
4. DO WE NEED ANY GOVERNMENTAL APPROVALS TO BEGIN MARKETING?
For us to market our testing device to hospitals and other medical facilities in
the United States, we must first obtain the approval of the United States Food
and Drug Administration. We currently expect to submit our product to the FDA
for approval not earlier than the third quarter of 2000. Based on current
experiences of other companies, we expect to get such approval not earlier than
100 days later. However, we cannot assure you that the FDA will approve and, if
such agency approves our product, as to when such approval will be given. Once
our development work is completed and a manufacturing operation is in
place -- which we expect to be not earlier than the third quarter of 2000 -- we
can begin to market our product to law enforcement agencies, industrial safety
sensitive companies and other non-medical users.
5. WHAT SECURITIES ARE THE COMPANY OFFERING PURSUANT TO THIS PROSPECTUS?
We are not offering any securities pursuant to this prospectus. All sales
pursuant to this prospectus will be by the Company's stockholders named in the
list beginning on page 52 of this prospectus. Such persons will be referred to
in this prospectus as the "Selling Stockholders." We, not pursuant to this
prospectus, will offer, or have offered, to the Selling Stockholders the
following shares of the Common Stock: (1) 12,000,000 shares upon the conversion
of the Company's Series A 10% Cumulative Preferred Stock, (2) up
3
4
to 500,000 shares which is our current estimate as to the dividends which may be
issuable with respect to the shares of the Series A Preferred Stock during the
next three years and (3) 1,535,452 shares upon the exercise of certain Common
Stock purchase warrants with expiration dates ranging between December 7, 2002
and January 20, 2004 and with exercise prices ranging between $.50 and $2.41 per
share. Such warrants will be referred to in this prospectus as the "Selling
Stockholders Warrants." For additional information as to these securities, see
the sections "Series A Preferred Stock" and "Selling Stockholders Warrants"
under the caption "Description of Securities" and "Plan of Distribution" in this
prospectus.
6. WHAT IS THE OFFERING PRICE PURSUANT TO THIS PROSPECTUS?
The Selling Stockholders have advised us that, after conversion of their shares
of the Series A Preferred Stock or exercise of their Selling Stockholders
Warrants, they will sell these shares of the Common Stock received upon any such
conversion or exercise, from time to time, at the prices quoted for the Common
Stock in the over-the-counter market. Our Common Stock is currently reported on
the NASD's OTC Bulletin Board under the symbol: LFPT. On March 23, 1999, the
high bid and low asked prices as so reported were $2.60 and $2.375,
respectively, per share. The Selling Stockholders have also advised us that they
may sell their shares in isolated transactions, at negotiated prices, with
institutional or other investors. There will be no underwriter's discounts or
commissions, except for the charges if the Selling Stockholder sells through
his, her or its broker-dealer. See "Plan of Distribution."
7. WILL THE COMPANY RECEIVE ANY PROCEEDS AS A RESULT OF SALES OF SHARES
PURSUANT TO THIS PROSPECTUS?
We will not receive any proceeds from the sales of shares of the Common Stock by
the Selling Stockholders pursuant to this prospectus. We will, however, receive
$2,071,737 if all of the Selling Stockholders' Warrants are exercised.
4
5
RISK FACTORS
Before you invest in our Common Stock by purchasing shares from a Selling
Stockholder named in this prospectus (see the list beginning on page 52 of this
prospectus), you should be aware that there are various risks, including those
described below. You should consider carefully these risk factors, together with
all of the other information included in this prospectus, before you decide to
purchase shares of our Common Stock.
Some of the information in this prospectus may contain forward-looking
statements. Such statements can be identified by the use of forward-looking
terminology such as "may," "will," "expect," "anticipate," "estimate,"
"continue" or other similar words. These statements discuss future expectations,
contain projections of results of operations or of financial condition or state
other "forward looking" information. When considering such forward-looking
statements, you should keep in mind the risk factors and other cautionary
statements in this prospectus. The risk factors noted in this section and other
factors noted throughout this prospectus, including certain risks and
uncertainties, could cause our actual results to differ materially from those
contained in any forward-looking statement.
THE FOLLOWING RISK FACTORS RELATE TO OUR OPERATIONS:
WE HAVE HAD A HISTORY OF OPERATIONAL LOSSES AND EXPECT OUR LOSSES TO CONTINUE.
From the date we incorporated on October 8, 1992 through December 31, 1998, we
incurred net losses of $13,786,545. These losses are due to the fact we have had
no product or service to offer for sale or rental and, as a result, have
incurred only expenses without generating any revenues. We are still developing
our first marketable product, a device using a person's saliva to test on-site
for the presence in his or her body of (1) drugs of abuse, such as cocaine,
heroin and marijuana, and (2) alcohol. Through December 31, 1998, we incurred
$6,537,218 in expenses for research and development of this product and
$7,249,327 for other costs and expenses.
We anticipate completing the development of a working prototype of the testing
device not earlier than the first quarter of 2000. Assuming we receive the
necessary financing (see the next section under this caption "Risk Factors"), we
anticipate completing the development of the product and having a manufacturing
operation in place not earlier than the third quarter of 2000. We would then
begin to market our product to law enforcement agencies, industrial safety
sensitive companies and other non-medical users because there is no governmental
approval required as a prerequisite for us to market to them. However, for us to
market our product in the United States to hospitals and other medical
facilities, we must first obtain approval by the Food and Drug Administration
(the "FDA") of the product. We currently expect to obtain FDA approval not
earlier than the fourth quarter of 2000. Many potential non-medical users of our
product may want to wait until we have obtained FDA approval before they use the
testing device, even though there is no such legal requirement for us to sell
the product to them. Such a delay would further defer our receipt of revenues.
We are unable to assure you that we shall meet the schedule described in the
preceding paragraph. Even if we do, we cannot expect to produce product revenues
until the third quarter of 2000 at the earliest. In the interim period, we
expect to have income from other sources such as research grants and partnering
agreements. We, therefore, expect that our losses will continue until at least
the third quarter of 2000, if not longer. We cannot be certain when our expected
revenues will exceed expenses. See "Business -- Seeking a Product -- Preliminary
Background" and "Financial Statements."
5
6
WE HAVE A NEED FOR ADDITIONAL FINANCING.
We estimated that we would require approximately $13,000,000 to bring the drugs
of abuse/alcohol testing product to market. We have raised $6,000,000 in a
recently completed private placement. We believe that this amount will permit us
to complete the working prototype of the product. However, we cannot assure you
that the additional funding will be readily available to us even if we complete
the prototype within budget. Also our estimate as to the required funds may be
too low. An external consultant in June 1997 estimated that we would require
$18,400,000 to complete the project compared to our forecast of $16,000,000. In
addition, any delays in our program may also increase our costs.
Based on our discussions with various persons, we believe that, if we develop
the working prototype, we may persuade an investment banking firm to do a public
offering of our securities to raise the balance of funding we require. However,
we do not know whether the stock market will be receptive at that
time -- estimated to be the first quarter of 2000 -- to a public offering by us.
We also believe that development of the working prototype will facilitate the
efforts of Burrill & Company, a consulting firm whose services we have engaged,
to obtain a large pharmaceutical or medical diagnostic company to fund the
project through a strategic alliance with us. We are excited about the
possibilities for growth of our product. However, we cannot be certain that a
large pharmaceutical or medical diagnostic company will also be so impressed as
to enter into a strategic alliance with us or, even if they do so, when this
will occur. Burrill & Company believes that it will take at least five months
from now to secure a strategic partner. Some potential strategic partners may
want to wait until we actually have the working prototype.
We have applied for three small business research grants from the National
Institute of Health, in conjunction with Cedars Sinai Medical Center. If we
receive all three grants, the Company may receive up to $3,000,000 in additional
funding. However, we cannot assure you that we will receive any of the grants.
We have consummated three private placements pursuant to Regulation D under the
Securities Act since November 1997. Accordingly, we can always attempt to use
this financing method to raise the balance of the approximately $7,000,000 we
need to complete the development project. Again, we cannot assure you that
investors will be receptive to making an investment, particularly in our
Company, at that time because of the then stock market conditions.
In addition to adverse conditions in the stock market that may adversely impact
our efforts to obtain public and private financing, as described above,
competitive conditions in our industry may also influence adversely prospective
sources of financing. See the section "Competition" under this caption "Risk
Factors."
If all of the Common Stock purchase warrants (including the Selling Stockholders
Warrants) and stock options which were outstanding as of February 26, 1999 were
subsequently exercised, we would realize $3,298,966 in gross proceeds. However,
we cannot assure you as to when and if these warrants and options will be
exercised by the respective holder, so we cannot rely on these exercises as a
source of financing. See "Description of Securities -- Warrants" and
"Management -- Option/SAR Grants."
We recognize that without additional financing we cannot bring our product to
market. Without such product we cannot produce revenues. In such an event, your
investment in our Common Stock may become a complete loss. See "Business -- Need
for Financing."
6
7
WE WILL FACE MAJOR COMPETITION.
If our product to test for drugs of abuse and alcohol is successfully developed,
we will compete with many companies of varying size that already exist or may be
founded in the future. The current tests available either use urine samples as a
specimen to test for drugs of abuse or use breath or saliva to test for alcohol.
We are not aware of any products that can currently perform an on-site test for
drugs in blood or saliva. We recognize that such a product or products may be
developed in the future.
With respect to testing for the presence of alcohol, we will compete with
Intoxmeter, Inc., LifeLock, Inc. and other small manufacturers.
With respect to testing for the presence of drugs of abuse in saliva, we may
face as competitors at least eight major pharmaceutical companies which
currently use urine as the specimen for testing. Almost all of these prospective
competitors have substantially greater financial resources than we do to develop
and market their products. Their names and their testing products are listed
under "Business -- Competition."
We believe that our saliva sample testing product will be unique because, to our
knowledge, no company is currently offering an on-site substance abuse detection
method using saliva as a specimen. In addition, we are not aware of any products
that can deliver an immediate "blood equivalent" drug test that indicates
current impairment in a person from drugs. However, we have been told that two
or more companies may be developing a saliva-based testing device to test for
drugs, although the technology they are using is very different from that of the
Company. Accordingly, by the time we first offer our product for sale, there may
already be competition to our product also using saliva as a specimen for
testing. This competition would be in addition to that of the companies already
using urine as the specimen for testing. In addition, because of the extensive
time frame it will take for us to bring our product to market, our competition
may have developed name recognition among customers that will handicap our
future marketing efforts.
OUR INDUSTRY IS SUBJECT TO TECHNOLOGICAL CHANGES.
The substance abuse testing industry is a technologically sensitive industry.
Companies are constantly developing new methods and making changes to current
methods for substance abuse detection in order to remain competitive. When our
product is launched, we shall compete with larger companies such as those named
under "Business -- Competition." Many of such companies have substantially
greater resources to invest in the research and development of their products
than we do. Such competitors may develop products in the future that make our
products obsolete or non-competitive from a pricing point of view. For us to
remain competitive, we may require substantial financial resources for personnel
and other costs to conduct research and update our products to reflect the
technological advances. However, we may not be able to obtain such financial
resources when we require the same or, if we do obtain the financing, the terms
thereof may adversely affect our results of operations.
OUR EFFORTS TO LEGALLY PROTECT OUR PRODUCT MAY NOT BE SUCCESSFUL.
We will be dependent on our patents and trade secret law to legally protect the
uniqueness of our testing product. However, legal action against those companies
which we believe may have improperly used our technology may result in long and
costly litigation, thereby increasing our costs of operations and thus adversely
affecting our results of operations. In addition, should it be successfully
claimed that we have infringed on the technology of another company, we may have
to pay such company a royalty or licensing fee. Such a
7
8
result would also add to our costs of operations and thereby adversely affect
our results of operations. See "Business -- Patents and Technology."
THE FOLLOWING RISK FACTORS RELATE TO OUR COMMON STOCK:
OUR STOCKHOLDERS MAY FACE LIQUIDITY PROBLEMS WHEN THEY SEEK TO SELL THEIR
SHARES.
We currently do not meet the requirements to list our Common Stock on a national
securities exchange or on the Nasdaq SmallCap Market. Accordingly, trading in
our Common Stock is conducted in the over-the-counter market and reported on the
NASD's OTC Bulletin Board. Consequently, selling our shares may be more
difficult because smaller quantities of shares may be bought and sold,
transactions may be delayed and security analysts' and news media's coverage of
our Company may be reduced. These factors could result in lower prices and
larger spreads in the bid and asked prices for our shares.
In addition, because the bid price of our Common Stock is below $5.00 per share,
the shares became subject to Rule 15g-9 and the other penny stock regulations
under the Securities Exchange Act of 1934, as amended (the Exchange Act"). Rule
15g-9 imposes additional sales practice requirements on broker-dealers that sell
low-priced securities to persons other than established customers and
institutional accredited investors. For transactions covered by this Rule, a
broker-dealer must make a special suitability determination for the prospective
purchaser and have received the purchaser's written consent to the transaction
prior to the sale. Consequently, the Rule and the other "penny stock"
regulations may adversely affect the ability of broker-dealers to sell our
shares and may adversely affect the ability of holders to sell their shares of
the Common Stock in the secondary market. See "Market for the Common Stock and
Related Stockholder Matters -- Penny Stock Rules."
We intend, when appropriate, to seek a listing of the Common Stock on a national
securities exchange or the Nasdaq SmallCap Market, which listing would exempt us
from the penny stock regulations described in the preceding paragraph. However,
we cannot assure you as to when and if any such listing will occur.
SHARES ELIGIBLE FOR FUTURE SALE MAY ADVERSELY AFFECT MARKET PRICE OF THE
COMMON STOCK.
Of the 11,818,403 shares of the Common Stock outstanding as of February 26,
1999, we had previously registered under the Securities Act of 1933, as amended
(the "Securities Act"), 1,918,097 of those shares. Accordingly, a holder of any
of such shares may sell his, her or its shares without any requirement that the
holder deliver to his, her or its purchaser a prospectus naming the holder as a
selling stockholder, unless the holder is an affiliate of the Company as defined
in Rule 144(a)(1) under the Securities Act. Even the holder who is an affiliate
may sell his, her or its shares as permitted by Rule 144 without delivery of
such a prospectus.
In addition, as of February 26, 1999, an additional 8,775,306 shares were
restricted securities as defined in Rule 144(a)(3) under the Securities Act. A
holder of any of such shares may sell them pursuant to the exemption from
registration of Rule 144. Furthermore, 1,125,000 shares were also restricted
securities as of January 20, 1999 and may be sold pursuant to Rule 144 on
various dates thereafter (1,000,000 shares on and
8
9
after July 24, 1999, 25,000 shares on and after August 27, 1999 and 100,000
shares on and after August 31, 1999).
In summary, all 11,818,403 shares of the Common Stock outstanding as of February
26, 1999 are, or will become in the summer of 1999, saleable without the
necessity of the Company filing a registration statement under the Securities
Act naming the holders as selling stockholders.
As of February 26, 1999, we had reserved 1,958,803 shares of the Common Stock
for the exercise of stock options (the "Options") granted or to be granted
pursuant to the LifePoint, Inc. 1997 Stock Option Plan (the "Stock Option
Plan"). For further information as to the Options already granted and when
Options became or will become exercisable under the Stock Option Plan, see
"Management -- Option/SAR Grants." All of the shares issuable upon the exercises
of the Options have been registered under the Securities Act. Accordingly,
unless the optionee is an affiliate of the Company as defined in Rule 144(a)(i)
under the Securities Act, he or she may, after exercise of an Option, resell the
shares received upon exercise without the use of a reoffer prospectus.
In addition, as of February 26, 1999, the Company had reserved an aggregate of
1,560,289 shares for the exercise of outstanding Common Stock purchase warrants
(the "Warrants"), other than the Selling Stockholders Warrants. The Warrants
expire on various dates ranging from October 26, 2002 to January 7, 2003 and
have an exercise price of $.50 per share, except for one Warrant to purchase
100,000 shares which has an exercise price of $1.00 per share. The shares of the
Common Stock issuable upon exercises of the Warrants have not been registered
under the Securities Act. Accordingly, these shares will be restricted
securities as defined in Rule 144(a)(3) under the Securities Act after issuance.
The holder (including an affiliate of the Company) may, one year after the
exercise of the Warrant, resell his, her or its shares received upon such
exercise pursuant to the exemption from registration of Rule 144 under the
Securities Act.
We are unable to predict the effect that sales of our shares of the Common Stock
made under Rule 144 and the delayed sales of shares subject to the Options and
the Warrants may have on the then prevailing market price of our shares. It is
likely that market sales of large amounts of these shares of the Common Stock
and/or the 14,035,452 shares offered by this prospectus (or the potential for
those sales even if they do not actually occur) will have the effect of
depressing the market price of the Common Stock. See "Description of
Securities -- Shares Eligible for Future Sale."
CONTROL OF THE COMPANY CURRENTLY RESTS WITH FOUR PERSONS.
As of March 23, 1999, three of the four directors and a person related to two of
them owned in the aggregate 6,157,306 shares of the Common Stock. As a result,
they have 6,157,306 votes of the 13,222,934 votes currently eligible to elect
the directors of the Company or 46.6% of such votes. A plurality of the shares
voting is necessary to elect a director of the Company. Accordingly, if these
four persons vote together and if they obtain the votes from the holders of
454,162 shares of the remaining shares (6,507,903 shares of the Common Stock and
557,725 shares of the Series A Preferred Stock), they could elect all of the
directors and the holders of the remaining shares would not be able to elect a
single director. See "Description of Securities -- Non-Cumulative Voting."
9
10
WE DO NOT ANTICIPATE PAYING DIVIDENDS ON OUR COMMON STOCK IN THE FORESEEABLE
FUTURE.
We intend to retain future earnings, if any, to fund operations and expansion of
our business. In addition, our expected continuing operational losses and the
outstanding shares of the Series A Preferred Stock (and any other series of the
Preferred Stock that may hereafter be issued) will limit legally our ability to
pay dividends on the Common Stock. Accordingly, we do not anticipate paying cash
dividends on shares of our Common Stock in the foreseeable future. See
"Description of Securities -- Dividends."
10
11
USE OF PROCEEDS
The Company will not receive any proceeds upon the conversions of the shares of
the Series A Preferred Stock into shares of the Common Stock or upon the
subsequent sales by Selling Stockholders of the shares of the Common Stock
issued to them upon such conversions. If the Selling Stockholders Warrants are
exercised in their entirety, the Company will receive $2,071,737 upon such
exercises. However, the Company will not receive any of the proceeds from the
subsequent sales by the holders of the underlying shares of the Common Stock
received upon exercise of the Selling Stockholder Warrants.
BUSINESS
SAFE HARBOR STATEMENT UNDER THE PRIVATE LITIGATION REFORM ACT OF 1995
With the exception of historical information, the matters discussed in this
prospectus include certain forward-looking statements that involve risks and
uncertainties. Among the risks and uncertainties to which the Company is subject
are the risks that:
- it will not obtain the substantial financing necessary to complete the
development of its products and, accordingly, not develop any revenue
source;
- it will not secure the additional personnel required first to complete
the development program and, if that is successful, later to implement
the manufacturing process, especially in its current location;
- it will not complete the product development program on a timely or
successful basis and the costs will be higher than projected;
- during the period before the third quarter of 2000 when the Company's
management currently believes that its saliva based drugs of abuse and
alcohol testing product will be submitted for United States governmental
approval, competitors with greater financial resources will have produced
and offered for sale a saliva based competitive product; and
- because of the delays, the potential market for the Company's products
will not be as large as currently anticipated.
As a result, the actual results realized by the Company could differ materially
from the statements made herein. Stockholders of the Company are cautioned not
to place undue reliance on forward-looking statements made in this prospectus.
See also "Management's Discussion and Analysis of Financial Condition and
Results of Operations -- Forward Looking Statements."
AVAILABLE INFORMATION
The Company files reports, proxy and information statements and other
information with the Securities and Exchange Commission (the "Commission"). Such
reports, proxy and information statements and other information filed by the
Company can be inspected and copied at the public reference facilities
maintained by the Commission at 450 Fifth Street, N.W., Room 1024, Washington,
D.C. 20549, as well at the following regional offices of the Commission: 7 World
Trade Center, Suite 1300, New York, New York 10048 and Northwestern Atrium
Center, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661-2511.
Copies of this material can also be obtained at prescribed rates from the Public
Reference Section of the Commission at its principal office at 450 Fifth
11
12
Street, N.W., Washington, D.C., 20549. The Commission maintains a Web site that
contains reports, proxy and information statements and other information
regarding registrants (including the Company) that file electronically with the
Commission at the following Web site address: http://www.sec.gov.
Copies of the Company's reports, proxy and information statements and other
information filed with the Commission can be obtained from the Company by
writing Assistant Secretary Anne Craven at LifePoint, Inc., 10400 Trademark
Street, Rancho Cucamonga, CA 91730 or by calling her at (909) 466-8047,
extension 222. They can also be obtained by contacting the Company on its Web
site: www.lifepoint.com.
HISTORY OF THE COMPANY
The Company was incorporated on October 8, 1992 under the laws of the State of
Delaware, under the name "U.S. Drug Testing Inc.," as a wholly owned subsidiary
of Substance Abuse Technologies, Inc. ("SAT"). The Company's name was changed to
"LifePoint, Inc." on February 25, 1998. When the Company was incorporated, the
Common Stock, $.01 par value (the "SAT Common Stock"), of SAT was traded on the
American Stock Exchange.
Effective as of January 1, 1993, SAT sublicensed or transferred to the Company
certain rights or assets to develop drug testing products in exchange for
3,500,000 shares of the Company's Common Stock, $.001 per value (the "Common
Stock"). In October and November 1993, the Company had a public offering of the
Common Stock in which an aggregate of 1,721,900 shares was sold. As of September
30, 1997, SAT owned 5,575,306 shares of the Common Stock or 76.4% of the
7,297,206 shares of the Common Stock then outstanding. From its inception until
October 31, 1997, the Company was a subsidiary of SAT or otherwise under its
control.
SAT ceased providing advances to the Company in August 1997 as a result of SAT's
inability to secure financing for its own programs. On September 10, 1997, SAT
filed a petition under Chapter 11 of the Federal Bankruptcy Code. The Company
temporarily suspended its product development activities on September 19, 1997,
but did not file for bankruptcy.
On October 29, 1997, SAT sold the controlling stockholder interest in the
Company to Meadow Lane Partners, LLC ("Meadow Lane"), then an unaffiliated
party, for $250,000. The Company then resumed its product development efforts.
On October 31, 1997, two directors of the Company who were directors of SAT (and
one of whom was SAT's Chief Executive Officer) resigned. On November 4, 1997,
Linda H. Masterson, the President and Chief Executive Officer of the Company,
resigned as a director of SAT, thereby terminating SAT's last relationship with
the Company. For additional information as to certain of the prior relationships
between the Company and SAT, its former parent, see the sections "Material
Contracts -- Management Agreement," "Certain Relationships with SAT," "Loans
from SAT to the Company" and "Transfer of Assets from SAT to the Company" under
this caption "Business."
SEEKING A PRODUCT-PRELIMINARY BACKGROUND
The Company has not produced any revenues through December 31, 1998 because its
products are still in the developmental stage. The Company is developing
proprietary systems that will test for substance abuse, specifically the
following five commonly used drugs of abuse: cocaine, opiates (heroin, morphine
and codeine), phencyclidine hydrochloride (PCP), amphetamines (including
methamphetamines), and tetrahydrocannabinol
12
13
(THC, marijuana) (collectively the "Drugs of Abuse"). As indicated below, the
Company's first efforts were to develop a device to test for the Drugs of Abuse
using urine as the test specimen. However, based on its review of the potential
market in 1995, the Company decided to develop a saliva specimen testing product
first. In late 1996, it expanded the development program to also test for the
presence of alcohol.
In January 1992, the United States Navy (the ("USN") and SAT signed a ten-year
license agreement (the License Agreement") covering the exclusive use by SAT of
the USN's technology for the five Drugs of Abuse and any other drugs that might
be added to the National Institute of Drug Abuse ("NIDA") list of drugs of
abuse. By an amendment dated March 15, 1994, the scope of the License Agreement
was broadened to permit SAT to use the technology for testing for methadone,
benzodiazapines, barbiturates, propoxyphene, tricyclic antidepressants and
anabolic steroids. Except as set forth in the two preceding sentences, SAT under
the License Agreement could not use the USN technology to test for other
substances.
By an amendment dated June 16, 1995, the term of the exclusive right under the
License Agreement was extended to terminate ten years from June 27, 1995. In
addition, SAT was granted a nonexclusive right to use the technology thereafter
for the balance of the patent term, unless the License Agreement was terminated
sooner because of SAT's default. By letter dated May 15, 1995, the USN notified
SAT that, because the expiration date of the USN patent had been extended to
February 23, 2010 under the GATT/WTO treaty, the expiration date of the License
Agreement was extended to February 23, 2010.
The Company's line of products under development was initially based on its
sublicense dated September 23, 1993 (the "Sublicense") from SAT for Drugs of
Abuse detection utilizing the USN patent for flow immunosensor technology.
However, with the sale of the SAT majority stockholder interest in the Company
(see the section "History of the Company" under this caption "Business"), the
license agreement with the USN was transferred directly to the Company from SAT
and the Sublicense between SAT and the Company was canceled. On March 3, 1998,
the notification period in the Federal Register was completed.
The USN has agreed in principle to expand the license to a worldwide, exclusive
license for human diagnostic testing on saliva. The Company and the USN are
currently negotiating the terms of such expanded license. The Company is further
developing the USN-developed technology for application in its own proprietary
test system. See the sections "Material Contracts" and "Patents and Technology"
under this caption "Business."
Until the saliva based test system is submitted to the FDA and/or marketing has
commenced, no revenues from product sales are likely to be produced. The Company
conducted an internal feasibility study on the product that was completed in
November 1996. Based on the results of the feasibility study, the Company
proceeded to the next stage of development. Assuming subsequent success in the
remainder of the development program, the Company currently expects to submit
its five-panel screening assay to the FDA, and to begin selling to non-medical
markets, in the third quarter of 2000 at the earliest, and to begin selling to
non-medical markets after obtaining FDA approval. However, there can be no
assurance that such submission will occur by such date or that the product will
be successfully developed.
SAT commissioned an unaffiliated consulting firm in June 1997 to review the
product. The consultant confirmed management's belief that the contemplated
product could be
13
14
developed and that, once developed, there was a significant market for such a
product, especially with the added alcohol testing capability. However, the
consultant estimated that it may take several months longer and a higher cost
than had been estimated by management to bring the product to market. See the
section "Need for Financing" under this caption "Business."
Once the product is submitted to the FDA, the Company will be able to market it
in the United States for non-medical purposes, such as law enforcement agencies'
testing and safety sensitive testing by industrial companies, and in Europe
where no FDA clearance is required. The Company will be able to commence
marketing of the product in medical markets when FDA clearance is obtained. The
Company anticipates such clearance to occur approximately 100 days (based on the
current experience of other companies at the FDA) after submission if such
approval is obtained. There can be no assurance as to when the Company will
submit such assay to the FDA, if at all, as to when the FDA will give its
clearance and as to when marketing in either medical or non-medical markets will
commence. Management recognizes that, although FDA clearance is not required for
use of drug testing for non-medical purposes, such as law enforcement agencies'
testing and industrial safety sensitive testing, FDA clearance of the product
will assist the Company's marketing in the United States to such customers. A
definitive marketing plan has not been finalized or implemented. See the
sections "Governmental Regulation" and "Marketing and Distribution" under this
caption "Business."
Management anticipates that the Company's saliva based drugs of abuse and
alcohol test will be evidentiary in the law enforcement market. In addition,
management expects that the Company's tests will be performed on a
non-evidentiary basis in the industrial marketplace. If a drug of abuse is
detected in the screening test, the sample may need to be forwarded to a
laboratory, where an expensive confirmatory analysis will be performed. Usually
gas chromatography/mass spectrometry ("GC/MS") is employed for the evidentiary
test. The Company's marketing analysis has indicated a greater market potential
for a saliva sample portable testing instrument for drugs of abuse by law
enforcement agencies, occupational health clinics, hospitals and other medical
facilities than a urine sample instrument. However, the use of this product in
other potential markets that are testing for transportation "lifestyle," such as
pre-employment testing, may be limited with the initial product.
Currently, to the Company's knowledge, no competitor is currently offering a
saliva sample testing product on an "on site" basis. However, management has
been advised that two or more companies may have such product under development,
although the technology they are using is very different from that of the
Company. There can be no assurance that a competitor will not begin to offer
such a product in the future, whether before or after the Company completes its
research and development. See the section "Competition" under this caption
"Business." There also can be no assurance that the Company's product will be
developed for use in the manner contemplated in this section.
NEED FOR FINANCING
As indicated in the section "History of the Company" under this caption
"Business," the Company temporarily suspended its product development activities
on September 19, 1997 because of SAT's cessation in August 1997 of providing
financing to the Company and SAT's subsequent filing for bankruptcy protection
on September 10, 1997. The Company was able to resume such activities on October
27, 1997 as a result of a loan by Meadow Lane that was repaid from the proceeds
from the private placement conducted by the
14
15
Company pursuant to Regulation D under the Securities Act described in the
succeeding paragraph.
On November 21, 1997, the Company closed as to the sale of 1,690,000 shares of
the Common Stock. On December 10, 1997, the Company closed as to the sale of an
additional 1,510,000 shares of the Common Stock. The aggregate of 3,200,000
shares was sold at $.50 per share and the Company realized $1,600,000 in gross
proceeds. There were no underwriting discounts or commissions allowed or paid
pursuant to the private placement. A finder's fee of $160,000 was paid to
Jonathan J. Pallin who was a member of Meadow Lane and who, on October 31, 1997,
was elected as the Chairman of the Board and a director of the Company.
On July 23, 1998, the Company closed as to the sale of 1,000,000 shares of the
Common Stock. On August 26, 1998, the Company sold an additional 25,000 shares
of the Common Stock. An aggregate of 1,025,000 shares of the Common Stock was,
accordingly, sold pursuant to this second private placement pursuant to
Regulation D under the Securities Act. This offering of a minimum of 1,000,000
and a maximum of 5,000,000 shares of the Common Stock expired by its terms on
October 14, 1998 without any additional shares being sold. The aggregate of
1,025,000 shares was sold at $1.00 per share and the Company realized $1,025,000
in gross proceeds. There were no underwriting discounts or commissions paid
related to the private placement. However, a Selling Stockholders Warrant
expiring December 13, 2003 to purchase 50,000 shares of the Common Stock at
$1.08 was granted to Ira Jay Mitchell for his assistance in completing $500,000
of this offering.
The Company has applied for three small business grants from the National
Institute of Health, in conjunction with Cedars Sinai Medial Center. If the
Company was to receive all three grants, the Company may receive up to
$3,000,000 in additional funding. However, there can be no assurance that the
Company will receive any of these grants.
On January 21, 1999, the Company closed as to the sale of 600,000 shares of the
Company's Series A 10% Cumulative Convertible Preferred Stock, $.001 par value
(the "Series A Preferred Stock"), pursuant to a third private placement pursuant
to Regulation D under the Securities Act. The aggregate of 600,000 shares was
sold at $10.00 per share and the Company realized $6,000,000 in gross proceeds.
Finders' fees were paid to various consultants and bankers for their assistance
in helping the Company to complete
15
16
this private placement. For their assistance in completing this private
placement, finders' fees were paid as follows:
SELLING STOCKHOLDERS
NAME OF FINDER CASH FEE WARRANTS(1)
- -------------- -------- --------------------
Alan Stone & Company.............................. $ 2,500 0
Ambient Capital Group, Inc........................ 0 10,000
Corporate Capital Management, L.L.C. ............. 10,000 14,000
Charles Dargan.................................... 20,000 56,000
Global Capital Corporation........................ 13,951 42,275
The Gramercy Partnership, L.L.C. ................. 72,169 144,338
The Kriegsman Group............................... 15,000 40,000
Libra Finance S.A. ............................... 13,951 42,275
Ira Jay Mitchell.................................. 0 50,000
Online Capital GmbH............................... 24,056 48,112
Jonathan J. Pallin................................ 420,451 0
-------- -------
Total................................... $592,078 447,000
- -------------------------
(1) All of these Selling Stockholders Warrants expire on January 20, 2004 and
have an exercise price of $2.41 per share.
Management believes that, with the net proceeds from the private placement
described in the preceding paragraph, the Company has sufficient funds to
complete the working prototype for the testing product for drugs of abuse and
alcohol and that the prototype will be completed not earlier than the first
quarter of 2000. There can be no assurance that management's estimate as to
costs and timing will be correct. Any delays may further increase the Company's
costs of development.
The latest estimate which management has is that completion of the development
and launching of a saliva based drugs of abuse and alcohol testing product after
the prototype will require an additional cost of approximately $7,000,000 beyond
the $6,000,000 recently completed funding and that the product will not be
launched earlier than the third quarter of 2000. This contrasts with SAT's June
1997 publicly announced incremental costs for the Company of $16,000,000 to
$18,000,000 (including the costs to develop the prototype) and a launch date of
the first quarter of 1999 at the earliest.
Since October 1997, management had been pursuing parallel paths for financing:
venture capital, strategic partnering, a public offering and/or a private
placement for all or part of the required funding.
Management had initially believed that one likely source for the additional
funding would have been an investment by a venture capital investor or
investors. Any such investment would have been likely to dilute substantially
the stock interest of the current stockholders. In addition, to make the
investment more attractive to potential venture capital investors, the Company
may have had to transfer its operations to a private subsidiary in which such
investor or investors could have invested. This is because venture capital
investors generally prefer the vehicle of an initial public offering as their
"out" strategy rather than invest in an already public company. Management does
not currently believe that an investment in the Company by a venture capital
investor to be a likely source of funding at this time.
16
17
Management has also been exploring the possibility of obtaining a strategic
partner for the Company. To this end, the Company has an agreement with Burrill
& Company ("Burrill"), a San Francisco-based merchant bank focused exclusively
on servicing life science companies. Burrill assists its portfolio companies in
maximizing their value through various strategic partnering relationships.
Burrill was founded by G. Stephen Burrill, an internationally recognized
financial, business, and management advisor to the life sciences industry. The
team is augmented by the Burrill's Business Advisory Board which includes a
group of former chief executives of major pharmaceutical, medical, and
diagnostic companies. Burrill has been engaged to introduce the Company to
potential partners with an on-going interest in saliva-based diagnostics or
point-of-care diagnostics and which might be otherwise interested in partnering
with or acquiring the Company.
As compensation for its services Burrill received a Selling Stockholders Warrant
expiring November 30, 2003 to purchase 250,000 shares of the Common Stock at
$1.15 per share (see "Description of Securities-Warrants"). Burrill is also paid
a monthly retainer of $10,000 per month during the one-year term of the
agreement, which term is terminable by either party on 60 days' notice to the
other party. If a strategic partner is obtained, Burrill is entitled to a
"success fee" varying by percentage of the value of the strategic alliance,
which is payable 20% in cash or in "freely tradeable" shares of the Common Stock
and the balance in the "currency of the transaction." Burrill is also entitled
to an additional Common Stock purchase warrant to purchase 250,000 shares of the
Common Stock at a specified exercise price.
Burrill has advised the Company that the process to ascertain and close with a
strategic partner may take five months or more. In addition, management believes
that a potential marketing partner could be obtained on more acceptable terms
when there is a working prototype for the instrument and the disposables and
certain preliminary clinical data are obtained. Management currently anticipates
that the prototype will be completed by the first quarter of 2000 at the
earliest.
Management has also pursued the possibility of an underwritten public offering
and has received expressions of interest from several well-known small national
and large regional firms. These firms have suggested, however, that the Company
wait to conduct such an offering until the working prototype is completed (the
first quarter of 2000 at the earliest). There can be no assurance that stock
market conditions would be receptive to a public offering by the Company at that
time. In addition, competitive conditions in the substance abuse testing
industry at that time may make the Company less attractive to potential public
investors. See the section "Competition" under this caption "Business."
Having successfully consummated three private placements pursuant to Regulation
D under the Securities Act since November 1997, the Company may seek to raise
the additional necessary financing through this method. As with a public
offering, there can be no assurance that potential investors would be receptive
to a private placement by the Company at that time, either because of general
stock market conditions or conditions generally in the substance abuse testing
industry.
There can be no assurance that the Company will be successful in securing
additional financing, whether through a strategic partner, a public offering or
a private placement.
If all of the Warrants and the Selling Stockholders Warrants to purchase an
aggregate of 3,095,741 shares of the Common Stock which were outstanding on
February 26, 1999 were subsequently exercised, the Company would realize
$2,901,882 in gross proceeds. If all of the Options to purchase an aggregate of
794,167 shares outstanding on February 26, 1999
17
18
were subsequently exercised, the Company would realize $397,084 in gross
proceeds. However, there can be no certainty as to when and if any of these
securities may be exercised, especially as to the Options and a Selling
Stockholders Warrant which were not all currently exercisable as of February 26,
1999. Accordingly, management believes that the Company cannot rely on these
exercises as a source of financing.
DRUG TESTING PRODUCTS
(1) URINE SAMPLE TESTING. The Company's original product was a Drugs of Abuse
test system, consisting of an instrument and a reusable column that would
test for any or all of five Drugs of Abuse. The life of each column was
expected to be between 50 and 75 tests. Testing on a urine sample took
approximately 20 minutes per drug selected. FDA clearance was obtained for
the five tests for Drugs of Abuse and the instrument. However, because
additional development work was required before this product could be
marketed, work on this product has been abandoned. As indicated in the
section "Seeking a Product-Preliminary Background" under this caption
"Business," the Company is focusing its efforts on the development of the
saliva sample testing product described below.
(2) SALIVA SAMPLE TESTING. Research is being conducted by the Company, using
the flow immunosensor technology, to test for drugs of abuse and alcohol
from saliva samples and for submission to the FDA for approval to use saliva
as a testing specimen. This research utilizes much of the development work
done for the Company's urine Drugs of Abuse testing system. See the section
"Government Regulation" under this caption "Business" for information as to
obtaining FDA clearance. Management anticipates that the earliest that the
saliva testing system and drugs assays for all five Drugs of Abuse and
alcohol will be ready for submission to the FDA is in the third quarter of
2000. There can be no assurance that the Company will meet such timetable.
(a) IMMUNOSENSOR ANALYZER. The Company anticipates manufacturing a small
portable device in conjunction with the flow immunosensor technology.
When used with the drug assays described below, the Company expects
that this unit will provide portable, flexible and non-invasive
detection capability when used with saliva samples. The Company expect
that the assay time will be under five minutes per sample. There can
be, however, no assurance that the Company will be able to complete the
development and then market this product.
(b) DRUG ASSAYS FOR IMMUNOSENSOR ANALYZER. The Company intends to develop
disposable assay cartridges for use with its desktop model using saliva
samples. After the sample has been collected, it will be automatically
transferred to an assay cartridge containing up to ten target analytes
(drugs of abuse and alcohol) in one panel, read by the instrument, and
the results printed. The disposable cartridge will be thrown away after
use, with the waste self-contained. Assay time is expected to be less
than five minutes per sample. The Company plans to continue its
research and development efforts for the drug assays concurrently with
the instrument. There can be no assurance that the Company will be able
to complete the development and then market the assay cartridges.
MANUFACTURING
Whenever the Company commences manufacturing, the Company will be required in
the United States to follow current Good Manufacturing Practices ("GMP") as
prescribed by the FDA. See the section "Government Regulation" under this
caption "Business." There
18
19
can be no assurance that the Company will be able to bring its plant into
compliance and/or cause its prospective third party manufacturers to comply with
GMP. The Company's future dependence on third parties for the manufacture and
supply of product components could have a material adverse effect on the
Company's profit margins and its ability to deliver its products on a timely and
competitive basis.
MARKETING AND DISTRIBUTION
Although the Company had engaged the services of a consultant to undertake a
marketing survey in 1995, because of the delays in the development of its
products due to the decision to have a test using a saliva sample, a definitive
marketing program has not been finalized or implemented. The Company will be
looking to employ a Vice President, Marketing to begin developing such a program
and to advise on the research and development program. The Company had engaged
such an officer in January 1997. However, because of SAT's failure to fund (see
the section "History of the Company" under this caption "Business"), her
services were terminated by the Company as an employee. She continues to furnish
services as a consultant on a project by project basis.
GOVERNMENT REGULATION
The Company's proposed medical screening and diagnostic products will be subject
to significant government regulation in the United States and other countries.
In order to conduct clinical tests, manufacture and market products for human
diagnostic use, the Company must comply with mandatory procedures and safety
standards established by the FDA and comparable foreign regulatory agencies.
Typically, such standards require that products be approved by the FDA, or by
comparable foreign regulatory agencies, as appropriate, as safe and as effective
for their intended use prior to being marketed.
The FDA regulates the introduction, manufacturing, labeling, record-keeping, and
advertising for all medical devices in the United States. There are two
principal methods by which FDA clearance may be obtained to market in the United
States medical device products such as the Company's proposed screening and
diagnostic test kits. One method is to seek FDA clearance through a pre-market
notification filing under Section 510(k) ("510(k)") of the Food, Drug and
Cosmetics Act. Applicants under the 510(k) procedure must prove that the device
for which approval is sought is "substantially equivalent" to devices on the
market prior to the Medical Device Amendments of 1976 or devices approved
thereafter pursuant to the 510(k) procedure. In some cases, data from clinical
studies must be included in the 510(k) application. The review period for a
510(k) application was supposed to be 90 days from the date of filing the
application. However, the FDA has recently been taking significantly longer in
approving other companies' products. Management believes that approximately 100
days has lately been the time period for approval.
If the 510(k) procedure is not available, then pre-market approval (the "PMA")
must be obtained from the FDA. Under the PMA procedure, the applicant must
obtain an Investigational Device Exemption (the "IDE") before beginning the
substantial clinical testing which is required to determine the safety, efficacy
and potential hazards of the product. Safety and efficacy must be established
through extensive clinical studies, which are conducted after the FDA's
acceptance of the IDE application. On completion of all of the requirements for
the IDE and once the results are evaluated, a PMA application is submitted to
the FDA. The review period under a PMA application is generally 180 days from
the date of filing. However, the application is not automatically deemed cleared
if not
19
20
rejected during that period. The FDA may grant marketing clearance, request
additional data about the product's safety and efficacy or deny the application
if it determines that the product does not meet the regulatory approval
criteria. In addition, the preparation of a PMA application is significantly
more complex and time consuming than the 510(k) procedure. Also the FDA's review
of a PMA is more extensive than that required for a 510(k) application. Based on
its discussions with the FDA, management believes that the 510(k) procedure will
be followed.
There can be no assurance that the FDA or any foreign governmental agency will
grant approval for the sale of the Company's products for routine screening and
diagnostic applications or that the length of time the approval process will
require will not be extensive.
The cost associated with the filing of applications with the FDA and of research
and development activities to support such applications, including clinical
trials, can be significant.
There can be no assurance that the costs of the Company's research and
development activities will not exceed that which is budgeted. In addition,
there can be no assurance that any of the Company's proposed products will ever
obtain the necessary FDA or foreign regulatory clearances for commercialization.
Pursuant to applications filed by the Company, to date, the Company had received
approval to manufacture and market the original urine test instrument and five
urine drug assays. However, as indicated in the section "Drug Testing Products"
under this caption "Business," because additional development work was necessary
before the product could be marketed, the Company has abandoned further
development work on this product. As indicated in the section "Seeking a
Product-Preliminary Background" under this caption "Business," the Company is
focusing its efforts on the development of the saliva sample testing product.
In addition, regulations implementing the Clinical Laboratory Improvement
Amendments of 1988 (the "CLIA") promulgated by the United States Department of
Health and Human Services (the "HHS") and the Health Care Financing
Administration on February 28, 1992, which were to become effective September 1,
1992, require that all employment drug testing, including on-site testing, be
processed by a federally approved laboratory. On August 28, 1992, the HHS
announced that the application of the CLIA to workplace testing would not go
into effect on September 1, 1992 because of comments made on the final
regulations. The comments raised questions about, among other things, whether
bringing employee drug testing under the CLIA might have an unintended chilling
effect on efforts to encourage drug-free workplace programs. As reported in the
January 19, 1993 Federal Register, the final decision on the regulations will be
delayed until further investigation is completed. Such decision has not been
made as of the date hereof.
The Company believes that these proposed CLIA regulations will not be made
effective because:
(1) the increased costs and burdensome procedures imposed by the CLIA will
significantly reduce the volume of drug tests conducted, which is in
direct conflict with the government's long-standing war on drugs;
(2) workplace testing is forensic in nature (i.e., for the purpose of
determining whether an individual is using illegal drugs) and not for
medical purposes (i.e., to
20
21
make a health assessment for diagnostic or treatment purposes) as was
the original intent of the CLIA; and
(3) inclusion of employment drug testing may be a direct violation of the
Federal Administrative Procedures Act under Title 5 of the United
States Code and the United States Constitution.
If the regulations are not adopted, on-site drug testing in the workplace will
continue to be exempt from the CLIA. Although the Company can obtain access to a
forensic laboratory, management believes that the consequences of adoption of
the regulations would add to a potential customer's costs and, accordingly, have
a material adverse impact upon the Company's business with respect to employment
testing in the private sector.
RESEARCH AND DEVELOPMENT
During the fiscal years ended March 31, 1998 ("fiscal 1998"), 1997 ("fiscal
1997"), and 1996 ("fiscal 1996"), the Company incurred approximately $1,052,000,
$1,735,000, and $949,000, respectively, in expenses for development of the
saliva drug testing technology. During the nine months ended December 31, 1998,
the Company incurred $818,000 in expenses for such research and development.
From October 8, 1992 (inception) to December 31, 1998, the Company has incurred
approximately $6,537,000 on development of the drug testing technology. See the
section "Need for Financing" under this caption "Business" for information as to
the estimated expenses to complete the product development.
PATENTS AND TECHNOLOGY
In addition to its rights under the USN patent license (see the section "Seeking
a Product-Preliminary Background" under this caption "Business"), the Company
has rights under the following patents:
(1) U.S. Patent No. 5,183,740, "Flow Immunosensor Method and Apparatus,"
issued on February 2, 1993;
(2) U.S. Patent No. 5,354,654, "Lyophilized Ligand-Receptor Complexes for
Assay and Sensors" issued on October 11, 1994; and
(3) On November 2, 1998, the Company filed a patent application (Patent
Application #09/183,295) which includes 26 claims for a saliva
aspiration system used for diagnostic purposes. Management believes
that this patent will provide broad patent protection for its unique
saliva collection system that has significant advantages over the
currently accepted method of absorption for saliva collection. The
Company is not certain whether and when this patent may issue.
The Company previously had rights to use Patent No. 5,066,859, "Hematocrit and
Oxygen Saturation Blood Analyzer," issued on November 19, 1992, but the
assignment agreement dated January 16, 1992 between and Maurice N. Karkur and
James C. Velnosky was terminated on November 7, 1996. Management does not
consider termination of the Company's rights to use this patent material to the
future development and marketing of the Company's products.
The expiration date of the USN patent is February 23, 2010. The terms of the
other patents are 17 years from the respective dates of issuance, subject to
renewal. Termination of the Licensing Agreement for the USN patent, which would
occur only on the Company's default, would end the Company's rights to develop
products under the patent.
21
22
Termination of the other patents or licenses to use the same would require the
Company to make changes to its products that could further delay development and
marketing thereof. For additional information, see the section "Material
Contracts" under this caption "Business."
The patent position of technology firms is highly uncertain and involves complex
legal and factual questions. Competitors have filed applications for, and in
some instances have been issued, patents and may obtain additional patents and
other proprietary rights relating to products or processes, such as the
Company's proposed immunoassay sensor, which may be competitive with those of
the Company. The Company does not currently know the scope and validity of these
patents. Management is not aware of any patents covering an immunoassay sensor
similar to the Company's.
Companies which have or may obtain patents relating to products or processes
competitive with those of the Company could bring legal actions against the
Company claiming damages and seeking to enjoin it from manufacturing, licensing
and marketing the affected product. To date, no claims have been made against
the Company for infringement of any patents. However, marketing of the Company's
products has not begun and claims, if any, would not likely be asserted until
market introduction of such products. If such a claim was to be made, its
defense would be costly and the Company's business would be adversely affected,
even if the Company were to prevail. No assurance can be given that the Company
would be able to prevail in any such action or that any license required under
any such patent would be made available on acceptable terms.
Process patents have certain disadvantages when compared with product patents.
It is more difficult to detect and prove infringement of process patents because
it is sometimes impossible to ascertain the method by which any product has been
produced. In addition, the value to the Company of receiving a process patent
may be reduced if products that can be derived from such processes have been
patented by others. The patents owned by, or licensed to, the Company include
both process patents and product patents.
The Company maintains a policy of seeking patent protection in the United States
and other countries in connection with certain elements of its technology when
it believes that such protection will benefit the Company. Lyophilization patent
applications have been filed in Canada, certain European countries and Japan.
The saliva aspiration patent has only been applied for in the United States. The
Company has one year to initiate filings of this patent in other countries.
The patent laws of foreign countries may differ from those of the United States
as to the patentability of the Company's products and processes. Accordingly,
the degree of protection afforded by foreign patents, if issued, may be
different from protection afforded under associated United States patents. There
can be no assurance that patents will be obtained either in the United States or
in foreign jurisdictions with respect to the Company's inventions or that, if
issued, the patents will be of substantial protection or commercial benefit to
the Company.
Certain inventions of the Company may prove to be unpatentable or the Company
may conclude that it would be more advisable to retain a patentable invention as
a trade secret. In either case, the Company would have to rely on trade secrets,
proprietary know how and continuing technological innovation to develop and
maintain its competitive position. All key employees and consultants of the
Company have executed, and project sponsors and manufacturers will be required
to execute, agreements to maintain the confidentiality of the Company's
proprietary information to which they have access. There can be no
22
23
assurance that these confidentiality agreements will be honored or will be
effective. Manufacturers, project sponsors and consultants may be engaged in
competing research projects outside the scope of their agreements with the
Company. There can be no assurance that such sponsors and consultants will not
develop similar or superior technology independently. To the extent that such
persons apply technical information independently developed by them to projects
undertaken by the Company, disputes may arise as to the proprietary rights to
such information.
COMPETITION
The Company has not generated any revenues to date because its products are
still in the developmental stage. If the products are developed, the Company
will compete with many of the companies of varying size that already exist or
may be founded in the future. The current tests available use either urine or
blood as a specimen to test for drugs of abuse or use breath or saliva to test
for alcohol. Management is not aware of any products that can currently perform
an on-site test for drugs in blood or saliva or that can test simultaneously for
drugs of abuse and alcohol. However, management recognizes that such products
may be developed in the future.
With respect to testing for the presence of alcohol, the Company will compete
with Intoxmeter, Inc., LifeLock, Inc. and other small manufacturers.
Although management is not aware of any current competitors with respect to
testing for drugs of abuse in saliva, management anticipates that the Company
will face competition from at least eight major companies that provide urine
substance abuse testing products: (1) enzyme-multiplied immunoassay technique
(EMIT) manufactured and distributed by Syva, a division of Dade International;
(2) radioimmunoassay (RIA) manufactured and distributed by Diagnostic Products
Corp. ("DPC") and others; (3) thin layer chromatography (TLC) manufactured and
distributed by Marion Laboratories, Inc. ("Marion"); (4) a fluorescence
polarization immunoassay (FPIA) manufactured by Abbott Laboratories, Inc.
("Abbott"); and (5) other immunoassay tests provided by Hoffman La Roche, Inc.
("Roche"), Editek, Inc. ("Editek"); Hycor Biomedical, Inc. ("Hycor"); Princeton
Biotech, Inc. ("Princeton"); and BioSite Inc. ("BioSite"). Almost all of these
companies (i.e., Syva, Roche, Marion, Abbott, Editek, Hycor, Princeton and
BioSite) have substantially greater financial resources available to them than
does the Company to develop and to market their products.
Management believes that saliva sample testing is unique in that, to
management's knowledge, no company is currently offering a substance abuse
detection method using saliva samples as a specimen on an "on-site" basis.
However, the Company has been advised that such a product may be under
development by two or more companies. Accordingly, there can be no assurance
that such a product will not be offered by a competitor. In addition, even if no
such product is developed, the Company anticipates, as indicated above,
competition from other substance abuse detection methods such as Syva's EMIT,
Roche's RIA, Marion's TLC, Abbott's FPIA methods, and other immunoassay tests
provided by Editek, Hycor, Princeton and BioSite.
The Company's market research to date has indicated a greater market potential
for a saliva sample portable testing instrument for use in detecting drugs of
abuse by law enforcement agencies, safety sensitive industrial companies,
hospitals and other medical facilities than a urine sample instrument. However,
because of the blood-equivalent, current status result, the use of this product
in other potential markets that require a "lifestyle" result may be limited.
23
24
If the Company successfully completes the development of its saliva sample
testing method, as to which there can be no assurance, the Company may not have
the financial resources to compete successfully with other companies which have
greater financial resources available to them. In addition, the Company's delay
in bringing a drugs of abuse and alcohol testing product to market may adversely
affect its future marketing efforts because of the name recognition gained by
competitors actively marketing a product during this interim period.
MATERIAL CONTRACTS
(a) LICENSE AND SUBLICENSE AGREEMENTS
With the sale of SAT's majority owned position in the Company (see the section
"History of the Company" under this caption "Business"), the USN agreed to
transfer its License Agreement with SAT directly to the Company. An amendment
dated November 12, 1997 to the License Agreement was executed to modify the
up-front $100,000 annual minimum payment so that it will be paid in several
payments over the year during 1998. The amendment also included a one-time
payment of $10,000 in satisfaction of any outstanding debt due to the USN from
SAT. The Company has assumed all of SAT's rights, and undertaken all of SAT's
obligations, under the License Agreement.
The License Agreement initially provided that the USN would be paid a royalty
equal to six percent of the Net Selling Price (as defined in the License
Agreement) for each Royalty-Bearing Product (as defined in the License
Agreement) made, used or sold by SAT or its sublicensees in the Licensed
Territory. There were minimum annual royalty payments of $180,000 for 1993,
$375,000 for 1994, $600,000 for 1995 and $1,000,000 for 1996 and each calendar
year thereafter throughout the term of the License Agreement. The License
Agreement provides that the USN shall approve all sublicenses and, in accordance
with such provision, the Sublicense was approved by the USN on September 24,
1993. As a result of the USN agreeing to the assignment of the License Agreement
to the Company as described in the preceding paragraph, the Sublicense was
canceled. The aforementioned minimum annual royalties were amended November 28,
1994 as follows: the minimum annual royalty for 1995 was reduced to $375,000 and
for 1996 it was reduced to $600,000. In June 1995, the License Agreement with
the USN was renegotiated and amended to provide for minimum annual royalties of
$100,000 per year commencing October 1, 1995 and terminating September 30, 2005.
Additional royalties will be paid pursuant to a schedule based upon sales of
products. By letter dated May 15, 1995, the USN notified SAT that, because the
expiration date of the USN patent had been extended to February 23, 2010 under
the GATT/WTO treaty, the expiration date of the License Agreement was extended
to February 23, 2010.
The Company and the USN are currently negotiating terms of the License Agreement
to include a worldwide license for diagnostic testing of all analytes in saliva.
(b) CRDA
On April 16, 1992, SAT entered into a 12-month cooperative research agreement
("CRDA") with the Naval Research Laboratory section of the USN (the "NRL") to
further develop the licensing technology of the "Flow Immunosensor".
Pursuant to an agreement dated as of January 1, 1993 by and between SAT and the
Company, SAT assigned to the Company all of its rights under the CRDA. The
purpose of the CRDA was to develop the prototype instruments based on the Flow
Immunosensor Method and Apparatus Technology. Pursuant to the CRDA, each party
retains title to any
24
25
patent obtained by such party in the performance of work under the CRDA. The NRL
had the right of first election to file a patent application in the United
States on joint inventions made in the performance of work under the CRDA. The
Company, as assignee, had the right of first election to file a patent
application on such joint inventions in all other countries.
Pursuant to an amendment dated May 1993 to the CRDA, the NRL waived such right
of first election with respect to the lyophilization process for the
freeze-drying of immunoassay chemicals, provided that SAT filed an approved
patent application on such process within three months from the date of
execution of the amendment. The approved patent application was filed on July
16, 1993 and issued as U.S. Patent No. 5,354,654 "Lyophilized Ligand-Receptor
Complexes for Assays and Sensors" on October 11, 1994. SAT assigned the patent
to the Company. See the section "Patents and Technology" under this caption
"Business."
(c) MANAGEMENT AGREEMENT
From April 1, 1993 until June 30, 1997, the Company paid SAT a management fee
pursuant to successive management agreements for services performed by SAT on
the Company's behalf. Such services included management, administrative,
accounting and other financial services and advice, including, without
limitation, the services then performed by the Treasurer of the Company (who was
also the Treasurer of SAT), for which he was not directly compensated by the
Company; services relating to the Company's financial and banking relationships;
services relating to the preparation of financial statements, budgets, forecasts
and cash flow projections; cash management advice; and other miscellaneous
services and advice. The management fee was discontinued after June 30, 1997
because no services were being provided after that date.
CERTAIN RELATIONSHIPS WITH SAT
From October 1992 until January 1993, SAT conducted the Company's business
operations. Effective January 1, 1993, SAT transferred to the Company all of its
drug testing assets, including cash amounting to $11,626 and hard assets valued
at their carrying value of $437,060 and intellectual property rights associated
with the drug testing operations, for 3,500,000 shares of the Common Stock. SAT
also granted the Company the Sublicense with respect to the USN technology.
As of September 30, 1997, SAT owned 76.4% of the outstanding shares of the
Common Stock. From incorporation on October 8, 1992 until October 31, 1997, all
directors of the Company were also directors and security holders of SAT. In
addition, during that period executive officers of SAT also served as executive
officers of the Company.
As a result of the sale by SAT to Meadow Lane of the controlling stockholder
interest in the Company and their relationship to SAT, on October 31, 1997,
Robert M. Stutman and Michael S. McCord resigned as directors of the Company,
with Mr. Stutman also resigning as its Chairman of the Board. Messrs. Stutman
and McCord were directors of SAT, with Mr. Stutman also serving as SAT's
Chairman of the Board and Chief Executive Officer. At the same meeting, Jonathan
J. Pallin who, as the transferee of Meadow Lane, is the beneficial owner of
4,625,595 shares of the Common Stock or 38.2% of the outstanding shares as of
January 29, 1999, was elected as the Chairman of the Board and a director of the
Company. Since October 16, 1997, Mr. Pallin had been serving as a financial
consultant to the Company. In addition, Robert Muccini resigned as the Vice
President, Finance, the Treasurer, the Chief Financial Officer and the Chief
25
26
Accounting Officer of the Company because he held comparable positions with SAT.
No person has been appointed in the Company as yet to replace Mr. Muccini. Linda
H. Masterson, the President, the Chief Executive Officer and a director of the
Company, resigned on November 4, 1997 as a director of SAT, thereby severing the
final interlocking relationship between the Company and SAT.
Since October 31, 1997, the Company has sole responsibility for its
administrative and financial operations, with independent directors and
executive officers and no management service arrangements with SAT.
SAT had filed in February 1996 a Registration Statement on Form S-4 under the
Securities Act to merge the Company with and into a wholly-owned subsidiary of
SAT (the "LifePoint Merger"). In consideration of their consent to such merger,
the minority stockholders of the Company were to receive shares of the SAT
Common Stock. As a result of SAT's bankruptcy and its subsequent sale of its
shares of the Common Stock to Meadow Lane, this SAT proposal to take the Company
private was abandoned.
LOANS FROM SAT TO THE COMPANY
SAT had authorized loans to the Company not to exceed $2,000,000. The loans bore
interest at the rate of 8% per annum and were to become due on the earlier of
(1) five business days after the date the proposal for the then minority
stockholders of the Company to consent to the LifePoint Merger was rejected or
(2) the effective date of the LifePoint Merger. On May 23, 1997, the SAT Board
and, on May 26, 1997, the Company's Board authorized the capitalization of
$2,210,250 in indebtedness (including interest) owed by the Company to SAT as of
April 30, 1997, in consideration of the issuance by the Company to SAT of
1,768,202 shares of the Common Stock. These shares are included in the 2,075,306
shares described in the succeeding paragraph. The Boards had also authorized the
additional investment by SAT of $2,500,000 in exchange for 2,000,000 shares of
the Common Stock on the same basis of one share of the Common Stock for each
$1.25 of investment. On May 26, 1997, the Board of Directors of the Company
authorized the issuance of additional shares of the Common Stock to SAT on the
basis of a share of the Common Stock for each $1.25 of indebtedness owed by the
Company to SAT. As a result of SAT's inability to obtain its own financing, SAT
notified the Company in July 1997 that it would cease advances to the Company in
August 1997.
Based on SAT's advice that the amount of indebtedness owed by the Company to SAT
was $2,594,133, all of which SAT agreed to treat as a capital contribution, the
Company authorized the issuance to SAT of 2,075,306 shares of the Common Stock.
Such shares were issued as of June 30, 1997 prior to the sale of the shares of
the Common Stock held by SAT to Meadow Lane. Subsequent to the sale, SAT advised
the Company that the amount of indebtedness was $3,426,994. As such, the
forgiveness of the remaining indebtedness to SAT of $832,861 was reflected as
additional paid in capital as of September 30, 1997.
Recognizing that had SAT correctly reported the Company's indebtedness to SAT,
an additional 666,289 shares of the Common Stock would have been issued to SAT
and then sold to Meadow Lane, the Company's Board, on January 8, 1998,
authorized the issuance to Meadow Lane of a Common Stock purchase warrant
expiring January 7, 2003 (the "Meadow Lane Warrant") to purchase 666,289 shares
of the Common Stock at $.50 per share. The Board concluded that, as a result of
structuring the transaction in this manner, Meadow Lane would receive what it
thought it was buying, i.e., all of SAT's shares in the
26
27
Company, and the Company, not SAT, would receive $383,144 if the Meadow Lane
Warrant was exercised.
TRANSFER OF ASSETS FROM SAT TO THE COMPANY
Included in the indebtedness that was converted to additional paid in capital as
noted above was approximately $345,000 relating to the purchase by the Company
of various fixed assets from SAT at the Rancho Cucamonga, California premises.
Certain of these assets, as well as other assets already owned by the Company,
were not required for the ongoing operations of the Company and were
subsequently sold for gross proceeds of approximately $126,000.
EMPLOYEES
As of February 26, 1999, the Company employed 10 employees, of whom 8 were
directly involved in its research and development program. Additional personnel
will be required to complete the development project and, if the project is
completed successfully, to manufacture the product.
Prior to October 31, 1997, the Company was dependent on SAT for fulfilling its
accounting and other financial requirements. Since that date the Company has
used an outside accounting firm to prepare its financial statements. The Company
plans to add its own internal accounting and financial staff. As a result of the
private placement in January 1999, the Company is currently seeking to engage
the services first of a Chief Accounting Officer and subsequently a Chief
Financial Officer.
PROPERTIES
The Company maintains its principal executive offices, manufacturing space and
laboratory facilities in Rancho Cucamonga, California. The premises, which
consist of approximately 10,000 square feet, are leased at $72,000 per year
pursuant to a lease that expires March 31, 2002. Management believes that
additional space will be required when and if manufacturing of the drug and
alcohol test product commences.
LEGAL PROCEEDINGS
The Company is not a party to any material litigation and is not aware of any
pending litigation or contemplated proceedings by any governmental authority
that could have a material adverse effect on the Company's business, results of
operations or financial condition.
MARKET FOR THE COMMON STOCK AND RELATED STOCKHOLDER MATTERS
EXCHANGE MARKET DATA
The Common Stock was traded on the Pacific Exchange, Inc. (the "Pacific
Exchange") under the symbol "U.S.D.P" until May 12, 1997 when trading was
suspended because the Company failed to meet the Pacific Exchange's maintenance
criteria. The quarterly high
27
28
and low sales prices for the Common Stock as reported by the Pacific Exchange
are set forth below during the period indicated:
QUARTER ENDED HIGH LOW
- ------------- ------ ------
FISCAL 1996
June 30, 1995........................................ $ 5.50 $ 2.50
September 30, 1995................................... 4.75 2.50
December 31, 1995.................................... 4.50 2.625
March 31, 1996....................................... 4.50 3.00
FISCAL 1997
June 30, 1996........................................ $ 4.25 $ 3.50
September 30, 1996................................... 3.75 2.375
December 31, 1996.................................... 2.875 0.75
March 31, 1997....................................... * *
- -------------------------
* According to the National Quotation Bureau, Inc., there were no sales reported
during the quarter ended March 31, 1997 and the high bid and low asked prices
were $1.875 and $2.00, respectively. These quotations reflected inter-dealer
process, without retail mark-up, mark-down or commission, and may not have
represented actual transactions. On May 12, 1997, the last day on which there
was a reported market price, the closing sale price was $1.6875 per share.
Effective October 28, 1997, the Commission granted the Pacific Exchange's
application to delist and deregister the Common Stock under Section 12(b) of the
Exchange Act.
SUBSEQUENT TRADING
Effective February 4, 1998, the Company registered the Common Stock under
Section 12(g) of the Exchange Act. On February 13, 1998, a broker-dealer filed a
Rule 15c2-11 notice with the National Association of Securities Dealers, Inc.
(the "NASD") to initiate quotations with respect to the Common Stock. The Common
Stock was subsequently quoted on the NASD's OTC Bulletin Board under the symbol:
LFPT. Based on its latest reported financial statements, the Company does not
currently meet the entry requirements for the Nasdaq system or any major
national securities exchange. Secondary trading (i.e., by its stockholders) is
currently permissible in 50 states and the District of Columbia.
OVER-THE-COUNTER MARKET DATA
There have been quotations in the over-the-counter market for the Common Stock
since June 25, 1998. The quarterly high bid and low asked prices as quoted by
the NASD's
28
29
OTC Bulletin Board for the fiscal year ending March 31, 1999 ("fiscal 1999") are
as follows:
QUARTER ENDED HIGH LOW
- ------------- ----- ------
June 30, 1998(1)...................................... $0.50 $ 1.50
September 30, 1998.................................... 2.75 1.00
December 31, 1998..................................... 1.75 0.75
March 31, 1999(2)..................................... 4.00 2.375
- -------------------------
(1) June 25 to 30, 1998 only.
(2) Through February 26, 1999.
The foregoing quotations reflected inter-dealer prices, without retail mark-up,
mark-down or commission, and may not have represented actual transactions.
The high bid and low asked prices of the Common Stock on March 23, 1999 were
$2.60 and $2.375, respectively, as reported by the NASD's OTC Bulletin Board.
"PENNY STOCK" RULES
Because the bid price of the Common Stock has been below $5.00 per share, the
security has become subject to Rule 15g-9 promulgated under the Exchange Act.
This Rule imposes additional sales practices requirements on a broker-dealer
which sells Rule 15g-9 securities to persons other than the broker-dealer's
established customers and institutional accredited investors (as such term is
defined in Rule 501(a) under the Securities Act). For transactions covered under
Rule 15g-9, the broker-dealer must make a suitability determination of the
purchaser and receive the purchaser's written agreement to the transaction prior
to the sale. In addition, broker-dealers, particularly if they are market makers
in the Common Stock, have to comply with the disclosure requirements of Rules
15g-2, 15g-3, 15g-4, 15g-5 and 15g-6 under the Exchange Act unless the
transaction is exempt under Rule 15g-1. Consequently, Rule 15g-9 and these other
Rules may adversely affect the ability of broker-dealers to sell or to make
markets in the Common Stock and also may adversely affect the ability of
purchasers of the shares offered by this prospectus to resell their shares.
HOLDERS
As of February 26, 1999, there were 128 holders of record and, based on requests
for copies in connection with the last Annual Meeting of Stockholders, the
Company believes that there are approximately 750 beneficial owners of the
Common Stock.
DIVIDENDS
The Board of Directors has not declared any dividends on the Common Stock and,
in view of the continuing losses, the Company's cash requirements, and the
provisions of the Series A Preferred Stock, the Board has no current intention
to pay any such dividends.
29
30
MANAGEMENT
DIRECTORS AND EXECUTIVE OFFICERS
The following table contains certain information relating to the directors and
executive officers of the Company as of February 26, 1999:
NAME AGE POSITION
- ---- --- --------
Linda H. Masterson................... 47 Chief Executive Officer, President and a
director
Thomas J. Foley...................... 59 Vice President, Research and Development
Peter S. Gold........................ 74 Director
Jonathan J. Pallin................... 49 Director
Paul Sandler......................... 59 Director
Each director of the Company is elected to serve until the next Annual Meeting
of Stockholders or until his or her successor is elected and shall have
qualified. Each director listed above was reelected at the Annual Meeting of
Stockholders held on August 13, 1998. Each officer of the Company is elected by
the Board of Directors to serve at the discretion of the Board.
BUSINESS HISTORY
Linda H. Masterson has had substantial experience in marketing, sales and
business development in the medical diagnostics, healthcare and biotechnology
fields. She was elected a director of SAT on September 26, 1995. Effective May
13, 1996, she became the President and Chief Operating Officer of SAT. On May
31, 1996, she was elected a director of the Company and, on July 31, 1996, the
President and Chief Operating Officer of the Company. Effective November 19,
1996, she relinquished her duties as the Chief Operating Officer of SAT in order
to devote more time to supervising the development program of the Company and
the operations of the then Alcohol Products and BioTox Divisions of SAT. On May
23, 1997, she resigned as the President of SAT in order to become the Chief
Executive Officer of the Company (formally designated as such on May 26, 1997).
On November 4, 1997, she resigned as a director of SAT, thereby terminating her
last position with the former parent of the Company. Until May 13, 1996 when she
became an employee of SAT, she was employed as the Executive Vice President of
Cholestech, Inc., a start-up diagnostic company, for which she developed and
restructured the company's business strategy. In November 1993, Ms. Masterson
founded Masterson & Associates, a company of which she was the President and
owner until she joined Cholestech, Inc. in May 1994, which was engaged in the
business of providing advice to start-up companies, including the preparation of
technology and market assessments and the preparation of strategic and five-year
business plans for biotech, medical device, pharmaceutical and software
applications companies. From April 1992 to November 1993, Ms. Masterson was
employed as the Vice President of Marketing and Sales of BioStar, Inc., a
start-up biotech company focused on the commercialization of a new detection
technology applicable to both immunoassay and hybridization based systems. From
1989 to 1992, she was employed as Senior Vice President of Marketing, Sales and
Business Development by Gen-Probe, Inc., a specialized genetic probe
biotechnology company focused on infectious diseases, cancer and therapeutics.
Prior to 1989, Ms. Masterson was employed for 12 years in various domestic and
international marketing and sales positions at Johnson & Johnson, Inc., Baxter
International Inc. and Warner Lambert Co. Ms. Masterson has a BS in Medical
Technology from the University of
30
31
Rhode Island, an MS in Microbiology/Biochemistry from the University of Maryland
and attended the Executive Advanced Management Program at the Wharton School of
Business at the University of Pennsylvania.
Thomas J. Foley has over 25 years' experience in the medical diagnostic
industry. He was elected to an officership in the Company effective March 9,
1998. From November 1997 to March 1998, he was a consultant to various
companies. From November 1994 to November 1997, he served as the Executive Vice
President of Business and Product Development at HiChem/Elan Diagnostics
("HiChem"), where he managed research and development, regulatory affairs
(including FDA submissions), strategic and business planning, technology
assessment for acquisitions, and manufacturing operations. Prior to joining
HiChem in November 1994, Dr. Foley was Vice President of Research and
Development at Hycor Biomedical, Inc. ("Hycor"), where he was responsible for
research and development of all products, including drugs of abuse products,
over an eight-year period from May 1986 to November 1994. Prior to Hycor, Dr.
Foley was Vice President of Research and Development at Gilford Instruments from
1983 to 1986 and Worthington Diagnostics from 1981 to 1983. Prior to Worthington
Diagnostics, Dr. Foley worked at Beckman Instruments, Inc. and was the chemistry
product development manager for the Astra, one of Beckman's most successful
product lines. Dr. Foley has a Ph.D. in Biochemistry from Trinity College,
Dublin.
Peter S. Gold was elected as a director of the Company on December 5, 1997. He
retired in 1988 as Chairman and Chief Executive Officer of Price Pfister, Inc.,
the largest manufacturer of faucets in the world. Mr. Gold did a leveraged
buyout and purchased the company in 1983; he subsequently took the company
public in 1987; and sold the company in 1988. Price Pfister is now owned by
Black & Decker. Mr. Gold is a Director Emeritus of The Home Depot, Inc. and has
major investments in commercial real estate in various parts of the United
States. Mr. Gold is Chairman of the Board of Trustees of Pitzer College
(Claremont College), Claremont, CA, and a member of the Board of Trustees of the
City of Hope. Mr. Gold received a Doctor of Humane Letters from Pitzer College,
Claremont, CA, and received a law degree at Southwestern University, Los
Angeles, CA.
Jonathan J. Pallin was elected Chairman of the Board and a director of the
Company on October 31, 1997. He resigned as the Chairman of the Board on January
8, 1999. He continued to serve the Company as a financial consultant until March
31, 1999. He has over 22 years experience in the financial markets as an
institutional fixed income broker, financial consultant, and served in an
investment banking advisory role. Mr. Pallin served as Senior Vice President,
Retail Brokerage for PaineWebber Incorporated from January 1991 to July 1993, as
a Senior Vice President Investments, Retail Brokerage for Baraban Securities
Incorporated from July 1993 to May 1996 and as a Vice President, Retail
Brokerage for Sutro & Co. Incorporated from May 1996 to October 1997. Mr. Pallin
has an MBA from Arizona State University with a major emphasis on Accounting,
and a BS from Long Island University (Southampton) in Business and Psychology.
Paul Sandler was elected as a director of the Company on December 5, 1997. He is
a Board Certified pediatric nephrologist at the Arizona Kidney Disease &
Hypertension Center in Phoenix. Additionally, Dr. Sandler is the Medical
Director at Walter Boswell Memorial Hospital, the Phoenix Artificial Kidney
Center, and South Phoenix Dialysis Center, the South Mountain Dialysis Services,
and Phoenix Memorial Hospital PPG. Dr. Sandler was a fellow at Albert Einstein
College of Medicine in New York City, and received his post-graduate training at
Kings County Hospital, New York City. Dr. Sandler
31
32
received his MD at the State University of New York, and received his BA from
Emory University.
FAMILY RELATIONSHIPS
Jonathan J. Pallin and Paul Sandler are brothers-in-law. There are no other
family relationships between the officers and directors of the Company.
SUMMARY COMPENSATION TABLE
The following table provides certain summary information concerning compensation
paid or accrued by the Corporation during fiscal 1998, fiscal 1997 and fiscal
1996 to any person who served as Chief Executive Officer during fiscal 1998 and
to each other executive officer whose total annual salary and bonus exceeded
$100,000 during any such year.
LONG TERM COMPENSATION
OTHER -----------------------
ANNUAL COMPENSATION ANNUAL SECURITIES ALL
------------------- COMPEN- UNDERLYING OTHER
NAME AND PRINCIPAL POSITION YEAR SALARY BONUS SATION COMPENSATION OPTIONS
- --------------------------- ---- -------- -------- -------- ------------ --------
Robert M. Stutman......... 1998 $ 0(2)
Chief Executive Officer 1997 0(2)
and Chairman(1) 1996 0(2)
Linda H. Masterson........ 1998 125,249(4) 700,000
Chief Executive Officer 1997 0(5)
and President(3) 1996 0(5)
Stephen J. Kline.......... 1998 20,131(7) 150,000(8)
Vice President, Research 1997 125,000 50,000(8)
and Development(6) 1996 117,000 10,000(8)
- -------------------------
(1) Mr. Stutman served as Chief Executive Officer of the Company from May 31,
1996 until May 26, 1997 and as Chairman of the Board of the Company from May
31, 1996 to October 31, 1997.
(2) Mr. Stutman's salary was paid entirely by SAT and, to the extent his
services were on behalf of the Company, this was reflected in SAT's
management fee to the Company.
(3) Ms. Masterson was elected President of the Company effective August 1, 1996
and designated as its Chief Executive Officer on May 26, 1997.
(4) The amount shown in the table does not reflect $33,654 paid by SAT to Ms.
Masterson for the period April 1 to June 1, 1997 nor $19,385 in deferred
salary which was paid in October 1998. Effective August 11, 1997, the
Company directly paid all compensation for Ms. Masterson.
(5) Ms. Masterson became an employee of SAT on May 13, 1996 and all compensation
paid to her for fiscal 1997 was paid by SAT. To the extent any such services
were on behalf of the Company, this was reflected in SAT's management fee to
the Company.
(6) Mr. Kline resigned on September 12, 1997.
(7) The amount shown in the table does not reflect $50,000 paid by SAT to Mr.
Kline during fiscal 1998.
(8) These options were canceled upon his resignation. See Note (6) to this
table.
32
33
OPTION/SAR GRANTS
On August 14, 1997, the Board of Directors adopted, subject to stockholder
approval, the Stock Option Plan providing for the granting of Options to
purchase up to 1,000,000 shares of the Common Stock to employees (including
officers) and persons who also serve as directors and consultants of the
Company. On June 5, 1998, the Board increased the number of shares subject to
the Stock Option Plan to 2,000,000, again subject to stockholder approval.
Stockholder approval was given on August 13, 1998. The Options may either be
incentive stock options as defined in Section 422 of the Internal Revenue Code
of 1986, as amended (the "Code") to be granted to employees or nonqualified
stock options to be granted to employees, directors or consultants.
As of February 26, 1999, Options to purchase an aggregate of 794,167 shares of
the Common Stock granted to employees (including officers) were outstanding. As
of such date, Options to purchase an aggregate of 41,197 shares of the Common
Stock had been exercised and Options to purchase an aggregate of 85,509 shares
of the Common Stock were then exercisable. Options granted to date under the
Stock Option Plan have generally become exercisable as to one-quarter of the
shares subject thereto on the first anniversary date of the date of grant and as
to 1/36th of the remaining shares on such calendar day each month thereafter for
a period of 36 months. Certain Options will become exercisable upon the
achievement of certain goals. The exercise price per share for incentive stock
options under the Code may not be less than 100% of the fair market value per
share of the Common Stock on the date of grant. For nonqualified stock options,
the exercise price per share may not be less than 85% of such fair market value.
No Option may have a term in excess of ten years. Of the Options outstanding as
of February 26, 1999, all were incentive stock options except for Options to
purchase an aggregate of 120,000 shares and all had an exercise price of $.50
per share. The Options had expiration dates ranging from August 13, 2002 to June
4, 2003.
The Company has never granted any stock appreciation rights.
The following table shows the number of shares made subject to a stock option
and a Common Stock purchase warrant granted during fiscal 1998 to Linda H.
Masterson, the sole executive officer of the Company (i.e., its Chief Executive
Officer) whose compensation exceeded $100,000 in that fiscal year. No stock
options or Common Stock purchase warrants were ever granted to Robert M. Stutman
who served as Chief Executive Officer of the Company for part of fiscal 1998
(see the section "Summary Compensation Table" under this caption "Management").
Options granted to Steven J. Kline as shown in the Summary Compensation Table
were canceled as indicated in Note (8) to that table. He was never granted any
Common Stock purchase warrants.
33
34
INDIVIDUAL GRANTS TO LINDA H. MASTERSON
- ---------------------------------------------------- ALTERNATIVE
TO (F) AND
(G): GRANT
PERCENT POTENTIAL REALIZABLE DATE VALUE
OF TOTAL VALUE AT ASSUMED -------------
NUMBER OF OPTIONS/SARS ANNUAL RATES OF STOCK
SECURITIES GRANTED TO PRICE APPRECIATION FOR
UNDERLYING EMPLOYEES EXERCISE OF OPTION TERM GRANT DATE
OPTIONS/SARS IN FISCAL BASE PRICE EXPIRATION ---------------------- PRESENT
GRANTED(#) YEAR ($/SH) DATE 5%($) 10%($) VALUE $
(B) (C) (D) (E) (F) (G) (H)
- ------------ ------------ ----------- ---------- ---------- ---------- -------------
300,000 31.6% $.50(1) 8/13/07 244,344 389,061 $150,000(2)
400,000 42.1% $.50 10/26/02 255,256 322,102 $200,000(2)
- -------------------------
(1) Reduced from $1.25 to $.50 per share on December 5, 1997. See the section
"Report on Repricing of Options/SAR" under this caption "Management."
(2) Because there were no market prices for the Common Stock reported on the
respective date of grant, the sales price per share (i.e., $.50) in the
October to December 1997 private placement was used for valuation purposes.
AGGREGATE OPTION/SAR EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR-END
OPTION/SAR VALUES
There were no stock options exercised during fiscal 1998 and, as indicated in
the preceding section, the Company has never granted any stock appreciation
rights.
The following table shows the fiscal year-end option values for Linda H.
Masterson, the sole executive officer whose compensation for fiscal 1998
exceeded $100,000 as reported in the Summary Compensation Table under this
caption "Management." The options reported for another officer in such table
have been terminated. Robert M. Stutman, a former Chief Executive Officer, never
received any options or Common Stock purchase warrants.
CEO'S FY-END OPTION VALUES
NUMBER OF SECURITIES VALUE OF UNEXERCISED
UNDERLYING UNEXERCISED IN-THE-MONEY OPTIONS
OPTIONS AT FISCAL YEAR-END AT FISCAL YEAR END
(#)EXERCISABLE/UNEXERCISABLE ($)EXERCISABLE/UNEXERCISABLE
- ---------------------------- ----------------------------
200,000/500,000 $100,000/$250,000(1)
- -------------------------
(1) Because there were no market prices for the Common Stock reported at March
31, 1998, the sales price per share (i.e., $.50) in the October to December
1997 private placement was used for valuation purposes.
REPORT ON REPRICING OF OPTIONS/SARS
On August 14, 1997, Options to purchase an aggregate of 467,500 shares of the
Common Stock were granted to employees of the Company with an exercise price of
$1.25, which reflected the value of the Common Stock when trading on the Pacific
Exchange was suspended on May 12, 1997. A private placement was initiated and
completed during November and December 1997. See "Business -- Need for
Financing." On December 5,
34
35
1997, the Board of Directors re-priced the Options to the then current value of
$0.50 per share, which was the purchase price in the private placement.
OTHER COMPENSATION
The Company currently has no pension plan in effect and has in effect no
restricted stock plan, no stock appreciation rights nor any other long-term
incentive plan under which grants or allocations may be made in fiscal 1999 or
thereafter.
DIRECTOR COMPENSATION
The Company currently does not compensate the Board of Directors for their
services as directors to the Company. On January 8, 1999, the Board authorized
Robert W. Berend, the Company's Secretary and corporate counsel, to make a study
of what would be appropriate compensation for directors who were not employees
of the Company and to make a report to the Board for implementation after the
then pending private placement was consummated. See the section "Certain
Relationships and Related Transactions" under this caption "Management" for
information as to a compensation arrangement with Jonathan J. Pallin for his
former services as Chairman of the Board and currently as a financial consultant
to the Company.
EMPLOYMENT AND SEVERANCE AGREEMENTS
There are no employment agreements currently in effect in the Company.
Pursuant to a Severance Agreement dated as of October 27, 1997 (the "Masterson
Severance Agreement") between the Company and Linda H. Masterson, the Company
has agreed to pay Ms. Masterson for her services as Chief Executive Officer and
President of the Company a base salary of $165,000; provided, however, such
amount was to be $120,000 from October 27, 1997 to the date at least $5,000,000
in long term financing was obtained, at which time or upon her termination the
difference was to be paid to her. As a result of the consummation of the
Company's third private placement on January 21, 1999 (see "Business-Need for
Financing") this limitation has been ended and, effective January 29, 1999, she
is being paid at the authorized rate. $43,269 of the difference was paid to her
in October 1998.
The Masterson Severance Agreement also provided for the grant of:
(1) a stock option under the Stock Option Plan to purchase 150,000 shares
of the Common Stock at $.50 per share, the option to become immediately
exercisable as to all shares subject thereto in the event she is
terminated without cause, the Company is acquired or sold without the
Board's approval, the corporate headquarters are moved outside the
State of California, the positions of Chief Executive Officer or
President are eliminated or her duties are substantially changed;
(2) stock options to purchase 150,000 shares of the Common Stock, an option
to purchase 75,000 shares to be granted upon completion of the working
pilot plant project and an option to purchase 75,000 shares to be
granted upon product release into the first targeted market; and
(3) Common Stock purchase warrants to purchase 400,000 shares of the Stock
at $.50 per share, a warrant to purchase 200,000 shares which was
granted upon the purchase of SAT's shares by Meadow Lane and a warrant
to purchase 200,000
35
36
shares to be granted at the completion of the long term financing of at
least $5,000,000.
The stock options have all been granted as Options under the Stock Option Plan.
Also as a result of the private placement referred to in the preceding
paragraph, the second warrant has now become exercisable.
In the event that Ms. Masterson is terminated without cause (as defined in the
Masterson Severance Agreement), she will be paid severance pay in a lump sum
amount equal to her annual base salary that would have been paid to her had she
not been terminated during the period between the date of termination and
October 27, 2001.
The Company had a Severance Agreement dated as of October 24, 1997 (the "Benken
Severance Agreement") with William B. Benken, the then Vice President,
Operations of the Company. Because Mr. Benken was terminated for cause on
October 7, 1998, the Benken Severance Agreement did not become operative.
COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION
Because the Company was a majority-owned subsidiary of SAT during fiscal 1998
and, accordingly, the Company's employees participated in the benefit plans of
SAT, there was no Compensation Committee in the Company. On December 5, 1997,
after the sale by SAT of its majority interest in the Company, the Board
appointed Peter S. Gold, Paul Sandler and Joseph R. Shaya, the three then
non-employee, non-officer directors as members of the Compensation Committee,
with Dr. Sandler as the Chairman. Mr. Shaya subsequently resigned as a director,
for personal reasons, effective March 20, 1998. Such two appointments were
reconfirmed by the Board at its Annual Meeting on August 13, 1998.
BOARD COMPENSATION COMMITTEE REPORT ON EXECUTIVE COMPENSATION
Until October 31, 1997, all decisions as to executive compensation for the
Company were made by the SAT Board of Directors or Compensation Committee as
part of SAT's compensation planning for officers of SAT and its subsidiaries
(including the Company) and because all financing for the Company came from SAT.
Although, as indicated in the preceding section, a Compensation Committee was
appointed in December 1997, the independent directors elected simultaneously
with their appointment to such Committee determined to leave executive
compensation "as is" for at least the balance of fiscal 1998 as they become more
familiar with the Company and its executive officers.
PERFORMANCE GRAPH
Market activity in the Common Stock was limited during fiscal 1998 and 1997 (see
"Market for the Common Stock and Related Stockholder Matters -- Exchange Market
Data"). The market activity was undoubtedly influenced by SAT's proposal to take
the Company private first announced in February 1996 and the uncertainty as to
the Company's survival as a development stage enterprise because of SAT's
inability to fund. Accordingly, management concluded that a performance graph as
required by Item 402(1) of Regulation S-K under the Securities Act would be
misleading and, as a result, inappropriate for inclusion in the Company's Annual
Report on Form 10-K for fiscal 1998. Management also noted that such a graph
would not be required for a "small business issuer" under Regulation S-B and
that the Company would qualify as a "small business issuer" except for its prior
ownership by SAT.
36
37
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
See the sections "Material Contracts" and "Certain Relationships with SAT" under
the caption "Business" for information as to transactions between the Company
and SAT, its major stockholder, during fiscal 1998.
See the section "Employment and Severance Agreements" under this caption
"Management" for information relating to the severance agreements with Linda H.
Masterson, the President, the Chief Executive Officer and a director of the
Company, and William B. Benken, the former Vice President, Operations of the
Company.
As indicated in "Business -- Need for Financing," Jonathan J. Pallin, the
Chairman of the Board from October 31, 1997 until January 8, 1999 and a director
of the Company, received a finder's fee of $160,000 for a private placement,
which fee was authorized prior to his being elected to such positions.
On April 28, 1998, the Board authorized the following compensation arrangement
for Mr. Pallin for his services on a daily basis as Chairman of the Board of the
Company:
(1) a fee of $10,000 per month for a one-year period commencing April 1,
1998 and
(2) a bonus of (a) $75,000 if the Company obtains cash financing of
$5,000,000 to $6,900,000; (b) $100,000 if the Company obtains cash
financing of $7,000,000 to $9,900,000; and (c) $125,000 if the Company
obtains cash financing of over $10,000,000, subject to certain
limitations.
On January 8, 1999, the Board accepted the resignation of Mr. Pallin as the
Chairman of the Board, canceled the foregoing bonus compensation arrangement and
authorized his engagement as a financial consultant to the Company on the
following terms:
(1) he would continue to receive $10,000 per month through March 31, 1999
on the basis he would continue to serve the Company on a daily basis as
a financial consultant and
(2) he would receive a finder's fee of 10% of the gross proceeds from any
purchaser whom or which he secured for a Company financing.
He received $420,451 as his finder's fee for the Company's third private
placement closed on January 21, 1999 (see "Business -- Need for Financing").
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth, as of February 26, 1999, certain information
with respect to (1) any person who beneficially owned more than 5% of the Common
Stock, (2) each director of the Company, (3) the Chief Executive Officer of the
Company; and (5) all directors and executive officers as a group. Each
beneficial owner who is a natural person has advised the Company that he or she
has sole voting and investment power as to the shares of the Common Stock,
except that until a Warrant or an Option is exercised, there is no voting right.
See "Description of Securities -- Series A Preferred Stock -- Voting
37
38
Rights" for information as to the voting rights of the holders of shares of the
Series A Preferred Stock.
NUMBER OF SHARES PERCENTAGE OF
OF COMMON STOCK COMMON STOCK
NAME AND ADDRESS OF BENEFICIAL OWNER BENEFICIALLY OWNED BENEFICIALLY OWNED(1)
- ------------------------------------ ------------------ ---------------------
General Conference Corporation 5,535,000(2) 33.9%
of Seventh-day Adventists
12501 Old Columbia Pike
Silver Spring, MD 20804-6600
Melvin Simon & Associates, Inc.(3) 1,000,000(3) 8.1%
115 W. Washington Street
Indianapolis, IN 46204
Jonathan J. Pallin(4) 4,625,595(5) 38.2%
10400 Trademark Street
Rancho Cucamonga, CA 91730
Herman Sandler 1,700,000(6) 13.9%
2 World Trade Center, 104th Floor
New York, NY 10048
Peter S. Gold(7) 900,000(8) 7.5%
16027 Ventura Blvd., Suite 601
Encino, CA 91436
Linda H. Masterson(9) 462,500(10) 3.8%
10400 Trademark Street
Rancho Cucamonga, CA 91730
Paul Sandler(7) 200,000 1.7%
333 West Hatcher Road
Phoenix, AZ 85021
All directors and executive officers as a
group
(five persons) 6,215,178(11) 48.5%
- -------------------------
(1) The percentages computed in this column of the table are based upon
11,818,403 shares of the Common Stock which were outstanding on February
26, 1999. Effect is given, pursuant to Rule 13d-3(l)(i) under the Exchange
Act, to shares issuable upon the exercise of the Warrants and Options
currently exercisable or exercisable within 60 days of February 26, 1999
and, where applicable, to the conversion of the Series A Preferred Stock,
all of which shares was currently convertible as of such date.
(2) The shares reported in the table include 4,500,000 shares issuable upon the
conversion of 225,000 shares of the Series A Preferred Stock. See Note (2)
to the table under "Selling Stockholders."
(3) The shares reported in the table include 500,000 shares issuable upon the
conversion of 25,000 shares of the Series A Preferred Stock. In March 1999,
this stockholder requested that the shares reported in the table be equally
divided between Melvin Simon and Herbert Simon. See Note (5) to the table
under "Selling Stockholders."
(4) A director of the Company since October 31, 1997 and the Chairman of the
Board from that date until January 8, 1999.
38
39
(5) The shares reported in the table reflect (a) 4,325,306 shares of the
5,575,306 shares acquired by Meadow Lane from SAT (see section
"Business -- History of the Company") and then transferred to Mr. Pallin
and (b) 300,289 shares issuable upon the exercise of that portion of the
Meadow Lane Warrant transferred to him. 100,000 of the shares reported in
the table are subject to a warrant granted to an unaffiliated person in
October 1997.
(6) The shares reported in the table reflect (a) 1,250,000 shares of the
5,575,306 shares acquired by Meadow Lane from SAT and then transferred to
Mr. Sandler; (b) 150,000 shares issuable upon the exercise of that portion
of the Meadow Lane Warrant transferred to Mr. Sandler; and (c) 300,000
shares issuable upon the exercise of a Warrant expiring November 4, 2002
exercisable at $.50 per share.
(7) A director of the Company since December 5, 1997.
(8) The shares reported in the table include an aggregate of 200,000 shares
issuable upon the exercise of the two Warrants expiring November 4, 2002,
one for 100,000 shares exercisable at $.50 per share and the other
exercisable at $1.00 per share.
(9) A director of the Company since May 31, 1996; effective August 1, 1996, its
President; and, effective May 23, 1997, its Chief Executive Officer.
(10) The shares reported in this table reflect (a) 400,000 shares issuable upon
the exercise of two Warrants expiring October 26, 2002 at $.50 per share
and (b) 62,500 shares issuable upon the exercise at $.50 per share of an
Option expiring August 13, 2007. The shares do not reflect (a) 87,500
shares subject to that Option as to which the Option was not exercisable at
February 26, 1999 or within 60 days thereafter or (b) an aggregate of
200,000 shares subject to two other Options which were not exercisable at
February 26, 1999 or within 60 days thereafter.
(11) The shares reported in the table include (a) those issuable upon the
exercise of the Warrants and the Option described in Notes (5), (8) and
(10) to the table and (b) 27,083 shares issuable upon the partial exercise
at $.50 per share of an Option expiring March 19, 2008 granted to an
executive officer of the Company.
39
40
DESCRIPTION OF SECURITIES
CERTIFICATE OF INCORPORATION
The Certificate of Incorporation of the Company, as amended, describes the terms
of the Preferred Stock (including the Series A Preferred Stock) and the Common
Stock in greater detail than this prospectus and may provide information that
differs from this prospectus. If the information differs from this prospectus, a
prospective purchaser of the Common Stock is requested to rely on the
information in the Certificate of Incorporation, as amended. Such prospective
purchaser may obtain a copy of the Company's Certificate of Incorporation, as
amended, from the Company by writing to Anne Craven, Assistant Secretary,
LifePoint, Inc., 10400 Trademark Street, Rancho Cucamonga, CA 91730, or by
calling her at (909) 466-8047, extension 222.
CLASSES OF STOCK
The Company's Certificate of Incorporation, as amended, currently authorizes
3,000,000 shares of Preferred Stock, $.001 par value (the "Preferred Stock"),
and 50,000,000 shares of Common Stock, $.001 par value (the "Common Stock").
PREFERRED STOCK
The Certificate of Incorporation, as amended, provides for the issuance of
3,000,000 shares of the Preferred Stock. 600,000 of such shares were initially
designated as the Series A 10% Cumulative Convertible Preferred Stock (the
"Series A Preferred Stock"). The Board of Directors of the Company is authorized
to designate the remaining series, to determine the number of shares of the
Preferred Stock in each series and to fix the powers, preferences and rights of
the shares of each such series and the qualifications, limitations or
restrictions thereof. Unless the holders of at least 66 2/3% of the then
outstanding shares of the Series A Preferred Stock consent, all future series of
the Preferred Stock must be junior to the Series A Preferred Stock with respect
to dividends, redemption and liquidation. For purposes of the Series A Preferred
Stock, the term "Junior Stock" means the Common Stock and any other series of
the Preferred Stock hereafter authorized (unless the holders of the Series A
Preferred Stock permit otherwise as provided in the preceding sentence).
SERIES A PREFERRED STOCK
(1) DIVIDENDS
The holders of shares of the Series A Preferred Stock are entitled to receive,
when and as declared by the Board of Directors of the Company, out of the funds
of the Company legally available therefor, cumulative dividends at the annual
rate of $1.00 per share payable semiannually, commencing on July 1, 1999, and
thereafter on January 2 and July 1 of each year that any shares of the Series A
Preferred Stock are outstanding. Dividends on the Series A Preferred Stock
accrue on each share thereof from day to day from January 21, 1999, whether or
not earned or declared. Accordingly, if dividends with respect to any previous
dividend period at the rate provided therefor have not been paid on all shares
of the Series A Preferred Stock at the time outstanding, the deficiency will be
fully paid on such shares before any distribution shall be paid on the Junior
Stock.
At the option of the Company, a dividend may be paid either in cash or in the
form of shares of the Common Stock. The shares to be issued as a dividend will
be valued at the
40
41
then Average Market Price (as defined in the succeeding paragraph) of the Common
Stock during the 20 trading days immediately preceding the declaration of the
dividend.
The Average Market Price for a 20-trading-day period will be determined as
follows:
(1) if the Common Stock is then listed on a national securities exchange or
quoted on The Nasdaq Stock Market, Inc. ("Nasdaq"), the Average Market
Price will mean the average of the closing sale prices reported on the
exchange or quoted for Nasdaq on each trading day during such
20-trading-day period or,
(2) if the Common Stock is not then listed on an exchange or quoted on
Nasdaq, the Average Market Price will mean the average of the closing
bid and asked prices for the Common Stock reported by the NASD's OTC
Bulletin Board or in the pink sheets as reported by the National
Quotation Bureau, Inc., or similar organization performing similar
functions in the over-the-counter market, for each trading day during
such 20-trading-day period.
(2) CONVERSION
A holder of shares of the Series A Preferred Stock, but only as to 500 shares or
a multiple thereof (unless the holder owns less than 500 shares), may, at the
holder's option, at any time, convert such shares into shares of the Common
Stock at the conversion price of $.50 per share based on a stated value of
$10.00 per share of the Series A Preferred Stock. Accordingly, 500 shares of the
Series A Preferred Stock would convert into 10,000 shares of the Common Stock
(i.e., the product of 500 (the number of shares) and $10.00 (the stated value)
or $5,000 divided by $.50 (the conversion price)). If all 600,000 originally
authorized shares of the Series A Preferred Stock are converted, an aggregate of
12,000,000 shares of the Common Stock will be issued upon conversion. Upon
conversion, a holder is entitled to receive all accrued but unpaid dividends to
the date of conversion.
On March 1, 1999, the holders of an aggregate of 42,275 shares of the Series A
Preferred Stock converted such shares into an aggregate of 845,500 shares of the
Common Stock. They also received 1,306 shares of the Common Stock in payment for
accrued but unpaid dividends.
The number of shares issuable upon conversion and the conversion price will be
adjusted in the event of a stock dividend, a stock split, a reorganization, a
recapitalization, or a combination or subdivision of the Common Stock or a
similar event.
(3) OPTIONAL REDEMPTION
The Company may, upon not less than 30 nor more than 60 days' notice, redeem, in
whole or in part (but only in multiples of 500 shares unless the holder owns
less), the then outstanding shares of the Series A Preferred Stock at any time
on and after July 1, 1999 at a redemption price of $10.00 per share. The holder
will also receive all accrued but unpaid dividends to the date of redemption.
The Company, at its discretion, may pay the redemption price in cash or with
shares of the Common Stock on the basis of the Average Market Price of the
Common Stock for the 20 trading days immediately preceding the notice of
redemption. If the Company calls the shares of the Series A Preferred Stock for
redemption the holder may, at any time on or prior to the redemption date,
convert his, her or its shares into shares of the Common Stock as described in
the preceding subsection.
41
42
(4) MANDATORY REDEMPTION
In the event that the Average Market Price of the Common Stock for any 30-day
period is $4.00 or more, the Company shall, by notice to the holders of the
Series A Preferred Stock, call all of the then outstanding shares of the Series
A Preferred Stock for redemption as of a date not less than ten nor more than 30
days after the date the notice is given (the "Mandatory Redemption Date"). In
lieu of cash, the Company shall issue to each holder of the Series A Preferred
Stock that number of shares of the Common Stock as if the holder had converted
on the Mandatory Redemption Date. The holder of the Series A Preferred Stock
will also receive accrued but unpaid dividends to the Mandatory Redemption Date.
(5) REACQUIRED SHARES
Shares of the Series A Preferred Stock which have been converted, redeemed or
reacquired by the Company in any manner will, upon compliance by the Company
with the General Corporation Law of the State of Delaware (the "GCL"), have the
status of authorized and unissued shares of the Preferred Stock not constituting
part of any series of the Preferred Stock. As an alternative, the Board of
Directors may elect by resolution to retain the shares of the Series A Preferred
Stock that were converted, redeemed or otherwise reacquired as treasury shares
or to retire the same and reduce the capital of the Company in accordance with
the GCL.
The 42,275 shares of the Series A Preferred Stock which were converted on March
1, 1999 were restored to the status of authorized and unissued shares of the
Preferred Stock not constituting part of any series of the Preferred Stock.
(6) FRACTIONAL SHARES
No fractional shares will be issued upon either conversion of a share of the
Series A Preferred Stock or upon payment of a dividend in shares of the Common
Stock. Instead the holder shall be paid an amount in cash (computed to the
nearest cent) equal to the Market Value of such fractional share. The Market
Value of a share of the Common Stock shall be computed in the same manner as the
Average Market Value for a dividend except that the price shall be for the
trading day preceding the conversion date or the dividend payment date,
whichever is applicable, and not the average of the prices for the prior 20
trading days.
(7) VOTING RIGHTS
The holders of shares of the Series A Preferred Stock have the following voting
rights:
(1) to vote, one vote per share, with the holders of the Common Stock on
the election of directors and on all other matters submitted to a vote
of the holders of the Common Stock except where such holders of the
Series A Preferred Stock have the right under the GCL to vote
separately as a class, and
(2) to vote, one vote per share, separately as a class (a) where provided
by the GCL, such as where the matter to be voted on may adversely
affect the rights of the holders of the Series A Preferred Stock, (b)
where the holders' consent is requested by the Company and (c) as
hereinafter provided in the succeeding sentence. If and whenever the
Company will have failed to declare and pay the amount of dividends
payable on the Series A Preferred Stock for three consecutive
semiannual payment dates, the holders, voting as a class, will be
42
43
entitled to elect one director and the holders of the Common Stock and
such other of the Company's stock as shall then have the right to vote
for directors shall be entitled to elect the remaining members of the
Board of Directors. At such time as all dividends accumulated on the
outstanding shares of the Series A Preferred Stock have been paid, the
contingent right of the holders of the Series A Preferred Stock to
elect a member of the Board will cease, subject to reinstitution from
time to time upon the same terms and conditions.
Whenever the holders of shares of the Series A Preferred Stock have been granted
by law the right to vote separately as a class, or if the Company requires the
consent of the holders to some action, the vote of the holders of at least
66 2/3% of the then outstanding shares will be required for approval. Whenever
the holders of shares of the Series A Preferred Stock are voting separately as a
class to elect a director, a plurality of the shares voting will be necessary to
elect such director and a majority will be necessary for a quorum.
(8) LIQUIDATION, DISSOLUTION AND WINDING UP
Upon any voluntary or involuntary liquidation, dissolution or winding up of the
affairs of the Company, each holder of shares of the Series A Preferred Stock
will be entitled to receive out of the assets available for distribution to
stockholders an amount equal to $10.00 per share before any payments or
distributions will be made on shares of the Junior Stock. Each holder will also
receive, as a preferential payment, a sum equal to all accrued but unpaid
dividends, if any. After payment in cash to the holders of the shares of the
Series A Preferred Stock of the full preferential amounts fixed hereby, such
holders will have no right or claim to any of the remaining assets of the
Company.
A merger or consolidation of the Corporation in which it is not the survivor
will not be deemed a liquidation, dissolution or winding up of the Corporation,
provided that provision for the exchange of the shares of the Series A Preferred
Stock and for the payment of accrued but unpaid dividends thereon is made with
the approval of the holders of at least 66 2/3% of the then outstanding shares
of the Series A Preferred Stock. If such approval is obtained, such provision
will be binding on the remaining holders. Otherwise such merger or consolidation
will be deemed a liquidation of the Company.
(9) LIMITATION ON INDEBTEDNESS
The Company has agreed that, until the working prototype for its saliva based
testing product for drugs of abuse and alcohol is completed, it will not,
without the consent of the holders of at least 66 2/3% of the then outstanding
shares of the Series A Preferred Stock, incur indebtedness, other than the
anticipated up to $2,000,000 in indebtedness at any time outstanding incurred in
connection with the purchase or leasing of manufacturing, research and office
equipment and facilities. This restriction terminates if the General Conference
Corporation of Seventh-day Adventists does not exercise the right of first
refusal, granted to it in connection with the Company's third private placement
consummated on January 21, 1999 (see "Business -- Need for Financing"), as to a
proposal for new equity financing.
COMMON STOCK
Each holder of the Common Stock is entitled (1) to one vote for each share held
of record, (2) to notice of any meeting of the stockholders of the Company and
(3) to a pro rata share of any dividends declared on the Common Stock by the
Board of Directors.
43
44
Upon liquidation of the Company, each holder of the Common Stock is entitled to
share ratably any assets available for distribution after payment of all debts
and any distribution in respect of the then outstanding shares of the Preferred
Stock (or which only the Series A Preferred Stock is currently outstanding).
Holders of the Common Stock have no preemptive, subscription or conversion
rights. All outstanding shares of the Common Stock are, and all Common Shares to
be issued upon the conversion of the shares of the Series A Preferred Stock and
the exercise of the Selling Stockholders Warrants will be, fully paid and
nonassessable.
As of February 26, 1999, there were 11,818,403 shares of the Common Stock
outstanding. Additionally, there were
(1) 1,958,803 shares of the Common Stock reserved for the granting of
Options pursuant to the Stock Option Plan. As of February 26, 1999,
there were outstanding Options to purchase 794,167 shares of the Common
Stock, which expire on various dates from August 13, 2007 to June 29,
2008 and which are exercisable at $.50 per share, and
(2) 3,095,741 shares of the Common Stock reserved for issuance upon the
exercise of the Warrants (including the Meadow Lane Warrant) and the
Selling Stockholders Warrants which expire on various dates ranging
from October 26, 2002 to January 20, 2004 and which have exercise
prices ranging from $.50 to $2.41 per share.
Fully diluted and assuming Options are granted as to the remaining shares
subject to the Stock Option Plan, the Company may have as many as 28,872,947
shares of the Common Stock outstanding after giving effect to the up to
12,000,000 shares of the Common Stock which may be issued upon the conversion of
the 600,000 shares of the Series A Preferred Stock outstanding as of February
26, 1999. The total gives no effect to any shares which may be issued as
dividends.
The Common Stock is traded in the over-counter market and market price
quotations are reported on the OTC Bulletin Board of the NASD under the symbol
"LFPT". Secondary trading is currently permissible in 50 states and the District
of Columbia.
NON-CUMULATIVE VOTING
The holders of shares of the Common Stock do not have cumulative voting rights,
which means that the holder of more than 50% of such outstanding shares voting
for the election of directors of the Company can elect all of the directors to
be elected, if they so choose, and, in such event, the holder of the remaining
shares will not be able to elect any of the Company's directors.
As of March 23, 1999, Jonathan J. Pallin, a director of the Company, by virtue
of his ownership of 4,007,306 shares of the Common Stock, Herman Sandler, by
virtue of his ownership of 1,250,000 shares of the Common Stock, and Peter S.
Gold and Paul Sandler, directors of the Company, by virtue of their ownership of
an aggregate of 900,000 shares of the Common Stock together own an aggregate of
6,157,306 shares or 46.6% of the 13,222,934 shares eligible as of March 23, 1999
to vote for directors (12,665,209 votes by the holders of the Common Stock and
557,725 votes by the holders of the Series A Preferred Stock). Under the GCL a
plurality of the shares voting is necessary to elect a director of the Company.
Accordingly, if these four persons vote together and they obtain the votes of
the holders of 454,162 shares, they could elect all of the directors and the
holders of the remaining shares could not elect a single director.
44
45
The voting control described in the preceding paragraph will lessen as
additional shares of the Common Stock not held by any of these four
persons become outstanding. The new shares may become outstanding as a result of
conversions of shares of the Series A Preferred Stock, exercises of the Options,
the Warrants or the Selling Stockholders Warrants or sales of additional shares
of the Common Stock in a new financing. The percentage ownership is reduced to
25.8% of the 23,819,709 shares that would be outstanding if all 557,725 shares
of the Series A Preferred Stock outstanding as of March 23, 1999 were converted
into 11,154,500 shares of the Common Stock, assuming no exercises of outstanding
Options, Warrants or Selling Stockholders Warrants.
As of March 23, 1999, General Conference Corporation of Seventh-day Adventists
owned 1,235,000 shares of the Common Stock and 225,000 shares of the Series A
Preferred Stock which, if a stockholders' meeting to elect directors was held on
such date, would also allow such stockholder 1,460,000 votes or 11% of the
13,222,934 shares eligible to vote on such date. However, if such stockholder
converted all of its shares of the Series A Preferred Stock into shares of the
Common Stock, it would own 5,735,000 shares or 32.8% of the shares eligible to
vote if such stockholder was the only stockholder to convert shares of the
Series A Preferred Stock and 24.1% if all stockholders converted. If this
stockholder were to vote with the four stockholders named in the second
preceding paragraph on the election of directors, then they could elect all of
the directors and the remaining stockholders would elect none. When Jonathan J.
Pallin, a director, served as a Vice President with broker-dealer/investment
banker firms (see "Management -- Business History"), the General Conference
Corporation of Seventh-day Adventists was a customer of his. The percentages
used in this paragraph assume no exercises of outstanding Options, Warrants or
Selling Stockholders Warrants.
DIVIDENDS
The payment in the future by the Company of all dividends, if any, on the Common
Stock rests within the discretion of the Board of Directors and will depend,
among other things, upon the Company's earnings, its capital requirements, its
financial condition and the status of dividends on the any shares of the
Preferred Stock then outstanding (of which the Series A Preferred Stock is the
sole series currently outstanding), as well as other relevant factors. The
Company has never paid or declared any dividends on the Common Stock. Based upon
the Board's current intention of using funds for the product development
program, the current operational losses and the provisions of the Series A
Preferred Stock, the Company does not contemplate or anticipate paying any
dividends on the Common Stock in the foreseeable future.
TRANSFER AGENT
U.S. Stock Transfer and Trust Company, 1745 Gardena Avenue, Suite 200, Glendale,
CA 91204, is the Transfer Agent for the Common Stock. The Company acts as its
own Transfer Agent for the Series A Preferred Stock.
WARRANTS
As of February 26, 1999, there were outstanding Selling Stockholders Warrants to
purchase an aggregate of 1,535,452 shares of the Common Stock. Except as
indicated under "Plan of Distribution," all Selling Stockholders Warrants have
an expiration date of January 20, 2004 and an exercise price of $2.41 per share.
All were then currently exercisable except for that a Selling Stockholders
Warrant to purchase 250,000 shares of the Common Stock issued to Burrill (see
"Business-Need for Financing") which was, as
45
46
of February 26, 1999, only exercisable as to 62,490 shares. Such Selling
Stockholders Warrant becomes exerciseable as to 20,830 shares of the Common
Stock during each of the next eight months and as to 20,870 shares in the ninth
month.
As of February 26, 1999, there were outstanding Warrants (including the Meadow
Lane Warrant) to purchase an aggregate of 1,560,289 shares of the Common Stock.
These Warrants have expiration dates ranging from October 26, 2002 to January 7,
2003 and are all currently exercisable at $.50 per share except for a Warrant
expiring December 7, 2002 to purchase 100,000 shares which currently is
exercisable at $1.00 per share
The number of shares issuable upon exercise and the exercise price of the
Selling Stockholders Warrants and the Warrants will be adjusted in the event of
a stock dividend, a stock split, a reorganization, a recapitalization, or a
combination or subdivision of the Common Stock or a similar event.
SHARES ELIGIBLE FOR FUTURE SALE
Of the 11,818,403 shares of the Common Stock outstanding as of February 26,
1999, the Company had previously registered under the Securities Act 1,918,097
of those shares. Accordingly, a holder of any of such shares, as of that date,
could sell his, her or its shares without any requirement that the holder
deliver to his, her or its purchaser a prospectus naming the holder as a selling
stockholder, unless the holder was an affiliate of the Company as defined in
Rule 144(a)(1) under the Securities Act. Even the holder who is an affiliate can
sell his, her or its shares as permitted by Rule 144 without delivery of such a
prospectus.
In addition, as of February 26, 1999, an additional 8,775,306 shares were
restricted securities as defined in Rule 144(a)(3) under the Securities Act. A
holder of any of such shares could sell them pursuant to the exemption from
registration of Rule 144. Furthermore, 1,125,000 shares were also restricted
securities as of February 26, 1999 and may be sold pursuant to Rule 144 on
various dates thereafter (1,000,000 shares on and after July 24, 1999, 25,000
shares on and after August 27, 1999 and 100,000 shares on and after August 31,
1999).
In summary, all 11,818,403 shares of the Common Stock outstanding as of February
26, 1999 are, or will become in 1999, saleable without the necessity of the
Company to file a registration statement under the Securities Act naming the
holders as selling stockholders.
As of February 26, 1999, the Company had reserved 1,958,803 shares of the Common
Stock for the exercise of the Options granted or to be granted pursuant to Stock
Option Plan. As of that date, there were outstanding Options to purchase an
aggregate of 794,167 shares at $.50 per share expiring on various dates through
November 5, 2003. Each of the outstanding Options became, or will become,
exercisable on a cumulative basis as to one-quarter of the shares subject
thereto on the first anniversary of its respective date of grant and as to
1/36th of the remaining shares subject thereto each month during the ensuing
36-month period thereafter. As of February 26, 1999 or within 60 days
thereafter, Options were exercisable as to 135,032 shares of the Common Stock.
All of the shares issuable upon the exercises of the Options have been
registered under the Securities Act. Accordingly, unless the optionee is an
affiliate of the Company as defined in Rule 144(a)(i) under the Securities Act,
he or she may, after exercise of an Option, resell the shares received upon
exercise without the use of a reoffer prospectus. Of the optionees holding
Options outstanding on February 26, 1999, only Linda H. Masterson, the President
and Chief Executive Officer of the Company, and Thomas J. Foley, the Vice
President,
46
47
Research and Development of the Company, may be deemed affiliates requiring a
reoffer prospectus to resell shares received upon an exercise. As of such date,
Ms. Masterson and Mr. Foley held Options to purchase in the aggregate 570,000
shares of the Common Stock, of which Options to purchase an aggregate of 89,583
shares were then exercisable or exercisable within 60 days thereafter.
In addition, as of February 26, 1999, the Company had reserved an aggregate of
1,560,289 shares for the exercise of the Warrants which expire on various dates
through January 7, 2004 and which have exercise prices of either $.50 or $1.00
per share. As of February 26, 1999, all of the Warrants were exercisable. The
shares of the Common Stock issuable upon exercises of the Warrants have not been
registered under the Securities Act. Accordingly, such shares will be restricted
securities as defined in Rule 144(a)(3) under the Securities Act after issuance.
A holder (including an affiliate of the Company) may, one year after the
exercise of the Warrant, resell his, her or its shares received upon such
exercise pursuant to the exemption from registration of Rule 144 under the
Securities Act.
The Company is unable to predict the effect that sales of shares of the Common
Stock made under Rule 144 and the delayed sales of shares subject to the Options
and the Warrants may have on the then prevailing market price of the shares of
the Common Stock. It is likely that market sales of large amounts of these
shares of the Common Stock and/or the 14,035,452 shares offered by this
prospectus (or the potential for those sales even if they do not actually occur)
will have the effect of depressing the market price of the Common Stock.
PLAN OF DISTRIBUTION
Each of the holders of shares of the Series A Preferred Stock, of which 557,725
shares are currently outstanding, has advised the Company that, when and if such
Selling Stockholder converts his, her or its shares into shares of the Common
Stock, such Selling Stockholder may, from time to time, offer such underlying
shares of the Common Stock for sale pursuant to this prospectus at the prices
then prevailing on the NASD's OTC Bulletin Board or otherwise in the
over-the-counter market. Each share of the Series A Preferred Stock is currently
convertible into 20 shares of the Common Stock. Each such Selling Stockholder
has also indicated that he, she or it may sell the shares of the Common Stock in
isolated transactions, at negotiated prices, with institutional or other
investors. Each such Selling Stockholder has also advised the Company that he,
she or it has not engaged any underwriter to act for him, her or it. However,
each has indicated that sales may be effected for each Selling Stockholder
through his, her or its personal broker-dealer. If all 557,725 shares of the
Series A Preferred Stock are converted, an aggregate of 11,154,500 shares of the
Common Stock will be so offered pursuant to this prospectus.
On March 1, 1999, two Selling Stockholders converted 42,275 shares of the Series
A Preferred Stock into 845,500 shares of the Common Stock. These Selling
Stockholders have advised the Company that they will sell such shares of the
Common Stock, together with the aggregate of 1,306 shares of the Common Stock
they received as accrued but unpaid dividends through the date of conversion, in
the same manner as described in the preceding paragraph for the other Selling
Stockholders.
Those Selling Stockholders who or which own shares of the Series A Preferred
Stock acquired such shares in the Company's third private placement closed on
January 21, 1999. See "Business -- Need for Financing."
47
48
The Selling Stockholders who or which own shares of the Series A Preferred Stock
have indicated that they will also sell, in the same manner as described in the
third preceding paragraph, the shares of the Common Stock they receive upon
conversion as payment for accrued but unpaid dividends. The Company estimates
that it may issue up to an aggregate of 498,694 shares of the Common Stock as
dividends during the next three years.
In addition, each of the Selling Stockholders who or which holds a Selling
Stockholders Warrant has advised the Company that, when and if he, she or it
exercises his, her or its Selling Stockholder Warrant, the Selling Stockholder
may, from time to time, sell the shares of the Common Stock issued upon exercise
in the same manner as described for the other Selling Stockholders in the fourth
preceding paragraph. Each of the Selling Stockholders Warrants is currently
exercisable. If all of the Selling Stockholders' Warrants are exercised, an
aggregate of 1,535,452 shares will be so offered pursuant to this prospectus.
The Selling Stockholders who or which hold the Selling Stockholders Warrants
acquired such securities as follows:
(1) Burrill & Company holds a Selling Stockholders Warrant expiring
November 30, 2003 to purchase 250,000 shares of the Common Stock at
$1.15 per share received on December 3, 1998 for its services to seek
a strategic partner for the Company. See "Business -- Need for
Financing."
(2) Global Consultants holds Selling Stockholders Warrants expiring July
7, 2003 to purchase an aggregate of 239,452 shares of the Common
Stock at $.50 per share. Such warrants were acquired on July 8, 1998
in consideration of its financial public relations services on behalf
of the Company.
(3) Ira Jay Mitchell holds three Selling Stockholders Warrants to purchase
an aggregate of 175,000 shares of the Common Stock as follows: (a) a
Selling Stockholders Warrant expiring December 13, 2003 to purchase
50,000 shares at $1.08 per share received on December 14, 1998 as a
finder's fee with respect to the Company's second private placement in
July and August 1998, (b) a Selling Stockholders Warrant expiring
January 20, 2004 to purchase 50,000 shares at $2.41 per share received
on January 21, 1999 as a finder's fee with respect to the Company's
third private placement in January 1999 and (c) a Selling Stockholders
Warrant expiring December 7, 2002 to purchase 75,000 shares at $.50
per share received on December 8, 1997 as compensation for
management/real estate relocations consulting services. See
"Business -- Need for Financing" for information as to the two private
placements.
(4) The Gramercy Partnership, L.L.C. holds a Selling Stockholders Warrant
expiring January 20, 2004 to purchase 144,338 shares of the Common
Stock at $2.41 per share received on January 21, 1999 as a finder's
fee with respect to the Company's third private placement in January
1999. See "Business -- Need for Financing."
(5) The Kriegsman Group holds two Selling Stockholders Warrants to
purchase an aggregate of 120,000 shares of the Common Stock as
follows: (a) 80,000 shares issuable upon the exercise of a Selling
Stockholders Warrant expiring April 7, 2003 at $1.00 per share
received on April 8, 1998 as compensation for prospective investment
banking services and (b) 40,000 shares issuable upon the exercise of a
Selling Stockholders Warrant expiring January 20, 2004 at $2.41
48
49
per share received on January 21, 1999 as a finder's fee with respect to the
Company's third private placement in January 1999 (see "Business -- Need for
Financing").
(6) Dean Erickson holds a Selling Stockholders Warrant expiring September
10, 2003 to purchase 100,000 shares of the Common Stock at $2.16 per
share received on September 11, 1998 as compensation for his investor
relations services.
(7) WebStNews.com, Inc. holds a Selling Stockholders Warrant expiring
August 30, 2000 to purchase 100,000 shares of the Common Stock at $.75
per share. Such warrant was acquired on August 31, 1998 for services
in setting up a Web site for the Company and reporting as to the
Company on its Web site.
(8) Fred Reno holds two Selling Stockholders Warrants to purchase an
aggregate of 60,000 shares of the Common Stock as follows: (a) a
Selling Stockholders Warrant expiring December 7, 2002 to purchase
30,000 shares at $.50 per share and (b) a Selling Stockholders Warrant
expiring January 7, 2004 to purchase 30,000 shares at $1.02 per share,
the first being received on December 8, 1997 as consideration for Mr.
Reno agreeing to serve as a consultant on law enforcement and security
matters and the second being received on January 8, 1997 as
consideration for his agreeing to serve the Company for an additional
two years and broadening his duties to include public relations in
connection with television and radio.
(9) Charles Dargan holds a Selling Stockholders Warrant expiring January
20, 2004 to purchase 56,000 shares of the Common Stock at $2.41 per
share received on January 21, 1999 as a finder's fee with respect to
the Company's third private placement in January 1999. See
"Business -- Need for Financing."
(10) Online Capital GmbH holds a Selling Stockholders Warrant expiring
January 20, 2004 to purchase 48,112 shares of the Common Stock at
$2.41 per share received on January 21, 1999 as a finder's fee with
respect to the Company's third private placement in January 1999. See
"Business -- Need for Financing."
(11) Global Capital Corporation holds a Selling Stockholders Warrant
expiring January 20, 2004 to purchase 42,275 shares of the Common
Stock at $2.41 per share received on January 21, 1999 as a finder's
fee with respect to the Company's third private placement in January
1999. See "Business -- Need for Financing."
(12) Libra Finance S.A. holds a Selling Stockholders Warrant expiring
January 20, 2004 to purchase 42,275 shares of the Common Stock at
$2.41 per share received on January 21, 1999 as a finder's fee with
respect to the Company's third private placement in January 1999. See
"Business -- Need for Financing."
(13) Michael S. Rosenblum holds a Selling Stockholders Warrant expiring
December 7, 2002 to purchase 40,000 shares of the Common Stock at $.50
per share received on December 8, 1997 for his legal services in
connection with the purchase of SAT's majority interest in the
Company.
(14) Ambient Capital Group, Inc. holds two Selling Stockholders Warrants to
purchase an aggregate of 30,000 shares of the Common Stock as follows:
(a) 20,000 shares issuable upon the exercise of a Selling Stockholders
Warrant
49
50
expiring April 7, 2003 at $1.00 per share received on April 8, 1998 as
compensation for prospective investment banking services and
(b) 10,000 shares issuable upon the exercise of a Selling Stockholders
Warrant expiring January 20, 2004 at $2.41 per share received on
January 21, 1999 as a finder's fee with respect to the Company's third
private placement in January 1999 (see "Business -- Need for
Financing").
(15) Shohreh Moheb holds a Selling Stockholders Warrant expiring October
26, 2002 to purchase 30,000 shares of the Common Stock at $.50 per
share received on October 27, 1997 as a rehiring bonus because she was
then deemed a key employee to complete the chemistry aspects of the
Company's research and development program. Since January 1, 1999, she
has not been employed by the Company.
(16) Allan Stone & Company holds a Selling Stockholders Warrant expiring
January 13, 2003 to purchase 25,000 shares of the Common Stock at $.50
per share received on January 14, 1998 as consideration for its public
relations services on behalf of the Company.
(17) Guohong Wang holds two Selling Stockholders Warrants to purchase an
aggregate of 14,000 shares of the Common Stock as follows: (a) a
Selling Stockholders Warrant expiring March 19, 2003 to purchase
12,000 shares at $.50 per share and (b) a Selling Stockholders Warrant
expiring January 7, 2004 to purchase 2,000 shares of the Common Stock
at $1.57 per share, the first received on March 20, 1998 and the
second received on January 8, 1999, both as compensation for his
consulting services as an organic chemist in the research and
development program of the Company. In March 1999, he rejoined the
Company as an employee.
(18) Corporate Capital Management L.L.C. holds a Selling Stockholders
Warrant expiring January 20, 2004 to purchase 14,000 shares of the
Common Stock at $2.41 per share received on January 21, 1999 as a
finder's fee with respect to the Company's third private placement in
January 1999. See "Business -- Need for Financing."
(19) Lonna Williams holds a Selling Stockholders Warrant expiring March 19,
2003 to purchase 5,000 shares of the Common Stock at $.50 per share
received on March 20, 1998 as compensation for services as a
consultant to the Company on product marketing matters. She previously
served the Company as its Vice President, Marketing until September
1997.
The shares of the Common Stock offered by the Selling Stockholders, issued after
either the conversion of shares of the Series A Preferred Stock or the exercise
of the Selling Stockholders Warrants, may be sold pursuant to this prospectus by
one or more of the following methods, without limitation: (a) a block trade on
which the broker-dealer so engaged will attempt to sell the shares of the Common
Stock as agent, but may position and resell a portion of the block as principal
to facilitate the transaction; (b) purchases by the broker-dealer as principal
and resale by such broker-dealer for its account pursuant to this prospectus;
(c) ordinary brokerage transactions and transactions in which the broker
solicits purchasers; and (d) face-to-face transactions between the Selling
Stockholder and purchasers without a broker-dealer. In effecting sales, a
broker-dealer engaged by the Selling Stockholder may arrange for other brokers
or dealers to participate. Such brokers or dealers may receive commissions or
discounts from the Selling Stockholder in amounts
50
51
to be negotiated immediately prior to sale. Brokers or dealers and any
participating brokers or dealers acting as described in this paragraph may be
deemed to be "underwriters" within the meaning of Section 2(11) of the
Securities Act in connection with such sales.
Upon the Company being notified by a Selling Stockholder that any material
arrangement has been entered into with a broker-dealer for the sale of shares of
the Common Stock through a block trade, special offering, exchange distribution
or secondary distribution or a purchase by a broker or dealer, a supplement to
the prospectus will be filed, if required, pursuant to Rule 424(c) under the
Securities Act, disclosing (a) the name of each broker-dealer, (b) the number of
shares involved, (c) the price at which such shares were sold, (d) the
commissions paid or discounts or concessions allowed to such broker-dealer(s),
where applicable, (e) that such broker-dealer(s) did not conduct any
investigation to verify the information set out in this prospectus, as
supplemented, and (f) other facts material to the transaction.
Currently none of the shares of the Common Stock being offered pursuant to this
prospectus may be sold pursuant to Rule 144 under the Securities Act. Each of
the Selling Stockholders has advised the Company that, as his, her or its shares
become eligible for sale pursuant to Rule 144, he, she or it may, as an
alternative to use of this prospectus, sell such shares pursuant to Rule 144.
Because the Selling Stockholders may be deemed to be "underwriters" within the
meaning of Section 2(11) of the Securities Act, the Company will advise the
Selling Shareholders of the requirement under the Securities Act that each of
them, or any broker-dealer acting for him, her or it, must deliver a copy of
this prospectus in connection with any sale by such Selling Stockholder of
shares of the Common Stock registered hereunder. The Company will also
undertake, if, in the future in the opinion of the Company, this prospectus no
longer complies with Section 10(a)(3) of the Securities Act, to advise the
Selling Stockholders of this opinion, to request that the Selling Stockholders
cease use of this prospectus and to confirm the Company's then intention to
amend the Registration Statement, of which this prospectus constitutes Part I
thereof (the "Registration Statement"), in order to effect such compliance. The
Company will also advise each of the Selling Stockholders that, if it is
determined that he, she or it is an "underwriter," the Selling Stockholder may
be found liable for monetary damages to purchasers under Sections 11, 12(2) and
15 of the Securities Act if there are any defects in the Registration Statement
(i.e., material misstatements or omissions) and also may be found liable under
Section 10(b) of the Exchange Act and Rule 10b-5 thereunder for such material
misstatements or omissions, if any.
The Company, its officers and directors, and the Selling Stockholders are
obligated to take such steps as may be necessary to ensure that the offer and
sale by the Selling Stockholders of an aggregate of 14,035,452 shares of the
Common Stock offered by this prospectus shall comply with the requirements of
the federal security laws, including Regulation M.
In general, Rule 102 under Regulation M prohibits any Selling Stockholder or a
broker-dealer acting for such Selling Stockholder from, directly or indirectly,
bidding for or purchasing any shares of the Common Stock or attempting to induce
any person to bid for or to purchase shares of the Common Stock during a
restricted period (as defined in Rule 100) which ends when he, she or it has
completed his, her or its participation in the offering made pursuant to this
prospectus. Rule 102 sets forth certain exceptions for the Selling Stockholder,
including exercising a Common Stock purchase warrant (which, for purposes of the
Rule, would include exercise of a Selling Stockholders Warrant).
51
52
The Company is bearing all costs relating to the registration of the shares of
the Common Stock offered by this prospectus (other than fees and expenses, if
any, of counsel or other advisors to a Selling Stockholder). Any commissions,
discounts or other fees payable to broker-dealer in connection with any sale of
the Common Stock will be borne by the Selling Stockholder selling such shares.
THE SELLING STOCKHOLDERS
Each of the Selling Stockholders named in the next following table has advised
the Company that he, she or it may, from time to time, offer all of the shares
shown next to his, her or its name at the prices then prevailing in the
over-the-counter market or in isolated transactions, at negotiated prices, with
institutional or other investors. See "Plan of Distribution." Each Selling
Stockholder who is a natural person has advised the Company that he or she will
have sole voting and investment power with respect to his or her shares of the
Common Stock after he or she converts his or her shares of the Series A
Preferred Stock or exercises a Selling Stockholders Warrant. No Selling
Stockholder has any voting power with respect to the shares of the Common Stock
issuable upon the exercise of a Selling Stockholder Warrant until such security
is exercised. In addition, the Selling Stockholder may vote his, her or its
shares of the Series A Preferred Stock, but not the underlying shares of the
Common Stock until after conversion. See "Description of Securities -- Series A
Preferred Stock -- Voting Rights." No Selling Stockholder, if a natural person,
and no natural person affiliated with any entity which is a Selling Stockholder
is, or has ever been, an executive officer or director of the Company except
that Michael S. McCord served as a director from May 31, 1996 until October 31,
1997. The business relationships to the Company of those Selling Stockholders
who or which hold Selling Stockholders Warrants is described under "Plan of
Distribution."
The Selling Stockholders are offering, by this prospectus, an aggregate of
14,035,452 shares of the Common Stock, of which 13,188,646 shares will not be
outstanding until (1)(a) 557,723 shares of the Series A Preferred Stock are
converted into 11,154,500 shares of the Common Stock, and (b) up to 498,694
shares, as estimated over a three-year period, will not be outstanding until
they are issued as accrued but unpaid dividends and (2) 1,535,452 shares will
not be outstanding until all of the Selling Stockholders Warrants are exercised.
BENEFICIAL
NUMBER OF SHARES OWNERSHIP(1)
--------------------------------- --------------
BEFORE AFTER BEFORE AFTER
NAME AND ADDRESS OF SELLING STOCKHOLDER SALE OFFERED SALE SALE SALE
- --------------------------------------- --------- --------- --------- ------ -----
General Conference 5,535,000 4,500,000 1,035,000 33.9% 6.3%
Corporation of Seventh-day
Adventists(2)
12501 Old Columbia Pike
Silver Spring, MD 20804
Ira Jay Mitchell(3) 625,000 325,000 300,000 4.9% 2.4%
1718 Chastain Parkway East
Pacific Palisades, CA 90272
52
53
BENEFICIAL
NUMBER OF SHARES OWNERSHIP(1)
--------------------------------- --------------
BEFORE AFTER BEFORE AFTER
NAME AND ADDRESS OF SELLING STOCKHOLDER SALE OFFERED SALE SALE SALE
- --------------------------------------- --------- --------- --------- ------ -----
The Intergroup Corporation(4) 500,000 200,000 300,000 4.2% 2.5%
2121 Avenue of the Stars
Suite 2020
Los Angeles, CA 90067
Melvin Simon(5) 500,000 250,000 250,000 4.1% 2.1%
c/o Melvin Simon & Associates, Inc.
115 W. Washington Street
Indianapolis, IN 46204
Herbert Simon(5) 500,000 250,000 250,000 4.1% 2.1%
c/o Melvin Simon & Associates, Inc.
115 W. Washington Street
Indianapolis, IN 46204
Arthur D. Sterling and 500,000 500,000 0 4.1% 0
Marie E. Sterling
JTWROS(6)
3000 Northmoor Tr.
Long Beach, IN 46360
Austost Anstalt Schaan(7) 423,413 423,413 0 3.5% 0
163 Landstrasse, 9494
Furstentums Vadiz,
Liechtenstein
Balmore Funds S.A.(7) 423,393 423,393 0 3.5% 0
P.O. Box 4603
Zurich, Switzerland
CH-8022
Jerome Finkelstein(8) 332,000 300,000 32,000 2.7% nil
362 Elm Drive
Roslyn, NY 11576
Wales Securities Limited(6) 300,000 300,000 0 2.5% 0
% First Fidelity Capital
9100 Wilshire Blvd.
437 West Tower
Beverly Hills, CA 90212
Whyteburg, Limited(6) 300,000 300,000 0 2.5% 0
% Mark Tollner
1006 North Carol Drive
Suite 4
West Hollywood, CA 90069
Erik Moskowitz(6) 250,000 250,000 0 2.1% 0
% Mansur & Co
875 N. Michigan Avenue
Chicago, IL 60045
53
54
BENEFICIAL
NUMBER OF SHARES OWNERSHIP(1)
--------------------------------- --------------
BEFORE AFTER BEFORE AFTER
NAME AND ADDRESS OF SELLING STOCKHOLDER SALE OFFERED SALE SALE SALE
- --------------------------------------- --------- --------- --------- ------ -----
Augustine Fund, LP(6) 200,000 200,000 0 1.7% 0
141 West Jackson Blvd.
#2182
Chicago, IL 60604
William F. Blackburn, Jr.(6) 200,000 200,000 0 1.7% 0
2159 Century Hill
Los Angeles, CA 90067
John P. Gannon(9) 200,000 200,000 0 1.7% 0
925 S. Mason Road #248
Katy, TX 77450
Mansur Holdings III, Ltd.(6) 200,000 200,000 0 1.7% 0
875 North Michigan Avenue
Chicago, IL 60011
Robert van Coneghan(6) 200,000 200,000 0 1.7% 0
123 Radcliff Road
Staten Island, NY 10305
Paul A. Kaye Family Trust 180,000 80,000 100,000 1.5% nil
U/A dated October 6, 1993(10)
9 Diamente Road
Rancho Palos Verdes, CA 90275
The Gramercy Partnership, L.L.C.(11) 156,838 156,838 0 1.3% 0
100 Wall Street 2nd Floor
New York, NY 10005
Anglo American Partnership I(6) 150,000 150,000 0 1.3% 0
2049 Century Park East
#2330
Los Angeles, CA 90067
CMS Inc. Profit Sharing Trust(6) 150,000 150,000 0 1.3% 0
16830 Ventura Blvd. #266
Encino, CA 91436
Peter M. Way(6) 150,000 150,000 0 1.3% 0
5308 Ashbrook
Houston, TX 77081
Coury Family Trust(6) 120,000 120,000 0 1.0% 0
22682 Ledeana
Mission Viejo, CA 92691
M&J Investment Trust(6) 112,500 112,500 0 nil 0
14 Woodbridge Road
Hingham, MA 02043
Carl H. Spahr(12) 110,000 100,000 10,000 nil nil
2662 Ridge Pine Drive
La Crescente, CA 91214
54
55
BENEFICIAL
NUMBER OF SHARES OWNERSHIP(1)
--------------------------------- --------------
BEFORE AFTER BEFORE AFTER
NAME AND ADDRESS OF SELLING STOCKHOLDER SALE OFFERED SALE SALE SALE
- --------------------------------------- --------- --------- --------- ------ -----
Karim Amiryani(6) 100,000 100,000 0 nil 0
319 Copa De Oro Road
Los Angeles, CA 90077
Anglo American Partnership II(6) 100,000 100,000 0 nil 0
2049 Century Park East
#2330
Los Angeles, CA 90067
Erland & Company(6) 100,000 100,000 0 nil 0
77 Firenze Avenue
Los Angeles, CA 90046
Hussein A. Khashoggi(6) 100,000 100,000 0 nil 0
% The Gramercy Partnership, L.L.C.
100 Wall Street 2nd Flr.
New York, NY 10005
Michael S. McCord(6) 100,000 100,000 0 nil 0
2001 Kirby Drive
Suite 701
Houston, TX 77019
Michael J. Moser IRA(6) 100,000 100,000 0 nil 0
% Frost National Bank
P.O. Box 2479
San Antonio, TX 78298
Len Rothstein(6) 100,000 100,000 0 nil 0
134 Privateer Mall
Marina del Ray, CA 90292
Santa Fe Financial Corporation(6) 100,000 100,000 0 nil 0
2121 Avenue of the Stars
Suite 2020
Los Angeles, CA 90067
Johnny Thomas(6) 100,000 100,000 0 nil 0
12038 Canary Court
Grand Terrace, GA 92313
Meredith Y. Kelly and 93,000 93,000 0 nil 0
J. Joyce Kelly(6)
4813 Lori Street
Valdosta, GA 31605
Marlin Trust dated 10-31-92(13) 90,000 70,000 20,000 nil nil
22291 Cass Avenue
Woodland Hills, CA 91364
Herman T. Wilson, Jr.(6) 60,000 60,000 0 nil 0
2001 Kirby Drive
Suite 712
Houston, TX 77019
55
56
BENEFICIAL
NUMBER OF SHARES OWNERSHIP(1)
--------------------------------- --------------
BEFORE AFTER BEFORE AFTER
NAME AND ADDRESS OF SELLING STOCKHOLDER SALE OFFERED SALE SALE SALE
- --------------------------------------- --------- --------- --------- ------ -----
The Century Trust(6) 50,000 50,000 0 nil 0
2080 Century Park East
Penthouse Suite
Los Angeles, CA 90067
Dos Cuandos(6) 50,000 50,000 0 nil 0
827 Wade Hampton
Houston, TX 77024
J. Allan Dougherty(6) 50,000 50,000 0 nil 0
One Peachtree Center
Suite 2800
303 Peachtree Street NE
Atlanta, GA 30308
Barry Forwand and Arlene Forwand 50,000 50,000 0 nil 0
JTWROS(6)
8 Hampton Hill Ct.
Huntington, NY 11743
John P. Green(6) 50,000 50,000 0 nil 0
52 Haller Drive
Cedar Grove, NJ 07009
Warren S. Grundfest(6) 50,000 50,000 0 nil 0
8272 Skyline Drive
Los Angeles, CA 90046
Dorothy Hawkins(6) 50,000 50,000 0 nil 0
% J. Allan Dougherty,
Trustee U/T/D 5/31/96
3030 Peachtree Street N.E.
Suite 2800
Atlanta, GA 30308
Bruce S. Kerievsky(6) 50,000 50,000 0 nil 0
7 Arrandale Avenue
Great Neck, NY 11024
Andrew John Long(6) 50,000 50,000 0 nil 0
2480 E. Colorado Blvd.
Pasadena, CA 91107
Stephen L. McCord(6) 50,000 50,000 0 nil 0
8235 Douglas Avenue
Suite 990
Dallas, TX 75225
Richard McCullough(6) 50,000 50,000 0 nil 0
310 Arcadia Place
San Antonio, TX 78209
56
57
BENEFICIAL
NUMBER OF SHARES OWNERSHIP(1)
--------------------------------- --------------
BEFORE AFTER BEFORE AFTER
NAME AND ADDRESS OF SELLING STOCKHOLDER SALE OFFERED SALE SALE SALE
- --------------------------------------- --------- --------- --------- ------ -----
Thomas A. Miklusak(6) 50,000 50,000 0 nil 0
1418 El Vago
La Canada, CA 91011
Kristine K. Moser(6) 50,000 50,000 0 nil 0
7711 Kensico
Houston, TX 77036
Michael Mrkulic(6) 50,000 50,000 0 nil 0
345 Passaic Avenue #D13
Passaic, NJ 07055
Paul Musto and Rose Anne Musto 50,000 50,000 0 nil 0
JTWROS(6)
3 Hammerstein Drive
Saugus, MA 01906
George Szakacs(6) 50,000 50,000 0 nil 0
% Global Wire & Cable, Inc.
61 Willett Street
Passaic, NJ 07055
Robert Weinstein and 50,000 50,000 0 nil 0
Leslie Weinstein
JTWROS(6)
10 Marina Key
Secaucus, NJ 07094
Donald Hoffman(14) 30,000 30,000 0 nil 0
1110 North 24th Street
Allentown, PA 18104
Michael A. Rogawski(14) 30,000 30,000 0 nil 0
9637 Cold Star Court
Columbia, MD 21046
Paul L. Cormier and 28,000 28,000 0 nil 0
Susan E. Cormier
JTWROS(14)
9 Marathon Road
Trumball, CT 06611
Lester Bart and Amy Bart 25,000 25,000 0 nil 0
JTWROS(14)
47-53 188th Street
Flushing, NY 11358
Leanne Mitchell(14) 25,000 25,000 0 nil 0
300 East 74th Street
New York, NY 10021
Arnold Wandel(14) 25,000 25,000 0 nil 0
1041 Annapolis Street
West Lawrence, NY 11691
57
58
BENEFICIAL
NUMBER OF SHARES OWNERSHIP(1)
--------------------------------- --------------
BEFORE AFTER BEFORE AFTER
NAME AND ADDRESS OF SELLING STOCKHOLDER SALE OFFERED SALE SALE SALE
- --------------------------------------- --------- --------- --------- ------ -----
Robert M. Wysinski(14) 25,000 25,000 0 nil 0
6905 Lake Trail Drive
Westerville, OH 43082
Arthur A. Marquardt(14) 20,000 20,000 0 nil 0
133 Concord Street
Brooklyn, NY 11201
Louis F. Mazziotta and 20,000 20,000 0 nil 0
Nancy E. Mazziotta
JTWROS(14)
111 North 31st Street
Allentown, PA 18104
ISM Investments, L.L.C.(14) 17,500 17,500 0 nil 0
100 Wall Street 2nd Flr.
New York, NY 10005
Glenn M. Gardner(14) 17,000 17,000 0 nil 0
3332 N. Woodlawn Avenue
Metarie, LA 70006
Dorothy B. Gartner(14) 17,000 17,000 0 nil 0
24 Orpheum Avenue
Metarie, LA 70005
John J. Walsh(14) 17,000 17,000 0 nil 0
24 Orpheum Avenue
Metarie, LA 70005
Gregory Whitney-Perdon(14) 10,000 10,000 0 nil 0
9 Gracie Square
New York, NY 10028
Burrill & Company(15) 250,000 250,000 0 2.1% 0
120 Montgomery Street
Suite 1370
San Francisco, CA 94104
Global Consultants(15) 239,452 239,452 0 2.0% 0
9025 Wilshire Blvd
Beverly Hills, CA 90211
WebStNews.com.Inc.(16) 200,000 100,000 100,000 1.7% nil
445 Orchard Street
Santa Rosa, CA 95404
The Kriegsman Group(15) 120,000 120,000 0 1.0% 0
866 Iliff Street
Pacific Palisades, CA 90272
58
59
BENEFICIAL
NUMBER OF SHARES OWNERSHIP(1)
--------------------------------- --------------
BEFORE AFTER BEFORE AFTER
NAME AND ADDRESS OF SELLING STOCKHOLDER SALE OFFERED SALE SALE SALE
- --------------------------------------- --------- --------- --------- ------ -----
Dean Erickson(15) 100,000 100,000 0 nil 0
Erickson Consulting Group, Inc.
15332 Antioch Street
Suite 507
Pacific Palisades, CA 90272
Fred Reno(15) 60,000 60,000 0 nil 0
2545 Gardner Place
Glendale CA 91206
Charles Dargan(15) 56,000 56,000 0 nil 0
7551 Trask Avenue
Playa Del Rey, CA 90293
Online Capital GmbH(15) 48,112 48,112 0 nil 0
354 East 50th Street
New York, NY 10022
Global Capital Corporation(15) 42,275 42,275 0 nil 0
9025 Wilshire Boulevard
Beverly Hills, CA 90211
Libra Finance S.A.(15) 42,275 42,275 0 nil 0
160 Central Park South
Suite 3212
New York, NY 10019
Michael S. Rosenblum(15) 40,000 40,000 0 nil 0
Michael S. Rosenblum, PA
1875 Century Park East
Suite 700
Los Angeles, CA 90067
Ambient Capital Group, Inc.(15) 30,000 30,000 0 nil 0
10990 Wilshire Boulevard
Suite 1800
Los Angeles, CA 90024
Shohreh Moheb(15) 30,000 30,000 0 nil 0
5630 Van Gogh Way
Yorba Linda, CA 92887
Alan Stone & Company(15) 25,000 25,000 0 nil 0
10941 Wilshire Boulevard
Suite 1620
Los Angeles, CA 90024
Guohong Wang(15) 14,000 14,000 0 nil 0
937 Kingsley Drive
Arcadia, CA 91007
59
60
BENEFICIAL
NUMBER OF SHARES OWNERSHIP(1)
--------------------------------- --------------
BEFORE AFTER BEFORE AFTER
NAME AND ADDRESS OF SELLING STOCKHOLDER SALE OFFERED SALE SALE SALE
- --------------------------------------- --------- --------- --------- ------ -----
Corporate Capital
Management L.L.C.(15) 14,000 14,000 0 nil 0
2000 South Plymouth Road
Suite 210
Minnetonkia, MN 55305
Lonna Williams(15) 5,000 5,000 0 nil 0
6823 Adolphia Dr.
Carlsbad, CA 92009
- -------------------------
(1) The percentages computed in this column of the table are based upon
11,818,403 shares of the Common Stock which were outstanding on February
26, 1999. Effect is given, where applicable, (a) pursuant to Rule
13d-3(1)(i) under the Exchange Act, to shares issuable upon the exercise of
the Warrants and the conversion of the Series A Preferred Stock and (b) the
issuance of dividends in shares of the Common Stock where the shares of the
Series A Preferred Stock have been converted.
(2) The shares reported in the table as being beneficially owned by this
Selling Stockholder reflect (a) 430,000 shares of the Common Stock acquired
in the Company's first private placement in December 1997; (b) 500,000
shares acquired in the Company's second private placement in July 1998; (c)
105,000 shares acquired in open market purchases; and (d) 4,500,000 shares
issuable upon the conversion of 225,000 shares of the Series A Preferred
Stock acquired in the Company's third private placement in January 1999.
For information as to the three private placements, see "Business -- Need
for Financing." The shares reported in the table as being offered by this
Selling Stockholder reflect only those shares described in (d).
(3) The shares reported in the table as being beneficially owned by this
Selling Stockholder reflect (a) 300,000 shares of the Common Stock acquired
in the Company's first private placement in November 1997, (b) 75,000
shares issuable upon the exercise of a Selling Stockholders Warrant
expiring December 7, 2002 at $.50 per share, (c) 50,000 shares issuable
upon the exercise of a Selling Stockholder Warrant expiring December 13,
2003 at $1.08 per share, (d) 50,000 shares issuable upon the exercise of a
Selling Stockholders Warrant expiring January 20, 2004 at $2.41 per share
and (e) 150,000 shares issuable upon the conversion of 7,500 shares of the
Series A Preferred Stock. See "Business -- Need for Financing." The shares
reported in the table as being offered by this Selling Stockholder reflect
all of the foregoing shares except those described in (a).
(4) The shares reported in the table as being beneficially owned by this
Selling Stockholder reflect (a) 300,000 shares of the Common Stock acquired
in the Company's first private placement in December 1997 and (b) 200,000
shares issuable upon the conversion of 10,000 shares of the Series A
Preferred Stock acquired in the Company's third private placement in
January 1999. See "Business -- Need for Financing." The shares reported in
the table as being offered by this Selling Stockholder reflect only those
shares described in (b).
60
61
(5) The shares reported in the table as being beneficially owned by this
Selling Stockholder reflect (a) 250,000 of the 500,000 shares of the Common
Stock acquired by Melvin Simon & Associates, Inc. in the Company's second
private placement in July 1998 and (b) 250,000 of the 500,000 shares
issuable upon the conversion of 25,000 shares of the Series A Preferred
Stock acquired by Melvin Simon & Associates, Inc. in the Company's third
private placement in January 1999. See "Business -- Need for Financing."
Melvin Simon & Associates, Inc. subsequently divided its shares equally
between Melvin Simon and Herbert Simon. The shares reported in the table as
being offered by this Selling Stockholder reflect only those shares
described in (b).
(6) The shares reported in the table as being beneficially owned and as being
offered by this Selling Stockholder or Selling Stockholders reflect shares
of the Common Stock issuable upon the conversion of shares of the Series A
Preferred Stock acquired in the Company's third private placement in
January 1999. See "Business -- Need for Financing."
(7) The shares reported in the table as being beneficially owned and as being
offered by this Selling Stockholder reflect shares of the Common Stock (a)
issued upon the conversion of shares of the Series A Preferred Stock
acquired in the Company's third private placement in January 1999 (see
"Business -- Need for Financing") and (b) issued as a dividend (653 shares)
when this Selling Stockholder converted its shares of the Series A
Preferred Stock.
(8) The shares reported in the table as being beneficially owned by this
Selling Stockholder reflect (a) 25,000 shares of the Common Stock acquired
in the Company's second private placement in August 1998, (b) 7,000 shares
acquired in an open market purchase and (c) 300,000 shares issuable upon
the conversion of 15,000 shares of the Series A Preferred Stock acquired in
the Company's third private placement in January 1999. See "Business-Need
for Financing." The shares reported in the table as being offered by this
Selling Stockholder reflect only those shares described in (c).
(9) This Selling Stockholder, who acquired 10,000 shares of the Series A
Preferred Stock in the Company's third private placement in January 1999
(see "Business -- Need for Financing"), has advised the Company that he
acquired the shares for the benefit of his children (Brenda Marie Gannon,
Daniel Joseph Gannon, Heather Ann Gannon, Travis Kendall Hodges and Justin
Matthew Hodges) and will offer 40,000 shares of the Common Stock issuable
upon conversion on behalf of each child.
(10) The shares reported in the table as being beneficially owned by this
Selling Stockholder reflect (a) 100,000 shares of the Common Stock acquired
in the Company's first private placement in December 1997 and (b) 80,000
shares issuable upon the conversion of 4,000 shares of the Series A
Preferred Stock acquired in the Company's third private placement in
January 1999. See "Business -- Need for Financing." The shares reported in
the table as being offered by this Selling Stockholder reflect only those
shares described in (b).
(11) The shares reported in the table as being beneficially owned and as being
offered by this Selling Stockholder reflect (a) 12,500 shares issuable upon
the conversion of 625 shares of the Series A Preferred Stock acquired in
the Company's third private placement in January 1999 (see
"Business -- Need for Financing") and (b) 144,338
61
62
shares issuable upon the exercise of a Selling Stockholders Warrant (see
"Plan of Distribution").
(12) The shares reported in the table as being beneficially owned by this
Selling Stockholder reflect (a) 10,000 shares of the Common Stock acquired
in the Company" first private placement in December 1997 and (b) 100,000
shares issuable upon the conversion of 5,000 shares of the Series A
Preferred Stock acquired in the Company's third private placement in
January 1999. See "Business -- Need for Financing." The shares reported in
the table as being offered by this Selling Stockholder reflect only those
shares described in (b).
(13) The shares reported in the table as being beneficially owned by this
Selling Stockholder reflect (a) 20,000 shares of the Common Stock acquired
in the Company's first private placement in November 1997 and (b) 70,000
shares issuable upon the conversion of 3,500 shares of the Series A
Preferred Stock acquired in the Company's third private placement in
January 1999. See "Business -- Need for Financing." The shares reported in
the table as being offered by this Selling Stockholder reflect only those
described in (b).
(14) The shares reported in this table as being beneficially owned and as being
offered by this Selling Stockholder or Selling Stockholders reflect shares
issuable upon conversion of shares of the Series A Preferred Stock acquired
in the Company's third private placement. See "Business -- Need for
Financing." The shares of Series A Preferred purchased by this Selling
Stockholder or Selling Stockholders, who is or are an accredited investor
as such term is defined in Rule 501(a) under the Securities Act, were less
than the minimum permitted by the private placement (i.e., 2,500 shares),
but were subscribed for by The Gramercy Partnership, L.L.C. and then
transferred to this Selling Stockholder.
(15) The shares reported in the table as beneficially owned and as being offered
by this Selling Stockholder reflect shares of the Common Stock issuable
upon the exercise of one or two Selling Stockholders Warrants. See "Plan of
Distribution."
(16) The shares reported in the table as beneficially owned by this Selling
Stockholder reflect (a) 100,000 shares of the Common Stock received as a
fee for setting up a Web site for the Company and reporting on the Company
on its Web site and (b) 100,000 shares of the Common Stock issuable upon
the exercise of a Selling Stockholders Warrant received for the same
consideration (see "Plan of Distribution"). The shares reported in the
table as being offered reflect only those shares described in (b).
62
63
LEGAL MATTERS
The validity of the securities offered hereby will be passed upon for the
Company by Wachtel & Masyr, LLP, New York, New York.
EXPERTS
The financial statements of the LifePoint, Inc. (a development stage enterprise)
at March 31, 1998 and 1997 and for each of the three years in the period ended
March 31, 1998, appearing in this prospectus and the Registration Statement have
been audited by Ernst & Young LLP, independent auditors, and for the period
October 8, 1992 (inception) through March 31, 1995, by Wolinetz, Gottlieb &
Lafazan, P.C., independent auditors, as set forth in their respective reports
thereon appearing elsewhere herein, and are included in reliance upon such
reports given upon the authority of such firms as experts in accounting and
auditing.
COMMISSION POSITION ON INDEMNIFICATION
The Board of Directors has authorized indemnification of directors and officers
of the Company to the fullest extent permitted by Delaware law.
Section 145(a) of the GCL permits a corporation to indemnify any person who was
or is a party or is threatened to be made a party to any threatened, pending or
completed action, suit or proceeding, whether civil, criminal, administrative or
investigative (other than an action by or in the right of the corporation), by
reason of the fact that he or she is or was a director, officer, employee or
agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation, partnership,
joint venture, trust or other enterprise, against expenses (including attorneys'
fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred in connection with such action, suit or proceeding if he or she acted
in good faith and in a manner he or she reasonably believed to be in, or not
opposed to, the best interests of the corporation, and, with respect to any
criminal action or proceeding, had no reasonable cause to believe his or her
conduct was unlawful.
Under Section 145(b) of the GCL, a corporation also may indemnify any person who
was or is a party or is threatened to be made a party to any threatened, pending
or completed action or suit by or in the right of the corporation to procure a
judgment in its favor by reason of the fact that he or she is or was a director,
officer, employee or agent of the corporation, or is or was serving at the
request of the corporation as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other enterprise, against
expenses (including attorneys' fees) actually and reasonably incurred by him or
her in connection with the defense or settlement of such action or suit if he or
she acted in good faith and in manner he or she reasonably believed to be in, or
not opposed to, the best interests of the corporation. However, in such an
action by or on behalf of a corporation, no indemnification may be made in
respect of any claim, issue or matter as to which the person is adjudged liable
to the corporation unless and only to the extent that the Delaware Court of
Chancery or the court in which such action or suit was brought determines that,
despite the adjudication of liability but in view of all the circumstances, of
the case, the person is fairly and reasonably entitled to indemnity for such
expenses which the court shall deem proper.
63
64
Pursuant to Section 145(e) of the GCL, to the extent a current or former
director or officer of a corporation has been successful on the merits or
otherwise in defense of any action, suit or preceding referred to in subsections
(a) or (b), he or she shall be indemnified against expenses (including
attorneys' fees) actually and reasonably incurred in connection therewith.
Under Section 145(d) of the GCL, unless the determination as to indemnification
is made by a court, the determination as to a person who is a director or
officer at the time of determination must be made (1) by a majority vote of the
directors who are not parties to such action, suit or proceeding, even though
less than a quorum; (2) by a committee of such directors designated by a
majority vote of such directors, even though less than a quorum; (3) if there
are no such directors, or if the directors so direct, by independent legal
counsel in a written opinion; or (4) by the stockholders.
In addition, under Section 145(f) of the GCL, the indemnification provided by
Section 145 shall not be deemed exclusive of any other rights to which those
seeking indemnification may be entitled under any by-law, agreement, vote of
stockholders or disinterested directors or otherwise, both as to an action in
his or her official capacity and as to an action in another capacity while
holding such office.
Insofar as indemnification for liabilities arising under the Securities Act may
be permitted to directors, officers and controlling persons of the Company
pursuant to the foregoing provisions, or otherwise, the Company has been advised
that in the opinion of the Commission such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than
the payment by the Company of expenses incurred or paid by a director, officer
or controlling person of the Company in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person
in connection with the securities being registered, the Company will, unless in
the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue.
SELECTED FINANCIAL DATA
The following tables set forth selected financial data of the Company for each
of the five fiscal years ended March 31, 1998, the nine-month periods ended
December 31, 1998 and 1997 and cumulative from October 8, 1992 (inception) to
December 31, 1998. In the opinion of the Company, the unaudited financial
statements reflect all adjustments (which include only normal recurring
adjustments) necessary for a fair presentation of the financial data. This
selected financial data should be read in conjunction with "Management's
Discussion and Analysis of Results of Operations and Financial Condition" and
the Company's financial statements and related notes thereto included elsewhere
in this prospectus.
64
65
FOR THE NINE MONTHS
ENDED DECEMBER 31, FOR THE YEARS ENDED MARCH 31,
------------------------- ---------------------------------------
1998 1997 1998 1997 1996
----------- ----------- ----------- ----------- -----------
(UNAUDITED) (UNAUDITED)
Selected Statement of Operations
Data:
Revenues........................... $ -- $ -- $ -- $ -- $ --
Costs and Expenses:
Selling, General and
Administrative................. 1,194,048 407,022 672,998 268,668 318,510
Research and Development......... 818,117 851,376 1,052,233 1,735,449 949,439
Depreciation and Amortization.... 129,428 161,714 217,034 143,634 143,969
Interest Expense -- Parent....... -- 34,530 34,530 23,095 --
Management Fees -- Parent.......... -- 409,838 409,838 420,000 420,000
Interest Expense................. -- 956 956 5,822 71,882
----------- ----------- ----------- ----------- -----------
Total Costs and Expenses........... 2,141,593 1,865,466 2,387,589 2,596,668 1,903,800
----------- ----------- ----------- ----------- -----------
Loss from Operations............... (2,141,598) (1,865,466 (2,387,589) (2,596,668) (1,903,800)
----------- ----------- ----------- ----------- -----------
Other Income (Expense)............. 28,647 (185,228) (164,701) (33,905) 262,995
----------- ----------- ----------- ----------- -----------
Net Loss........................... $(2,112,946) $(2,050,694) $(2,552,290) $(2,630,573) $(1,640,805)
=========== =========== =========== =========== ===========
Earnings per Common Share -- Basic
Weighted Average Common Shares
Outstanding.................... 11,395,289 7,225,512 8,032,231 5,221,900 5,221,900
=========== =========== =========== =========== ===========
Net Loss per Common Share --
Basic.......................... $ (.19) $ (.28) $ (.32) $ (.50) $ (.31)
=========== =========== =========== =========== ===========
Earnings per Common Share, Assuming
Dilution
Weighted Average Common Shares... 14,671,047 7,668,912 8,863,276 5,221,900 5,221,900
=========== =========== =========== =========== ===========
Net Loss per Common Share, Assuming
Dilution......................... $ (.14) $ (.27) $ (.29) $ (.50) $ (.31)
=========== =========== =========== =========== ===========
CUMULATIVE
FROM
OCTOBER 8, 1992
FOR THE YEARS ENDED MARCH 31, (INCEPTION)
--------------------------- TO DECEMBER 31,
1995 1994 1998
----------- ----------- ---------------
(UNAUDITED)
Selected Statement of Operations
Data:
Revenues........................... $ -- $ -- $ --
Costs and Expenses:
Selling, General and
Administrative................. 475,400 604,185 3,778,596
Research and Development......... 1,261,219 728,272 6,537,218
Depreciation and Amortization.... 162,871 92,245 906,120
Interest Expense -- Parent....... 3,319 31,639 95,790
Management Fees -- Parent.......... 420,000 420,000 2,089,838
Interest Expense................. 40,640 -- 119,300
----------- ----------- ------------
Total Costs and Expenses........... 2,363,449 1,876,341 13,526,862
----------- ----------- ------------
Loss from Operations............... (2,363,449) (1,876,341) (13,526,862)
----------- ----------- ------------
Other Income (Expense)............. 31,232 (383,951) (259,683)
----------- ----------- ------------
Net Loss........................... $(2,332,217) $(2,260,292) $(13,786,545)
=========== =========== ============
Earnings per Common Share -- Basic
Weighted Average Common Shares
Outstanding.................... 5,221,900 4,342,458
=========== =========== ============
Net Loss per Common Share --
Basic.......................... $ (.45) $ (.52)
=========== =========== ============
Earnings per Common Share, Assuming
Dilution
Weighted Average Common Shares... 5,221,900 4,342,458
=========== =========== ============
Net Loss per Common Share, Assuming
Dilution......................... $ (.45) $ (.52)
=========== =========== ============
AS OF DECEMBER 31, AS OF MARCH 31,
-------------------------- -------------------------------------------------------------------
1998 1997 1998 1997 1996 1995 1994
----------- ----------- ---------- ----------- ---------- ---------- ----------
(UNAUDITED) (UNAUDITED)
Selected Balance Sheet Data:
Working Capital (Deficit)..... $(378,270) $ 884,589 $ 409,951 $(1,996,218) $ 536,880 $2,089,323 $4,360,362
========= ========== ========== =========== ========== ========== ==========
Total Assets.................. $ 736,865 $1,558,240 $1,073,284 $ 595,947 $1,175,390 $4,444,105 $5,268,820
========= ========== ========== =========== ========== ========== ==========
Stockholders' Equity
(Deficit)................... $(153,496) $1,237,427 $ 735,831 $(1,573,686) $1,056,887 $2,697,692 $5,029,909
========= ========== ========== =========== ========== ========== ==========
65
66
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
LIQUIDITY AND CAPITAL RESOURCES
The Company is a development stage enterprise with no earnings history. The
Company is developing, as its first product, proprietary systems that will test
for substance abuse and alcohol.
The Company temporarily suspended its product development activities on
September 19, 1997 because of the cessation by SAT, its then parent, in August
1997 of providing financing to the Company and SAT's subsequent filing for
bankruptcy protection on September 10, 1997. The Company was able to resume such
activities on October 27, 1997 as a result of a loan by Meadow Lane that was
repaid from the proceeds from the private placement conducted by the Company
pursuant to Regulation D under the Securities Act described in the succeeding
paragraph.
On November 21, 1997, the Company closed as to the sale of 1,690,000 shares of
the Common Stock. On December 10, 1997, the Company closed as to the sale of an
additional 1,510,000 shares of the Common Stock. The aggregate of 3,200,000
shares was sold at $.50 per share and the Company realized $1,600,000 in gross
proceeds. There were no underwriting discounts or commissions allowed or paid
pursuant to the private placement. A finder's fee of $160,000 was paid to
Jonathan J. Pallin who was a member of Meadow Lane and who, on October 31, 1997,
was elected as the Chairman of the Board and a director of the Company. Since
January 8, 1999, he has served the Company as a director and until March 31,
1999 as a financial consultant.
On July 23, 1998, the Company closed as to the sale of 1,000,000 shares of the
Common Stock. On August 26, 1998, the Company sold an additional 25,000 shares
of the Common Stock. An aggregate of 1,025,000 shares of the Common Stock was,
accordingly, sold pursuant to this second private placement pursuant to
Regulation D under the Securities Act. This offering of a minimum of 1,000,000
and a maximum of 5,000,000 shares of the Common Stock expired by its terms on
October 14, 1998 without any additional shares being sold. The aggregate of
1,025,000 shares was sold at $1.00 per share and the Company realized $1,025,000
in gross proceeds. There were no underwriting discounts or commissions related
to the private placement. However, a Selling Stockholder Warrant expiring
December 13, 2003 to purchase 50,000 shares of the Common Stock at $1.08 was
granted to an unaffiliated person for his assistance in completing $500,000 of
this offering.
The Company has applied for three small business grants from the National
Institute of Health, in conjunction with Cedars Sinai Medial Center. If the
Company was to receive all three grants, the Company may receive up to
$3,000,000 in additional funding. However, there can be no assurance that the
Company will receive any of these grants.
On January 21, 1999, the Company closed as to the sale of 600,000 shares of the
Series A 10% Preferred Stock, pursuant to a third private placement pursuant to
Regulation D under the Securities Act. The aggregate of 600,000 shares was sold
at $10.00 per share and the Company realized $6,000,000 in gross proceeds.
Finders' fees were paid to various consultants and bankers for their assistance
in helping the Company to complete this private placement. For their assistance,
these finders received an aggregate of $592,078 in cash fees (including $420,451
to Mr. Pallin) and Selling Stockholders Warrants expiring January 20, 2004 to
purchase an aggregate of 447,000 shares at $2.41 per share.
66
67
Management believes that, with the net proceeds from the private placement
described in the preceding paragraph, the Company has sufficient funds to
complete the working prototype for the testing product for drugs of abuse and
alcohol and that the prototype will be completed not earlier than the first
quarter of 2000. There can be no assurance that management's estimate as to
costs and timing will be correct. Any delays may further increase the Company's
costs of development.
The latest estimate which management has is that completion of the development
and launching of a saliva based drugs of abuse and alcohol testing product after
the prototype will require an additional cost of approximately $7,000,000,
beyond the recently raised $6,000,000, and that the product will not be launched
earlier than the third quarter of 2000. This contrasts with SAT's June 1997
publicly announced incremental costs for the Company of $16,000,000 to
$18,000,000 (including the costs to develop the prototype) and a launch date of
the first quarter of 1999 at the earliest. However, these estimates were prior
to the suspension of product development efforts and the subsequent reduced
product development efforts over the last 17 months.
Since October 1997, management had been pursuing parallel paths for long-term
financing: venture capital, strategic partnering, a public offering and/or a
private placement for all or part of the required funding.
Management had initially believed that one likely source for the additional
funding would have been an investment by a venture capital investor or
investors. Any such investment would have been likely to dilute substantially
the stock interest of the current stockholders. In addition, to make the
investment more attractive to potential venture capital investors, the Company
may have had to transfer its operations to a private subsidiary in which such
investor or investors could have invested. This is because venture capital
investors generally prefer the vehicle of an initial public offering as their
"out" strategy rather then invest in an already public company. Management does
not currently believe that an investment in the Company by a venture capital
investor to be a likely source of funding at this time.
Management has also been exploring the possibility of obtaining a strategic
partner for the Company. To this end, the Company has an agreement with Burrill,
a San Francisco-based merchant bank focused exclusively on servicing life
science companies. Burrill assists its portfolio companies in maximizing their
value through various strategic partnering relationships. Burrill has been
engaged to introduce the Company to potential partners with an on-going interest
in saliva-based diagnostics or point-of-care diagnostics and which might be
otherwise interested in partnering with or acquiring the Company. Burrill has
advised the Company that the process to ascertain and close with a strategic
partner may take five months or more. In addition, management believes that a
potential marketing partner could be obtained on more acceptable terms when
there is a working prototype for the instrument and the disposables and certain
preliminary clinical data are obtained. Management currently anticipates that
the prototype will be completed by the first quarter of 2000 at the earliest.
For additional information as to the Company's agreement with Burrill, see
"Business -- Need for Financing."
Management has also pursued the possibility of an underwritten public offering
and has received expressions of interest from several well-known small national
and large regional firms. These firms have suggested, however, that the Company
wait to conduct such an offering until the working prototype is completed (the
first quarter of 2000 at the earliest). There can be no assurance that stock
market conditions would be receptive to a public offering by the Company at that
time. In addition, competitive conditions in the substance
67
68
abuse testing industry at that time may make the Company less attractive to
potential public investors. See the "Business -- Competition."
Having successfully consummated three private placements pursuant to Regulation
D under the Securities Act since November 1997, the Company may seek to raise
the additional required financing through this method. As with a public
offering, there can be no assurance that potential investors would be receptive
to a private placement by the Company at that time, either because of general
stock market conditions or conditions generally in the substance abuse
technology industry.
There can be no assurance that the Company will be successful in securing
additional financing, whether through a strategic partner, a public offering or
a private placement.
If all of the Warrants and the Selling Stockholders Warrants to purchase an
aggregate of 3,095,741 shares of the Common Stock which are outstanding on
February 26, 1999 were subsequently exercised, the Company would realize
$3,298,966 in gross proceeds. If all of the Options to purchase an aggregate of
794,167 shares outstanding on February 26, 1999 were subsequently exercised, the
Company would realize $397,084 in gross proceeds. However, there can be no
certainty as to when and if any of these securities may be exercised, especially
as to the Options and a Selling Stockholders Warrant which were not all
currently exerciseable as of February 26, 1999. Accordingly, management believes
that the Company cannot rely on these exercises as a source of financing.
OPERATING CASH FLOWS
Net cash used by operating activities during the nine months ended December 31,
1998 amounted to $1,274,000 as compared to $1,893,000 during the nine months
ended December 31, 1997, which was primarily the result of reduced expenses
during 1998 due to cash restraints versus normal product development activities
during 1997.
Net cash used for operations during fiscal 1998 amounted to $2,322,000 as
compared to $2,119,000 and $1,656,000 in fiscal 1997 and fiscal 1996,
respectively, which was primarily the result of moving product development from
the research stage to the development stage.
INVESTING CASH FLOWS
During the nine months ended December 31, 1998, net cash used by investing
activities was $21,000 as a result of purchases of property and equipment and
patent related costs. Net cash provided by investing activities of $49,000
during the nine months ended December 31, 1997 was generated from sales of
property and equipment offset by the purchases of property and equipment and
patent costs.
During fiscal 1998, net cash provided by investing activities of $20,000 was
generated from the sale of property and equipment offset by the purchases of
property and equipment. Net cash used by investing activities of $53,000 during
fiscal 1997 was for purchases of property and equipment. During fiscal 1996, net
cash provided by investing activities of $3,248,000 resulted from the sale of
approximately $3,286,000 in marketable securities net of purchases of property
and equipment and patent costs.
FINANCING CASH FLOWS
Net cash provided by financing activities amounted to $1,020,000 during the nine
months ended December 31, 1998 related to the second private placement described
above with net proceeds of approximately $1,019,000.
68
69
Net cash provided by financing activities amounted to $2,965,000 during the nine
months ended December 31, 1997. Financing cash flows were provided by the first
private placement described above with net proceeds of approximately $1,500,000
and a loan by SAT of approximately $1,465,000.
Net cash provided by financing activities amounted to $2,900,000 during fiscal
1998. Financing cash flows were provided by loans from SAT of approximately
$1,465,000 and the private placement described above with net proceeds of
approximately $1,434,000.
Net cash provided by financing activities amounted to $1,922,000 during the
fiscal 1997. Financing cash flows were provided by loans from SAT of
approximately $1,668,000 and net proceeds from the repayment of not receivable
from SAT in the amount of approximately $282,000.
RESULTS OF OPERATIONS
FISCAL 1998 VS. FISCAL 1997
During fiscal 1998, the Company continued as a development stage enterprise with
no revenues. Selling, general and administrative expenses were $673,000 in
fiscal 1998 as compared to $269,000 in fiscal 1997, or an increase of $404,000
or 150.2%. Management fees paid to SAT were $410,000 in fiscal 1998 as compared
to $420,000 in fiscal 1997, a decrease of $10,000 or 2.4%. During fiscal 1998,
the management fees were based on the proportional costs for shared resources
and personnel. However, during the second quarter of fiscal 1998, the management
fee was discontinued because services were no longer provided by SAT. Overall,
selling, general and administrative expenses and management fees were $1,083,000
in fiscal 1998 versus $689,000 in fiscal 1997, and increased based on actual
incurred expenses rather than a previously negotiated fee. Research and
development expenditures totaled $1,052,000 in fiscal 1998 as compared to
$1,735,000 in fiscal 1997 or a decrease of $683,000 or 39.4%. The decrease was
primarily the result of the temporary suspension and subsequent reduced
expenditures for product development efforts by the Company, due to a cessation
of funding by its former parent SAT. As of March 31, 1998, the Company did not
anticipate generating revenues from product sales during the fiscal year ending
March 31, 1999 and not until after submission of the drugs of abuse/alcohol
testing product to the FDA in March 2000 at the earliest. Accordingly,
management anticipated that operating losses would continue for at least a
24-month period.
The net loss for fiscal 1998 was $2,552,000 as compared to $2,631,000 for fiscal
1997. The decrease of $79,000 or 2.8% was primarily the result of a suspension
and subsequent reduction in the product development expenditures due to a
cessation of funding by the Company's former parent SAT.
FISCAL 1997 VS. FISCAL 1996
During fiscal 1997, the Company continued as a development stage enterprise with
no revenues. Selling, general and administrative expenses were $269,000 in
fiscal 1997 as compared to $319,000 in fiscal 1996 or a decrease of $50,000 or
15.7%, primarily the result of lower travel, utility and telephone expenses.
Research and development expenditures totaled $1,735,000 in fiscal 1997 as
compared to $949,000 in fiscal 1996 or an increase of $786,000 or 82.8%. The
increase was primarily the result of expanded people requirements to bring the
saliva testing to the next phase of development. Costs included those for
engineering and chemist consulting time, as well as those for additional the
Company's full
69
70
time employees. Management fees paid to SAT were $420,000 in both fiscal 1997
and fiscal 1996.
The net loss for fiscal 1997 was $2,631,000 as compared to $1,641,000 for fiscal
1996. The increase of $990,000 or 60.3% was primarily the result of additional
people requirements. The costs include expenses for engineering and chemists
consulting time and additional employees.
NINE MONTHS ENDED DECEMBER 31, 1998 VS. NINE MONTHS ENDED
DECEMBER 31, 1997.
During the nine months ended December 31, 1998, the Company incurred $818,000 in
expenses for research and development and an additional $1,194,000 on general
and administrative expenses, as compared with $851,000 and $407,000,
respectively, during the nine months ended December 31, 1997. The general and
administrative expenses for the nine months ended December 31 1998 are higher
because, during the same period in 1997, significant general and administrative
expenses were paid to SAT as a management fee and these expenses are now
incurred directly by the Company. During the nine months ended December 31,
1997, an additional $410,000 was paid to SAT as the management fee. The research
and development expenses for the three months ended December 31, 1998 were
higher than those in the same period during 1997 due to the fact that during the
three months ended December 31, 1997 the Company temporarily ceased the product
development program.
The Company's net loss during the nine months ended December 31, 1998 was
$2,113,000 as compared with $2,051,000 during the nine months ended December 31,
1997. The increase of $62,000 or 3.0% was due to the reasons described in the
preceding paragraph. Because management does not anticipate that the Company
will commence marketing until the third quarter of 2000 at the earliest,
management anticipates that operating losses will continue until that date or
longer.
IMPACT OF THE YEAR 2000 ISSUE
The Year 2000 Issue is the result of computer programs being written using two
digits rather than four to define the applicable year. Any computer programs
that have date-sensitive software may recognize a date using "00" as the year
1900 rather than the year 2000. This could result in a system failure or
miscalculations causing disruptions of operations, including among other things,
a temporary inability to process transactions, send invoices, or engage in
similar normal business activities.
Based on a recent assessment, the Company determined that, with one exception,
all of the software currently in use on its computer system will properly
utilize dates beyond December 31, 1999. The program that is not currently
compliant will be updated to become compliant by March 1999. If the required
update does not become available, a more recent version of the program will be
purchased. The total cost for the Company's computer systems to become fully
compliant will be less than $5,000.
INFLATION
The Company believes that inflation has not had a material effect on its results
of operations.
70
71
FORWARD LOOKING STATEMENTS
This "Management's Discussion and Analysis of Financial Condition and Results of
Operations" contains forward looking statements that are subject to a number of
risks and uncertainties. Among the important factors that could cause actual
results to differ materially from those anticipated by the statements made above
are the following:
As indicated in the section "Liquidity and Cash Resources" under this caption
"Management's Discussion and Analysis of Financial Condition and Results of
Operations," management estimates an incremental cost of $7,000,000 over the
recently raised $6,000,000 to complete the development of a saliva-based drug
and alcohol testing product. Unless this financing is obtained and the product
development program successfully completed (which is not anticipated until the
third quarter of 2000 at the earliest), the Company will continue without
revenues from a product or service and, accordingly, will have to cease
operating. Although management is pursuing, or will pursue, these financial
routes: a strategic partner, a public offering and a private placement, there
can be no assurance that any additional financing will be consummated.
As indicated in "Business -- Employees," the Company, as of February 26, 1999,
employed 10 employees, of whom 8 were directly involved in its research and
development program. Management estimates that it will require approximately 24
scientists and engineers to complete this project and, if the product is
successfully developed, approximately 24 persons to commence manufacturing
thereof. There can be no assurance that such personnel will be available when
the Company requires them, especially at its current location in Rancho
Cucamonga, California. Management anticipates that the Company, in such
circumstances, may have to move to a different location in California where such
personnel may be more readily available, which move will add to the Company's
costs. There can be no assurance that the Company, in such circumstances, will
be any more successful in such new location in obtaining such personnel.
An independent consultant in June 1997 confirmed management's belief that the
Company's saliva-based drugs of abuse and alcohol testing products could be
developed and that, once developed, there would be a significant market
therefor. However, there are certain risks in any research and development
program that the product will not ultimately be developed, that it will be
developed later than anticipated, that the estimated costs will be higher than
projected and that the market may be smaller then anticipated when the product
is ultimately marketed.
Also, as indicated in "Business -- Competition," management believes that saliva
sample testing is unique in that, to its knowledge, no company is currently
offering a substance abuse detection method using saliva samples as a specimen
on an "on-site" basis. However, as noted therein, the Company has been advised
that such a product may be under development by two or more companies and,
accordingly, there can be no assurance that such a product will not be offered
by a competitor.
71
72
INDEX TO FINANCIAL STATEMENTS
ITEM PAGE
- ---- ----
AUDITED ANNUAL FINANCIAL STATEMENTS
1. Report of Ernst & Young LLP................................. F-2
2. Report of Wolinetz, Gottlieb & Lafazan, P.C. ............... F-3
3. Balance Sheets as of March 31, 1998 and 1997................ F-4
4. Statements of Operations for the years ended March 31, 1998,
1997 and 1996 and for the Period from October 8, 1992
(inception) to March 31, 1998............................... F-5
5. Statements of Stockholders' (Deficit) Equity for the years
ended March 31, 1998, 1997 and 1996 and for the Period from
October 8, 1992 (inception) to March 31, 1998............... F-7
6. Statements of Cash Flows for the years ended March 31, 1998,
1997 and 1996 and for the Period from October 8, 1992
(inception) to March 31, 1998............................... F-8
7. Notes to Financial Statements............................... F-10
UNAUDITED ANNUAL FINANCIAL STATEMENTS
1. Balance Sheets as of December 31, 1998 and March 31, 1998... F-19
2. Statements of Operations for the nine months ended December
31, 1998 and 1997 and for the Period from October 8, 1992
(inception) to December 31, 1998............................ F-20
3. Statements of Cash Flows for the nine months ended December
31, 1998 and 1997 and for the Period from October 9, 1992
(inception) to December 31, 1998............................ F-21
4. Notes to Financial Statements............................... F-23
F-1
73
REPORT OF INDEPENDENT AUDITORS
The Board of Directors
LifePoint, Inc.
We have audited the accompanying balance sheets of LifePoint, Inc. (a
development stage enterprise) (the "Company") as of March 31, 1998 and 1997, and
the related statements of operations, stockholders' (deficit) equity, and cash
flows for each of the three years in the period ended March 31, 1998, and for
the period October 8, 1992 (inception) through March 31, 1998. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits. The financial statements for the period October 8, 1992 (inception)
through March 31, 1995 were audited by other auditors whose report dated May 26,
1995 expressed an unqualified opinion on those statements. The financial
statements for the period October 8, 1992 (inception) through March 31, 1995
include total costs and expenses and a net loss of $4,497,000 and $4,850,000,
respectively. Our opinion on the statements of operations and cash flows for the
period October 8, 1992 (inception) through March 31, 1998, insofar as it relates
to amounts for prior periods through March 31, 1995, is based solely on the
report of other auditors.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits and the report of other auditors provide a reasonable
basis for our opinion.
In our opinion, based on our audit and the report of other auditors, the
financial statements referred to above present fairly, in all material respects,
the financial position of LifePoint, Inc. at March 31, 1998 and 1997, and the
results of its operations and its cash flows for each of the three years in the
period ended March 31, 1998 and the period from October 8, 1992 (inception)
through March 31, 1998, in conformity with generally accepted accounting
principles.
The accompanying financial statements have been prepared assuming that
LifePoint, Inc. will continue as a going concern. As more fully described in
Note 2, the Company has incurred recurring operating losses and will require
additional capital to continue the research, development and ultimate
manufacture and marketing of its product and to fund its working capital
requirements for the next 12 months. The aforementioned conditions raise
substantial doubt about the Company's ability to continue as a going concern.
Management's plans in regard to these matters are also described in Note 2. The
financial statements do not include any adjustments to reflect the possible
future effects on the recoverability and classification of assets or the amounts
and classification of liabilities that may result from the outcome of this
uncertainty.
/s/ ERNST & YOUNG LLP
--------------------------------------
Riverside, California
May 13, 1998
F-2
74
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
The Board of Directors and Shareholders
LifePoint, Inc.
(f/k/a U.S. Drug Testing, Inc.)
Rancho Cucamonga, California
We have audited the accompanying statements of operations, stockholders'
(deficit) equity and cash flows for the period October 8, 1992 (inception)
through March 31, 1995 of LifePoint, Inc. (a Development State Enterprise).
These financial statements are the responsibility of the Company's management.
Our responsibility is to express an opinion on these financial statements based
on our audit.
We conducted our audit in accordance with generally accepted auditing standards.
Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the results of operations and cash flows of LifePoint,
Inc. for the period October 8, 1992 (inception) through March 31, 1995, in
conformity with generally accepted accounting principles.
/s/ WOLINETZ, GOTTLIEB & LAFAZAN P.C.
-------------------------------------------
WOLINETZ, GOTTLIEB & LAFAZAN, P.C.
Rockville Center, New York
May 26, 1995
F-3
75
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
BALANCE SHEETS
MARCH 31
---------------------------
1998 1997
------------ -----------
ASSETS
Current assets:
Cash and cash equivalents........................ $ 597,254 $ --
Prepaid expenses and other current assets........ 150,150 49,996
------------ -----------
Total current assets.......................... 747,404 49,996
Property and equipment, net........................ 286,188 505,799
Patents and other assets, net...................... 39,692 40,152
------------ -----------
$ 1,073,284 $ 595,947
============ ===========
LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY
Current liabilities:
Cash overdraft................................... $ -- $ 119,514
Accounts payable................................. 119,577 216,687
Accrued expenses................................. 217,876 16,340
Current portion of capital lease obligations..... -- 25,494
Note payable -- parent........................... -- 1,668,179
------------ -----------
Total current liabilities..................... 337,453 2,046,214
Capital lease obligations.......................... -- 123,419
------------ -----------
337,453 2,169,633
Commitments and contingencies (Note 7)
Stockholders' (deficit) equity:
Common stock, $.001 par value; 50,000,000 shares
authorized, 10,497,206 and 5,221,900 shares
issued and outstanding at March 31, 1998 and
1997, respectively............................ 10,497 5,222
Additional paid-in capital....................... 12,398,933 7,542,401
Deficit accumulated in the development stage..... (11,673,599) (9,121,309)
------------ -----------
Total stockholders' (deficit) equity.......... 735,831 (1,573,686)
------------ -----------
$ 1,073,284 $ 595,947
============ ===========
See Accompanying Notes.
F-4
76
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
STATEMENTS OF OPERATIONS
CUMULATIVE
FROM
YEARS ENDED MARCH 31 OCTOBER 8, 1992
--------------------------------------- (INCEPTION) TO
1998 1997 1996 MARCH 31, 1998
----------- ----------- ----------- ---------------
Revenues..................... $ -- $ -- $ -- $ --
Costs and expenses:
Selling, general and
administrative
expenses................ 672,998 268,668 318,510 2,584,548
Research and development... 1,052,233 1,735,449 949,439 5,719,101
Depreciation and
amortization............ 217,034 143,634 143,969 776,692
Interest
expense -- parent....... 34,530 23,095 -- 95,790
Management
fees -- parent.......... 409,838 420,000 420,000 2,089,838
Interest expense........... 956 5,822 71,882 119,300
----------- ----------- ----------- ------------
Total costs and expenses
from operations....... 2,387,589 2,596,668 1,903,800 11,385,269
----------- ----------- ----------- ------------
Loss from operations......... (2,387,589) (2,596,668) (1,903,800) (11,385,269)
Other income (expense):
Interest income............ 13,895 -- 104,787 449,516
Loss on disposal of
property and
equipment............... (178,596) (33,905) -- (212,501)
Gain (loss) on sale of
marketable securities... -- -- 76,441 (627,512)
Interest
income -- parent........ -- -- 81,767 102,167
----------- ----------- ----------- ------------
Total other income
(expense)............. (164,701) (33,905) 262,995 (288,330)
----------- ----------- ----------- ------------
Net loss..................... $(2,552,290) $(2,630,573) $(1,640,805) $(11,673,599)
=========== =========== =========== ============
F-5
77
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
STATEMENTS OF OPERATIONS -- (CONTINUED)
CUMULATIVE
FROM
YEARS ENDED MARCH 31 OCTOBER 8, 1992
--------------------------------------- (INCEPTION) TO
1998 1997 1996 MARCH 31, 1998
----------- ----------- ----------- ---------------
Earnings per common share --
basic:
Weighted average common
shares outstanding...... 8,032,231 5,221,900 5,221,900
=========== =========== ===========
Net loss per common share--
basic................... $ (.32) $ (.50) $ (.31)
=========== =========== ===========
Earnings per common share,
assuming dilution:
Weighted average common
shares outstanding...... 8,863,276 5,221,900 5,221,900
=========== =========== ===========
Net loss per common share,
assuming dilution....... $ (.29) $ (.50) $ (.31)
=========== =========== ===========
See Accompanying Notes.
F-6
78
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY
FOR THE PERIOD OCTOBER 8, 1992 (INCEPTION) TO MARCH 31, 1998
DEFICIT
ACCUMULATED
ADDITIONAL IN THE
COMMON PAID-IN DEVELOPMENT
STOCK CAPITAL STAGE TOTAL
------- ----------- ------------ -----------
Balance at October 8, 1992............. $ -- $ -- $ -- $ --
Issuance of 3,500,000 shares of
common stock for value of assets
transferred from parent........... 3,500 445,186 -- 448,686
Net loss for the period ended March
31, 1993.......................... -- -- (257,422) (257,422)
------- ----------- ------------ -----------
Balance at April 1, 1993............... 3,500 445,186 (257,422) 191,264
Sale of 1,721,900 shares of common
stock in connection with initial
public offering, net of offering
costs of $1,510,663............... 1,722 7,097,215 -- 7,098,937
Net loss for the year ended March 31,
1994.............................. -- -- (2,260,292) (2,260,292)
------- ----------- ------------ -----------
Balance at March 31, 1994.............. 5,222 7,542,401 (2,517,714) 5,029,909
Net loss for the year ended March 31,
1995.............................. -- -- (2,332,217) (2,332,217)
------- ----------- ------------ -----------
Balance at March 31, 1995.............. 5,222 7,542,401 (4,849,931) 2,697,692
Net loss for the year ended March 31,
1996.............................. -- -- (1,640,805) (1,640,805)
------- ----------- ------------ -----------
Balance at March 31, 1996.............. 5,222 7,542,401 (6,490,736) 1,056,887
Net loss for the year ended March 31,
1997.............................. -- -- (2,630,573) (2,630,573)
------- ----------- ------------ -----------
Balance at March 31, 1997.............. 5,222 7,542,401 (9,121,309) (1,573,686)
Issuance of 2,075,306 shares of
common stock for forgiveness of
debt by former parent............. 2,075 3,424,919 -- 3,426,994
Sale of 3,200,000 shares of common
stock through private placement
offering, net of offering costs of
$165,187.......................... 3,200 1,431,613 -- 1,434,813
Net loss for the year ended March 31,
1998................................. -- -- (2,552,290) (2,552,290)
------- ----------- ------------ -----------
Balance at March 31, 1998.............. $10,497 $12,398,933 $(11,673,599) $ 735,831
======= =========== ============ ===========
See Accompanying Notes.
F-7
79
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
STATEMENTS OF CASH FLOWS
CUMULATIVE FROM
YEARS ENDED MARCH 31 OCTOBER 8, 1992
--------------------------------------- (INCEPTION) TO
1998 1997 1996 MARCH 31, 1998
----------- ----------- ----------- ---------------
OPERATING ACTIVITIES
Net loss............................. $(2,552,290) $(2,630,573) $(1,640,805) $(11,673,599)
Adjustments to reconcile net loss to
net cash used by operating
activities:
Depreciation and amortization...... 217,034 143,634 143,969 776,692
Loss on disposal of property and
equipment....................... 178,596 33,905 -- 237,976
(Gain) loss on marketable
securities...................... -- -- (76,441) 627,512
Amortization of bond discount...... -- -- (779) (4,855)
Changes in operating assets and
liabilities:
Change in prepaid expenses and
other current assets.......... (15,150) 20,203 (55,505) (115,749)
Change in other assets.......... (517) 1,174 2,502 (4,336)
Change in cash overdraft........ (119,514) 119,514 -- --
Change in accounts payable...... (97,110) 199,761 20,510 173,936
Change in accrued expenses...... 66,536 (6,580) (49,868) 82,876
----------- ----------- ----------- ------------
Net cash used by operating
activities......................... (2,322,415) (2,118,962) (1,656,417) (9,899,547)
INVESTING ACTIVITIES
Sale of marketable securities........ -- -- 3,285,625 3,285,625
Purchase of marketable securities.... -- -- -- (3,908,281)
Purchases of property and
equipment.......................... (59,380) (52,540) (21,514) (596,777)
Proceeds from sale of property and
equipment, net..................... 80,828 -- -- 80,828
Additional patent costs.............. (1,403) -- (15,687) (39,239)
----------- ----------- ----------- ------------
Net cash provided (used) by investing
activities......................... 20,045 (52,540) 3,248,424 (1,177,844)
FINANCING ACTIVITIES
Sales of common stock................ 1,600,000 -- -- 10,221,226
Expenses of stock offering........... (165,187) -- -- (1,675,850)
Payments of loan to parent........... -- -- (1,428,538) (1,917,057)
Payment of loan by parent............ -- -- 1,634,762 1,634,762
Proceeds of loan payable -- parent... 1,464,811 1,668,179 -- 4,715,067
Payment of loan payable -- parent.... -- -- -- (1,299,782)
F-8
80
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
STATEMENTS OF CASH FLOWS -- (CONTINUED)
CUMULATIVE FROM
YEARS ENDED MARCH 31 OCTOBER 8, 1992
--------------------------------------- (INCEPTION) TO
1998 1997 1996 MARCH 31, 1998
----------- ----------- ----------- ---------------
Proceeds of note
receivable -- parent............... -- 282,295 -- --
Proceeds of capital leases........... -- -- -- 101,572
Payments of capital leases........... -- (28,019) (28,960) (105,293)
Proceeds of brokerage loan payable... -- -- 1,000,000 2,674,683
Payments of brokerage loan payable... -- -- (2,569,592) (2,674,683)
----------- ----------- ----------- ------------
Net cash provided (used) by financing
activities......................... 2,899,624 1,922,455 (1,392,328) 11,674,645
----------- ----------- ----------- ------------
Increase (decrease) in cash and cash
equivalents........................ 597,254 (249,047) 199,679 597,254
Cash and cash equivalents at
beginning of period................ -- 249,047 49,368 --
----------- ----------- ----------- ------------
Cash and cash equivalents at end of
period............................. $ 597,254 $ -- $ 249,047 $ 597,254
=========== =========== =========== ============
SUPPLEMENTAL DISCLOSURE OF CASH
INFORMATION:
Cash paid for interest............... $ 35,486 $ 5,873 $ 71,882 $ 192,046
=========== =========== =========== ============
Noncash operating activities:
Value of common stock issued and
additional paid-in capital for
consulting services............. $ 150,000 $ -- $ -- $ 150,000
=========== =========== =========== ============
Noncash investing activities:
Value of assets transferred to
lessor in lieu of payment on
capital leases.................. $ 71,405 $ -- $ -- $ 71,405
=========== =========== =========== ============
Noncash financing activities:
Value of common stock issued and
additional paid-in capital for
the transfer of assets from
Parent.......................... $ 344,000 $ -- $ -- $ 781,060
=========== =========== =========== ============
Value of common stock issued to
Parent and additional paid-in
capital for the forgiveness of
debt............................ $ 3,160,502 $ -- $ -- $ 3,160,502
=========== =========== =========== ============
See Accompanying Notes.
F-9
81
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO FINANCIAL STATEMENTS
MARCH 31, 1998
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
ORGANIZATION AND BUSINESS
LifePoint, Inc. ("LifePoint"), formerly named U.S. Drug Testing, Inc., was
incorporated on October 8, 1992 under the laws of the State of Delaware as a
wholly-owned subsidiary of Substance Abuse Technologies, Inc. ("SAT" or
"Parent"), formally named U.S. Alcohol Testing of America, Inc., a
publicly-owned corporation and, as of September 30, 1997, SAT owned 5,575,306
shares of the LifePoint Common Stock, $.001 par value (the "LifePoint Common
Stock"), or 76.4% of the 7,297,206 then outstanding shares of the LifePoint
Common Stock. SAT ceased providing advances to LifePoint in August 1997 as a
result of its inability to secure financing for its own programs. On September
10, 1997, SAT filed a petition under Chapter 11 of the Federal Bankruptcy Code.
LifePoint temporarily suspended its product development activities on September
19, 1997, but did not file for bankruptcy. On October 29, 1997, the controlling
stockholder interest in LifePoint was sold to an unaffiliated party for
$250,000. LifePoint is now completely independent from SAT. LifePoint commenced
activities on January 1, 1993 and is engaged in the design of certain patented
technology known as the "Flow Immunosensor" developed by U.S. Navy Department
scientists for the detection of drugs of abuse.
BASIS OF PRESENTATION
As LifePoint is devoting its efforts to research and the development of its
products and there has been no revenue generated from product sales as yet,
LifePoint's financial statements are presented as statements of a development
stage enterprise.
USE OF ESTIMATES
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the amounts reported in the financial statements and accompanying notes.
Actual results could differ from those estimates.
CASH AND CASH EQUIVALENTS AND FAIR VALUE OF FINANCIAL INSTRUMENTS
LifePoint considers all highly liquid cash investments with an original maturity
of three months or less when purchased to be cash equivalents. The carrying
amount of all cash and cash equivalents approximates fair value because of the
short-term maturity of these instruments.
PROPERTY AND EQUIPMENT
Property and equipment is stated at cost. Depreciation is computed by the
straight-line method over the estimated useful lives of the related assets that
range from 5 to 13 years. Expenditures for maintenance and repairs are charged
to expense as incurred whereas major betterments and renewals are capitalized.
Property and equipment under capital leases are included with property and
equipment and amortization of these assets are included in depreciation expense.
F-10
82
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
PATENTS
The cost of patents is being amortized over its expected useful life of 17 years
using the straight-line method. At March 31, 1998 and 1997, accumulated
amortization of patents was approximately $6,300 and $2,600, respectively.
RESEARCH AND DEVELOPMENT COSTS
Research and development costs are expensed as incurred.
ACCOUNTING FOR STOCK BASED COMPENSATION
LifePoint grants stock options for a fixed number of shares to employees with an
exercise price equal to or above the fair value of the shares at the date of
grant. LifePoint accounts for stock option grants in accordance with APB Opinion
No. 25, Accounting for Stock Issued to Employees, and accordingly, recognizes no
compensation expense for employee stock option grants. (See Note 5.)
NET LOSS PER COMMON SHARE
Loss per common share is based upon the weighted average number of common shares
outstanding during the periods reported. Common stock equivalents have not been
included in this calculation because their inclusion would be anti-dilutive.
In February 1997, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 128, Earnings per Share (SFAS No. 128), which
is effective for annual and interim periods ending after December 15, 1997. SFAS
No. 128 replaced the previously required primary and fully diluted earnings per
share (EPS) with basic and diluted EPS. Unlike primary earnings per share, basic
earnings per share excludes any dilutive effects of options, warrants and
convertible securities. Diluted earnings per share is very similar to the
previously required fully diluted earnings per share. All earnings per share
amounts for all periods have been presented and, where necessary, restated to
conform to SFAS No. 128. There were no adjustments necessary to net loss in
calculating the income available to common stockholders after assumed
conversions of stock options and warrants that are considered to be dilutive.
The adjusted weighted average shares to give effect for the assumed conversion
of dilutive stock options and warrants is presented on the Statements of
Operations.
INCOME TAXES
LifePoint accounts for income taxes under SFAS No. 109, Accounting For Income
Taxes. In accordance with SFAS No. 109, deferred tax assets and liabilities are
established for the temporary differences between the financial reporting basis
and the tax basis of the Company's assets and liabilities at enacted tax rates
expected to be in effect when such amounts are realized or settled.
2. CONTINUING OPERATIONS
LifePoint has incurred recurring operating losses. LifePoint will require
additional capital to continue the research, development and ultimate
manufacture and marketing of its product and to fund its working capital
requirements for the next 12 months.
F-11
83
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
The aforementioned conditions raise substantial doubt about the Company's
ability to continue as a going concern. The financial statements do not include
any adjustments to reflect the possible future effects, if any, on the
recoverability and classification of assets or the amounts and classification of
liabilities that may result from the outcome of this uncertainty.
LifePoint continues to pursue parallel paths to secure funding: strategic
partnering, venture capital investors, a private placement, and a possible
public offering. There can be no assurance that any of these additional sources
of financing will be available and, in such event, LifePoint will not be able to
complete its research and development on a timely basis.
3. PROPERTY AND EQUIPMENT
Property and equipment is summarized as follows:
MARCH 31
--------------------
1998 1997
-------- --------
Furniture, Fixtures and Equipment......................... $287,502 $363,229
Test Equipment............................................ 425,768 400,798
Leasehold Improvements.................................... 209,155 208,822
-------- --------
922,425 972,849
Less: Accumulated Depreciation............................ 636,237 467,050
-------- --------
$286,188 $505,799
======== ========
4. NOTE FROM PARENT
To increase working capital, LifePoint converted outstanding indebtedness to
SAT, its former parent, into shares of the LifePoint Common Stock and additional
paid-in capital. Through August 1997, SAT advised LifePoint that the debt owed
was approximately $2,594,000, all of which SAT agreed to treat as a capital
contribution. LifePoint authorized the issuance to SAT of 2,075,306 shares of
the LifePoint Common Stock prior to the sale of the LifePoint Common Stock to an
outside third party. It was later determined that the outstanding debt was
approximately $3,427,000 and the remaining indebtedness of approximately
$833,000 was reflected as additional paid-in capital as of September 30, 1997.
5. STOCKHOLDERS' EQUITY
COMMON STOCK
On May 24, 1997, the Board of Directors of LifePoint authorized the issuance of
additional shares of the LifePoint Common Stock to SAT on the basis of a share
of the LifePoint Common Stock for each $1.25 of indebtedness of LifePoint to
SAT. Based on SAT's advice that the amount of indebtedness owed by LifePoint to
SAT was approximately $2,594,000 all of which SAT agreed to treat as a capital
contribution, LifePoint authorized the issuance to SAT of 2,075,306 shares of
the Common Stock. As of September 30, 1997, SAT owned 5,575,306 shares of the
LifePoint Common Stock or 76.4% of the 7,297,206 outstanding shares of the
LifePoint Common Stock. SAT ceased providing advances to LifePoint in August
1997 as a result of its inability to secure financing for its
F-12
84
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
own programs. On September 10, 1997, SAT filed a petition under Chapter 11 of
the Federal Bankruptcy Code. LifePoint temporarily suspended its product
development activities on September 19, 1997, but did not file for bankruptcy.
On October 29, 1997, the controlling stockholder interest in LifePoint was sold
to an unaffiliated party for $250,000. LifePoint is now completely independent
from SAT.
The purchaser of the LifePoint Common Stock also loaned money to LifePoint to
allow LifePoint to recommence product development. During the third quarter of
1997, LifePoint repaid the loans from the net proceeds of a private placement
pursuant to Regulation D under the Securities Act of 1933, as amended, which
sold 3,200,000 shares of the LifePoint Common Stock at $0.50 per share or an
aggregate purchase price of $1,600,000. The net proceeds of the private
placement totaled approximately $1,434,000 after the payment of capital
formation costs of approximately $166,000, including $160,000 in the form of a
finder's fee to Jonathan J. Pallin, who, on October 31, 1997 was elected
Chairman of the Board and a director of LifePoint. These capital formation costs
have been reflected as a reduction in additional paid-in capital.
STOCK OPTION/STOCK ISSUANCE PLAN
In August 1997, the Board of Directors ratified the 1997 Stock Option Plan (the
"Plan"), which reserves 1,000,000 shares of the LifePoint Common Stock to be
issued under the Plan. Options granted under the Plan may be either incentive
stock options designed to meet the requirements of Section 422 of the Internal
Revenue Code of 1986, as amended, or non-statutory options not intended to
satisfy such requirements. The exercise price per share for incentive stock
options will not be less than 100% of the fair market value per share of the
LifePoint Common Stock on the grant date. For non-statutory options, the
exercise price per share may not be less than 85% of such fair market value. No
granted option will have a maximum term in excess of ten years.
On August 14, 1997, options to purchase an aggregate of 467,500 shares were
granted to all LifePoint employees at an exercise price of $1.25, which
reflected the value of LifePoint Common Stock when trading was suspended on May
12, 1997. A private placement was initiated and completed during November and
December 1997; on December 5, 1997, the Board of Directors re-priced the options
to the then current value of $0.50 per share. Through March 31, 1998, options to
purchase an aggregate of 950,000 shares have been granted to a total of 11
employees:
INCENTIVE STOCK OPTIONS NON-STATUTORY OPTIONS
------------------------ ------------------------
NUMBER OF PRICE RANGE NUMBER OF PRICE RANGE
SHARES PER SHARE SHARES PER SHARE
--------- ----------- --------- -----------
Outstanding -- April 1, 1995............ 218,000 $7.00 10,000 $ 7.00
Canceled.............................. (66,000) 7.00 (10,000) 7.00
-------- ----- ------- ----------
Outstanding -- March 31, 1996........... 152,000 7.00 -- --
Canceled.............................. (152,000) 7.00 -- --
-------- ----- ------- ----------
Outstanding -- March 31, 1997........... -- -- -- --
Granted............................... 950,000 0.50 300,000 1.00-4.00
-------- ----- ------- ----------
Outstanding -- March 31, 1998........... 950,000 0.50 300,000 1.00-4.00
======== ===== ======= ==========
F-13
85
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
WARRANTS
In connection with its initial public offering in October and November 1993,
LifePoint granted to the underwriter, for a nominal fee, Common Stock purchase
warrants expiring October 13, 1998 to purchase 150,000 shares of the LifePoint
Common Stock at $7.50 per share. LifePoint granted Common Stock purchase
warrants, expiring on various dates through March 19, 2003, to purchase
1,577,289 shares of the LifePoint Common Stock at $0.50 to $1.00 per share
during fiscal 1998.
WARRANTS
-------------------------
NUMBER OF PRICE RANGE
SHARES PER SHARE
--------- ------------
Outstanding -- April 1, 1995........................... 150,000 $ 7.50
=========
Outstanding -- March 31, 1996........................ 150,000 7.50
=========
Outstanding -- March 31, 1997........................ 150,000 7.50
Granted.............................................. 1,577,289 0.50 - 1.00
---------
Outstanding -- March 31, 1998........................ 1,727,289 0.50 - 7.50
=========
A summary of the status of the stock option and warrant grants as of March 31,
1998, 1997 and 1996, and activities during the years ending on those dates, is
presented below:
1998 1997 1996
--------------------- -------------------- --------------------
WEIGHTED WEIGHTED WEIGHTED
OPTIONS AVERAGE OPTIONS AVERAGE OPTIONS AVERAGE
AND EXERCISE AND EXERCISE AND EXERCISE
WARRANTS PRICE WARRANTS PRICE WARRANTS PRICE
-------- -------- -------- -------- -------- --------
Outstanding at Beginning
of year................ 150,000 7.50 302,000 7.25 378,000
Granted.................. 2,827,289 0.75 -- -- -- --
Canceled................. -- -- (152,000) 7.00 (76,000) 7.00
--------- -------- -------
Outstanding at end of
year................... 2,977,289 1.09 150,000 7.50 302,000 7.25
========= ======== =======
Options and warrants
exercisable at year
end.................... 2,027,289 1.36 150,000 7.50 150,000 7.50
========= ======== =======
Weighted-average fair
value of options and
warrants granted during
the year............... $0.53 $-- $--
F-14
86
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
The following table summarizes information about stock options and warrants
outstanding as of March 31, 1998:
OPTIONS AND WARRANTS OPTIONS AND WARRANTS
OUTSTANDING EXERCISABLE
WEIGHTED- ---------------------------- ----------------------------
AVERAGE WEIGHTED- WEIGHTED-
RANGE OF REMAINING OPTIONS AND AVERAGE OPTIONS AND AVERAGE
EXERCISE PRICES LIFE (YEARS) WARRANTS EXERCISE PRICE WARRANTS EXERCISE PRICE
- --------------- ------------ ----------- -------------- ----------- --------------
$0.50 to $4.00 6.0 2,827,289 $0.75 1,877,289 $0.87
$4.01 to $7.50 0.5 150,000 $7.50 150,000 $7.50
The Company applies Accounting Principles Board Opinion No. 25, Accounting for
Stock Issued to Employees, and related interpretations in accounting for its
plans. Accordingly, no compensation expense has been recognized for the
Company's stock-based compensation plans other than for compensation and
performance-based stock awards. Had compensation cost for the Company's stock
option plan been determined based upon the fair value at the grant date for the
awards under the plan consistent with the methodology prescribed under Statement
of Financial Accounting Standards No. 123, Accounting for Stock-Based
Compensation ("FAS 123"), using the minimum value option pricing method due to
the lack of trading activity for the Company's stock, there would have been no
effect on the Company's net loss and net loss per share.
For income tax purposes, LifePoint has a net operating loss carryforward ("NOL")
at March 31, 1998 of approximately $10,109,000 expiring in 2008 to 2013 if not
offset against future federal taxable income. There may be certain limitations
as to the future annual use of the NOLs due to the fact that 50% or more of the
stock of the Company changed ownership during the current year. In addition,
LifePoint has a capital loss carryover of approximately $625,000 which expires
in 2001 if not offset against future capital gains.
Income tax benefit attributable to net loss differed from the amounts computed
by applying the statutory Federal Income tax rate applicable for each period as
a result of the following:
MARCH 31
--------------------------------
1998 1997 1996
-------- -------- --------
Computed "expected" tax benefit........................ $586,000 $869,000 $557,000
Decrease in tax benefit resulting from net operating
loss for which no benefit is currently available..... (586,000) (869,000) (557,000)
-------- -------- --------
$ -- $ -- $ --
======== ======== ========
F-15
87
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
The tax effects of temporary differences that give rise to significant portions
of the net deferred tax asset are presented below:
MARCH 31
------------------------
1998 1997
---------- ----------
Deferred tax assets:
Net operating loss carryforwards..................... $3,436,000 $2,850,000
Capital loss carryforwards........................... 213,600 213,600
---------- ----------
3,649,600 3,063,600
Less:
Valuation allowance under SFAS 109................... 3,649,600 3,063,600
---------- ----------
Net deferred tax assets................................ $ -- $ --
========== ==========
SFAS No. 109 requires a valuation allowance to reduce the deferred tax assets
reported if, based on the weight of the evidence, it is more likely than not
that some portion or all of the deferred tax assets will not be realized. After
consideration of all the evidence, both positive and negative, management has
determined that a $3,649,600 valuation allowance at March 31, 1998 is necessary
to reduce the deferred tax assets to the amount that will more likely than not
be realized. The change in the valuation allowance for the current year is
$586,000.
7. COMMITMENTS AND CONTINGENCIES
COMMITMENTS
LifePoint has entered into a lease agreement which commenced October 1, 1997 and
terminates on September 30, 1998, with a month-to-month option thereafter for
the office and research facilities in Rancho Cucamonga, California. In addition
to rent, LifePoint will pay for real estate taxes and other occupancy costs.
Rent expense for the fiscal years ended March 31, 1998, 1997 and 1996 was
$44,000, $45,000 and $36,000, respectively.
SIGNIFICANT CONTRACTS
Effective January 1, 1993, LifePoint entered into a sub-license agreement with
SAT in which LifePoint sublicensed all of SAT's rights under a license agreement
with the Department of the Navy (the License Agreement).
SAT and the Department of the Navy on January 24, 1992 had entered into a
ten-year agreement granting SAT a partial exclusive patent license to products
for drug testing in the United States and certain foreign countries. In June
1995, SAT's License Agreement with the Department of Navy was renegotiated and
amended to provide for minimum royalties of $100,000 per year which commenced
October 1, 1995 and terminate September 30, 2005. Additional royalties will be
paid pursuant to a schedule based upon sales of products. LifePoint was a
sub-licensee under this agreement from SAT and, accordingly, had an obligation
to SAT for the royalty payments required by the License Agreement. Royalties
expensed under the License Agreement by LifePoint were $40,000, $100,000 and
$50,000 for the years ended March 31, 1998, 1997 and 1996, respectively.
F-16
88
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
With the sale of SAT's majority owned position in LifePoint, the U.S. Navy also
agreed to transfer its License Agreement with SAT directly to LifePoint. An
amendment dated November 12, 1997 was executed to modify the up-front $100,000
annual minimum payment to be paid in several payments over the year; it also
included a onetime payment of $10,000 for any outstanding debt due to the Navy
from SAT. LifePoint has assumed all of SAT's rights and undertaken all of SAT's
obligations under the License Agreement. On March 3, 1998, the notification
period in the Federal Register was completed and the Navy agreed in principle to
expand the license to a worldwide, exclusive license for human diagnostic
testing on saliva. The terms of this agreement have not yet been negotiated.
LifePoint is developing its own proprietary "Immunoassay Chemistry" for these
five drugs that will work within the Navy-developed technology.
8. INTERCOMPANY ALLOCATIONS
LifePoint was originally obligated to pay a fixed annual management fee of
$420,000 plus three percent of its gross revenues to SAT. LifePoint paid
$420,000 per year for the years ended March 31, 1997 and 1996. In addition, the
Company was allocated overhead expenses such as rent, utilities, etc. based on
estimated usage. In March of 1997, the Management Agreement was again amended to
provide for a percentage of time and services agreement whereby the costs of
certain SAT employees and facilities were allocated to LifePoint based on a
percentage of usage. As the activity of LifePoint had been increasing, there had
been a tremendous increase in time required by SAT employees and expanded use of
leased space to satisfy LifePoint's needs. The services provided to LifePoint by
SAT pursuant to the Management Agreement included management, administrative,
accounting and other financial services and advice, including, without
limitation, the services then performed by the Treasurer of LifePoint (who was
also the Treasurer of SAT), for which he was not directly compensated by
LifePoint; services relating to LifePoint's financial and banking relationships;
services relating to the preparation of financial statements, budgets, forecasts
and cash flow projections; cash management advice; and other miscellaneous
services and advice. The management fee was discontinued after June 30, 1997
because no services were being provided after that date.
F-17
89
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
9. LOSS PER SHARE
The following table sets forth the computation of basic and diluted earnings per
share for the years ended March 31:
1998 1997 1996
----------- ----------- -----------
Numerator:
Net loss and numerator for basic and diluted
loss per share............................ $(2,552,290) $(2,630,573) $(1,640,805)
Denominator:
Denominator for basic loss per
share -- weighted-average shares.......... 8,032,231 5,221,900 5,221,900
Effect of dilutive options................... 831,045 -- --
----------- ----------- -----------
Denominator for diluted loss per
share -- adjusted weighted-average shares and
assumed conversions.......................... 8,863,276 5,221,900 5,221,900
=========== =========== ===========
Net loss per common share -- basic............. $ (.32) $ (.50) $ (.31)
=========== =========== ===========
Net loss per common share, assuming dilution... $ (.29) $ (.50) $ (.31)
=========== =========== ===========
For additional disclosures regarding the outstanding employee stock options, see
Note 5.
The following table discloses the number of vested and outstanding warrants
during fiscal 1998, 1997 and 1996 that were not included in the computation of
diluted earnings per share because the warrants' exercise price was greater than
the fair value of the common shares and, therefore, the effect would be
antidilutive.
1998 1997 1996
----------- -------- -----------
Number of antidilutive options and warrants....... 550,000 150,000 302,000
Range of option and warrant prices for the
antidilutive options and warrants............... $1.00-$7.50 $7.50 $7.00-$7.50
F-18
90
UNAUDITED FINANCIAL STATEMENTS
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
BALANCE SHEETS
DECEMBER 31
1998 MARCH 31
(UNAUDITED) 1998
------------- ------------
ASSETS
Current assets:
Cash and cash equivalents................................ $ 322,591 $ 597,254
Prepaid expenses and other current assets................ 189,500 150,150
------------- ------------
Total current assets.................................. 512,091 747,404
Property and equipment, net................................ 171,743 286,188
Patents and other assets, net.............................. 53,031 39,692
------------- ------------
$ 736,865 $ 1,073,284
============= ============
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Accounts payable......................................... $ 230,813 $ 119,577
Accrued expenses......................................... 659,548 217,876
------------- ------------
Total current liabilities............................. 890,361 337,453
Commitments and contingencies (Note 4)
Stockholders' equity (deficit):
Common stock, $.001 par value; 50,000,000 shares
authorized, 11,779,237 and 10,497,206 issued and
outstanding at December 31, 1998 and March 31, 1998,
respectively.......................................... 11,779 10,497
Additional paid-in capital................................. 13,621,270 12,398,933
Deficit accumulated in the development stage............... (13,786,545) (11,673,599)
------------- ------------
Total stockholders' equity (deficit).................. (153,496) 735,831
------------- ------------
$ 736,865 $ 1,073,284
============= ============
See accompanying notes.
F-19
91
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
STATEMENTS OF OPERATIONS
(UNAUDITED)
CUMULATIVE
FOR THE FOR THE FROM
THREE MONTHS ENDED NINE MONTHS ENDED OCTOBER 8, 1992
DECEMBER 31 DECEMBER 31 (INCEPTION) TO
----------------------- ------------------------- DECEMBER 31
1998 1997 1998 1997 1998
----------- --------- ----------- ----------- ---------------
Revenues.................... $ -- $ -- $ -- $ -- $ --
Costs and expenses:
General and administrative
expenses............... 536,557 236,488 1,194,048 407,022 3,778,596
Research and
development............ 259,924 150,702 818,117 851,376 6,537,218
Depreciation and
amortization........... 25,250 56,253 129,428 161,744 906,120
Interest
expense -- parent...... -- -- -- 34,530 95,790
Management
fees -- parent......... -- -- -- 409,838 2,089,838
Interest expense.......... -- 956 -- 956 119,300
----------- --------- ----------- ----------- ------------
Total costs and expenses.... 821,731 444,399 2,141,593 1,865,466 13,526,862
----------- --------- ----------- ----------- ------------
Loss from operations........ (821,731) (444,399) (2,141,593) (1,865,466) (13,526,862)
Other income/(expense)...... 4,851 (185,228) 28,647 (185,228) (259,683)
----------- --------- ----------- ----------- ------------
Net loss.................... $ (816,880) $(629,627) $(2,112,946) $(2,050,694) $(13,786,545)
=========== ========= =========== =========== ============
Earnings per common share:
Weighted average common
shares outstanding..... 11,731,031 8,255,902 11,395,289 7,225,512
=========== ========= =========== ===========
Net loss per common
share:.................... $ (0.07) $ (0.08) $ (0.19) $ (0.28)
=========== ========= =========== ===========
Earnings per common share,
assuming dilution:
Weighted average common
shares outstanding..... 15,282,298 9,343,728 14,671,047 7,668,912
=========== ========= =========== ===========
Net loss per common share,
assuming dilution......... $ (0.05) $ (0.07) $ (0.14) $ (0.27)
=========== ========= =========== ===========
See accompanying notes.
F-20
92
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
STATEMENTS OF CASH FLOWS
(UNAUDITED)
CUMULATIVE
FROM
FOR THE NINE MONTHS ENDED OCTOBER 8, 1992
DECEMBER 31, (INCEPTION) TO
------------------------- DECEMBER 31
1998 1997 1998
----------- ----------- ---------------
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss........................................ $(2,112,946) $(2,050,694) $(13,786,545)
ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED
BY OPERATING ACTIVITIES:
Depreciation and amortization................... 129,428 161,744 906,120
Consulting expense.............................. 311,800 -- 311,800
Disposal of property and equipment.............. -- 189,248 237,976
Unrealized loss on marketable securities........ -- -- 627,512
Amortization of bond discount................... -- -- (4,855)
CHANGES IN OPERATING ASSETS AND LIABILITIES:
(Increase) decrease in prepaid expenses and
Other current assets......................... 50,650 (25,000) (65,099)
(Increase) decrease in other assets............. (7,432) 133 (11,768)
Decrease in bank overdraft...................... -- (119,514) --
Increase (decrease) in accounts payable......... 111,236 (99,739) 285,172
Increase (decrease) in accrued expenses......... 243,212 50,933 326,088
----------- ----------- ------------
Net cash used by operating activities............. (1,274,052) (1,892,889) (11,173,599)
----------- ----------- ------------
CASH FLOW FROM INVESTING ACTIVITIES:
Sale of marketable securities................... -- -- 3,285,625
Purchases of marketable securities.............. -- -- (3,908,281)
Purchases of property and equipment............. (13,197) (55,625) (609,974)
Proceeds from sale of property and equipment,
net.......................................... -- 106,241 80,828
Patent costs.................................... (7,693) (1,402) (46,932)
----------- ----------- ------------
Net cash (used) provided by investing
activities...................................... (20,890) 49,214 (1,198,734)
----------- ----------- ------------
CASH FLOW FROM FINANCING ACTIVITIES:
Sales of common stock........................... 1,025,000 1,600,000 11,246,226
Expenses of stock offering...................... (5,736) (100,000) (1,681,586)
Exercise of stock options....................... 1,015 -- 1,015
Payment of loan to parent....................... -- -- (1,917,057)
F-21
93
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
STATEMENTS OF CASH FLOWS -- (CONTINUED)
(UNAUDITED)
CUMULATIVE
FROM
FOR THE NINE MONTHS ENDED OCTOBER 8, 1992
DECEMBER 31, (INCEPTION) TO
------------------------- DECEMBER 31
1998 1997 1998
----------- ----------- ---------------
Proceeds of loan by parent...................... -- -- 1,634,762
Proceeds of loan payable -- parent.............. -- 1,464,811 4,715,067
Payment of loan payable -- parent............... -- -- (1,299,782)
Proceeds of capital leases...................... -- -- 101,572
Payments of capital leases...................... -- -- (105,293)
Proceeds of brokerage loan payable.............. -- -- 2,674,683
Payments of brokerage loan payable.............. -- -- (2,674,683)
----------- ----------- ------------
Net cash provided by financing activities......... 1,020,279 2,964,811 12,694,924
----------- ----------- ------------
Increase (decrease) in cash and cash
equivalents..................................... (274,663) 1,121,136 322,591
Cash and cash equivalents -- beginning of
period.......................................... 597,254 -- --
----------- ----------- ------------
Cash and cash equivalents -- end of period........ $ 322,591 $ 1,121,136 $ 322,591
=========== =========== ============
Supplemental disclosure of cash information:
Cash paid for interest.......................... $ -- $ 956 $ 192,046
=========== =========== ============
NONCASH OPERATING ACTIVITIES:
Value of common stock granted and additional
paid-in capital for consulting services...... $ 53,340 $ -- $ 203,340
=========== =========== ============
NONCASH INVESTING ACTIVITIES:
Value of assets transferred to lessor in lieu of
payment on capital leases.................... $ -- $ -- $ 71,405
=========== =========== ============
NONCASH FINANCING ACTIVITIES:
Value of common stock issued and additional
paid-in capital for the transfer of assets
from parent.................................. $ -- $ 344,000 $ 781,060
=========== =========== ============
Value of common stock issued to parent and
additional paid-in capital for the
forgiveness of debt.......................... $ -- $ 3,082,944 $ 3,160,502
=========== =========== ============
Value of warrants granted for consulting
services..................................... $ 348,460 $ -- $ 348,460
=========== =========== ============
See accompanying notes.
F-22
94
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO FINANCIAL STATEMENTS
DECEMBER 31, 1998
(UNAUDITED)
NOTE 1 -- BASIS OF PRESENTATION
In the opinion of LifePoint, Inc. (the "Company"), the accompanying unaudited
financial statements reflect all adjustments (which include only normal
recurring adjustments except as disclosed below) necessary to present fairly the
financial position, results of operations and cash flows for the periods
presented. Results of operations for interim periods are not necessarily
indicative of the results of operations for a full year due to external factors
which are beyond the control of the Company. The unaudited financial statements
should be read in conjunction with the Company's audited financial statements on
pages F-1 to F-18 of this prospectus.
In February 1997, the Financial Accounting Standards Board issued Statement No.
128, Earnings per Share (FASB No. 128), which is effective for annual and
interim periods ending after December 15, 1997. FASB No. 128 replaced the
previously required primary and fully diluted earnings per share (EPS) with
basic and diluted EPS. Unlike primary earnings per share, basic earnings per
share excludes any dilutive effects of options, warrants and convertible
securities. Diluted earnings per share is very similar to the previously
required fully diluted earnings per share. All earnings per share amounts for
all periods have been presented and, where necessary, restated to conform to
FASB No. 128. There were no adjustments necessary to net loss in calculating the
income available to common stockholders after assumed conversions of stock
options and warrants that are considered to be dilutive. The adjusted weighted
average shares to give effect for the assumed conversion of dilutive stock
options and warrants is presented on the Statements of Operations.
NOTE 2. -- CONTINUING OPERATIONS AND LIQUIDITY
The Company has historically incurred recurring operating losses due to the fact
that it is still a development stage enterprise incurring research and
development expenses and deriving no revenues and has experienced an ongoing
deficiency in working capital. The Company financed its operations during the
quarter ended June 30, 1998 from the remainder of the net proceeds of $1,434,000
realized from a private placement in November and December 1997 pursuant to
Regulation D under the Securities Act of 1993, as amended (the "Securities
Act"), which sold 3,200,000 shares of the Company's Common Stock, $.001 par
value (the "Common Stock"), at $0.50 per share or an aggregate purchase price of
$1,600,000. Recognizing that such financing would only furnish sufficient
working capital through July 1998, the Company initiated a second private
placement in July 1998 pursuant to Regulation D under the Securities Act, with a
minimum of 1,000,000 shares and a maximum of 5,000,000 shares of the Common
Stock at $1.00 per share. The Company closed on the minimum of 1,000,000 shares
on July 17, 1998 and, on August 26, 1998, the Company sold an additional 25,000
shares of the Common Stock, or an aggregate of 1,025,000 shares of the Common
Stock offered pursuant to the second private placement. The offering of a
minimum of 1,000,000 and a maximum of 5,000,000 shares of the Common Stock
expired by its terms on October 14, 1998 without any additional shares being
sold.
F-23
95
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
On December 15, 1998, the Company initiated a third private placement pursuant
to Regulation D under the Securities Act, with a minimum of 25,000 shares and a
maximum of 600,000 shares of the Series A 10% Cumulative Convertible Preferred
Stock, $.001 par value (the "Series A Preferred Stock"), at $10.00 per share.
The Series A Preferred Stock is convertible into shares of the Common Stock on
the basis of 20 shares of the Common Stock for each share of the Preferred
Stock. The security will accrue a semi-annual dividend of $0.50 per share
payable in cash or shares of the Common Stock at the Company's option. The
Company closed on the entire 600,000 shares on January 21, 1999. The
approximately $5,400,000 in net proceeds the Company received provides the funds
that, in management's opinion, will allow the Company to develop a working
prototype of its drugs of abuse and alcohol testing system using saliva as the
testing medium.
The Company will require additional capital to continue the research and
development and ultimate manufacture and marketing of its product. The Company
estimates that, in addition to the approximately $5,000,000 needed to complete
the prototype of its first product, the Company will need an additional
$8,000,000 to bring the product to market. As a result of its continuing
operational losses and its continuing capital requirements at March 31, 1998,
there was raised substantial doubt about the Company's ability to continue as a
going concern. These unaudited financial statements do not include any
adjustments to reflect the possible future effects, if any, on the
recoverability and classification of assets on the amounts and classification of
liabilities that may result from the outcome of this uncertainty. Although the
Company's fund raising efforts will now cease temporarily, the Company will need
to continue to pursue parallel paths for the additional funding needed: private
placements, strategic partnering and a possible public offering. There can be no
assurance that any of these additional sources of financing will be available
and, in such event, the Company will not be able to complete its research and
development on a timely basis.
NOTE 3 -- PROPERTY AND EQUIPMENT
Property and equipment is summarized as follows:
DECEMBER 31, MARCH 31,
1998 1998
------------ ---------
Furniture and Fixtures........................ $300,699 $287,502
Test Equipment................................ 425,768 425,768
Leasehold Improvements........................ 209,155 209,155
-------- --------
935,622 922,425
Less: Accumulated Depreciation................ 763,879 636,237
-------- --------
$171,743 $286,188
======== ========
NOTE 4 -- COMMITMENTS AND CONTINGENCIES
In June 1995, the License Agreement with the Department of the Navy then held by
Substance Abuse Technologies, Inc. ("SAT"), the Company's then parent, was
F-24
96
LIFEPOINT, INC.
(A DEVELOPMENT STAGE ENTERPRISE)
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
renegotiated and amended to provide for minimum annual royalties of $100,000 per
year commencing October 1, 1995 and terminating September 30, 2005. Additional
royalties will be paid pursuant to a schedule based upon sales of products.
Through March 31, 1997, the Company sub-licensed this Agreement from its then
parent and, accordingly, had obligations to its then parent for the royalty
payments required by the License Agreement. This license was transferred from
SAT to the Company effective with the sale of SAT's majority ownership of the
Common Stock on October 29, 1997. The Navy settled all past liabilities for the
transferred license for $10,000.
On March 3, 1998, the license from the Navy was expanded to an exclusive,
worldwide license for all saliva diagnostics. The terms of the license expansion
are currently being negotiated.
NOTE 5 -- STOCKHOLDERS' EQUITY
During the quarter ended December 31, 1998, the Company issued a 5-year warrant
to purchase 50,000 shares of the Common Stock at $1.08 per share to Ira J.
Mitchell as a finder's fee for $500,000 of the $1,000,000 raised during the
Company's second private placement in July 1998. Additionally, the Company
issued a 5-year warrant to purchase 250,000 shares of the Common Stock at $1.15
per share, based on the closing price on December 3, 1998, to Burrill & Company
for its work in helping the Company to establish multiple partnering agreements
in the life sciences area. As of December 31, 1998, there were warrants
outstanding to purchase 2,616,741 shares of the Common Stock.
The LifePoint, Inc. 1997 Stock Option Plan (the "Plan"), as adopted by the Board
of Directors of the Company on August 14, 1997 and amended on June 5, 1998, now
provides for the granting of options to purchase an aggregate of 2,000,000
shares (originally 1,000,000 shares) of the Common Stock. Stockholders' approval
of the Plan was obtained at the Annual Meeting of Stockholders on August 13,
1998. Options granted under the Plan may either be incentive stock options
designed to meet the requirements of Section 422 of the Internal Revenue Code of
1986, as amended, or non-statutory or non-qualified stock options not intended
to satisfy such requirements. The exercise price per share for incentive stock
options will not be less than 100% of the fair market value per share of the
Common Stock on the grant date. For non-statutory or non-qualified stock
options, the exercise price per share may not be less than 85% of such fair
market value. No option may have a term in excess of ten years.
During the quarter ended December 31, 1998, no options were granted pursuant to
the Plan. As of December 31, 1998, there were options to purchase 833,333 shares
held by a total of 11 employees pursuant to the Plan.
F-25
97
- ------------------------------------------------------
- ------------------------------------------------------
NO DEALER, SALESPERSON OR OTHER PERSON HAS BEEN AUTHORIZED TO GIVE ANY
INFORMATION OR REPRESENTATIONS IN CONNECTION WITH THIS OFFERING OTHER THAN THOSE
CONTAINED IN THIS PROSPECTUS. IF ANY SUCH INFORMATION OR REPRESENTATIONS IS
GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATIONS MUST NOT BE RELIED UPON AS
HAVING BEEN AUTHORIZED BY THE COMPANY. THIS PROSPECTUS DOES NOT CONSTITUTE AN
OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY THE SECURITIES OFFERED HEREBY
TO ANY PERSON IN ANY STATE OR OTHER JURISDICTION IN WHICH SUCH OFFER OR
SOLICITATION WOULD BE UNLAWFUL. NEITHER THE DELIVERY OF THIS PROSPECTUS NOR ANY
SALE MADE HEREUNDER SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT
THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT TO THE
DATE HEREOF.
-------------------------
Until May 5, 1999 (40 days from the date of the prospectus), all dealers
that effect transactions in these securities, whether or not participating in
this offering, may be required to deliver a prospectus. This is in addition to
the dealers' obligation to deliver a prospectus when acting as underwriters and
with respect to their unsold allotments or subscriptions.
- ------------------------------------------------------
- ------------------------------------------------------
- ------------------------------------------------------
- ------------------------------------------------------
LIFEPOINT, INC.
14,035,452 SHARES OF COMMON
STOCK ($.001 PAR VALUE) OFFERED
BY SELLING STOCKHOLDERS
-------------------------
PROSPECTUS
-------------------------
April 5, 1999
- ------------------------------------------------------
- ------------------------------------------------------